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ABSTRACT 
Food allergy is a major health problem in the Western countries, notably in children, 
with an estimated prevalence of 2-8%, and is the most frequent reason for anaphylactic 
reactions at this age. Between the food allergies, Immunoglobulin E (IgE)-mediated cow's 
milk protein allergy (CMPA) and egg allergy are the most common in infants, affecting 
approximately 1-3% of children. Although these allergies are associated with a high rate of 
natural tolerance, the mechanisms of tolerance acquisition are not well understood. 
Moreover, about 50% of children do not overcome their allergy within the first years of life, 
which rekindle in the increasing incidence of the clinical disorder in adults. These food-
allergic processes may endanger children's health causing reactions from mild atopic 
dermatitis to severe systemic anaphylaxis, which can be life-threatening. Unfortunately, at 
present, the only treatment for cow's milk (CM) and egg allergies is a complete dietary 
restriction of implicated foods. Because of milk and egg protein is included in a wide range 
of cooked and manufactured foods, avoidance involves a wide dietary restriction, which 
leads to negative nutritional, social, psychological and economic consequences. However, 
and despite its importance, little information is known about which specific immune 
mechanisms constitute differential factors for the development of allergy or for the 
maintenance of tolerance. Consequently, new studies to clarify these important issues and 
novel strategies for immune intervention are currently pursued.  
Given this scenario, the first research conducted in this thesis compiled an extensive 
analysis of immune cell subsets and cytokine secreting cells in infants with symptoms 
compatible with CMPA, which is the first allergy to appear in children. Samples were 
collecting in the 1-4 days after the first adverse reaction, to decipher the immune alterations 
related with the establishment of this allergy. Interestingly, results revealed that children 
who developed CMPA had decreased regulatory T cell (Treg) counts and lower serum 
vitamin D levels. Furthermore, these parameters were statistically correlated and 
constituted good predictors to distinguish between healthy controls and CM allergic infants. 
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Therefore, they could be crucial factors behind the onset of the allergic process in infants 
and a therapeutic target for the treatment of this food allergy. 
Because of oral immunotherapy (OIT) is nowadays one of the most promising 
approaches toward a treatment for food allergy, further studies to lend more scientific 
evidence about such treatment are demanded. OIT involves giving regular, gradually 
increased dosages of the allergenic protein under medical supervision. The goal is induce 
desensitization firstly, defined as an increase in the threshold for reactivity but requiring a 
continued consumption of the allergen to prevent the reappearance of reactivity; and a later 
induction of oral tolerance, which means a long-lasting unresponsiveness against the food 
allergen. Pilot studies have yielded promising results, with success ratios frequently higher 
to 70%. However, differences between protocols employed, and the lack of knowledge 
about the specific immune mechanisms responsible of the desensitization and tolerance 
acquisition, prevent from drawing robust conclusion and make difficult the improvement and 
further development of this therapeutic strategy. Moreover, there is no yet evidence enough 
in the biomarkers that reflect the success of the intervention, as well as which children 
could be good candidates for treatment and have a reduced risk of adverse reactions.  
In this Thesis, the clinical efficacy and immunologic changes associated with OIT for 
IgE-mediated CMPA and egg allergy in infants were evaluated. The basal immunologic 
status of the allergic children enrolled was assessed through comparison with those of a 
non-allergic group of the same age range and sex. Three different OIT schedules were 
evaluated: i) a rush protocol for egg desensitization based on a first 5-days rapid up dosing, 
with a rate of success (defined as the ability to eat one undercooked egg) of 93.8% of 
patients  in 5 months of intervention; ii) a long-course regimen for egg desensitization, 
which allowed 60% children to eat the equivalent to a full egg (≥ 32 mL of pasteurized egg 
white) in an average period of 11.75 months; iii) a long-course OIT protocol for CM 
desensitization with 70% success (≥ 200 ml of CM) and, an average duration of 18.9 
months. A distinct feature of the long protocols is the progressive introduction of egg or 
milk-containing foods into the patient’s diet. Moreover, the long-term efficacy of 
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desensitization of these protocols was evaluated 24-48 months after being completed, 
reporting that 70-75% of the allergic children participants were consuming egg or CM as a 
part of their diet.  
Analysis of immunological outcomes underlying OIT studies showed a decrease in 
serum allergen-specific IgE levels along the therapy, accompanied by a rise in the allergen-
specific IgG4. Because the mechanisms by which OIT acts include modulation of T-cell 
responses, peripheral blood mononuclear cells (PBMCs) were isolated from blood samples 
and stimulated with ovalbumin (OVA) or β-casein (β-CN) for measuring T helper 2 (Th2), T 
helper 1 (Th1) and regulatory T (Treg) cells cytokine profile, as well as the expression of 
the master transcription factors of the corresponding T-cell differentiation (GATA3, T-bet 
and FoxP3). Results revealed a diminished allergic Th2 response in children successfully 
desensitized, with lower specific interleukin (IL)-13 and IL-5 production. Gene expression 
differences were not large enough to consider a significant change in either of the 
transcription factors studied. Higher baseline antigen-specific IgE levels are proposed 
predictors of a negative clinical response to OIT. 
In summary, main findings in this thesis highlighted that circulating Treg cells and 
serum vitamin D levels could be crucial factors behind the establishment of CMPA in 
infants. Oral rush immunotherapy protocols could be highly effective in inducing 
desensitization to egg proteins in few days with a long-term protection. Successful 
desensitization resulted in significant reductions in antigen-specific IgE with increases in 
antigen-specific IgG4 and a drop in Th2 cytokines associated with allergic processes. 
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RESUMEN 
La alergia alimentaria es un grave problema de salud en Occidente, especialmente en 
niños. Con una prevalencia estimada del 2-8%, es la causa más frecuentemente de las 
reacciones anafilácticas a dicha edad. La alergia a la proteína de la leche de vaca (APLV) 
y la alergia al huevo mediadas por inmunoglobulina E (IgE), son las alergias alimentarias 
más frecuentes en la edad infantil, afectando aproximadamente al 1-3% de los niños. 
Aunque estas alergias presentan una elevada tasa de resolución o tolerancia espontánea,  
cómo se produce este fenómeno no se conoce en profundidad. Además, alrededor del 
50% de los niños no revierten su alergia durante los primeros años de vida, lo cual 
repercute en una creciente incidencia de la enfermedad en la edad adulta. Los procesos 
alérgicos implicados pueden poner en peligro la salud de los niños, causando reacciones 
que van desde la dermatitis atópica leve a la anafilaxia sistémica grave, condición que 
pone en peligro la vida del paciente. Desafortunadamente, en la actualidad el único 
tratamiento para la APLV y la alergia al huevo es la total restricción en la dieta de los 
alimentos implicados y, puesto que las proteínas de la leche y del huevo se incluyen en 
una extensa gama de alimentos cocinados y manufacturados, su eliminación implica una 
amplia restricción dietética, con consecuencias nutricionales, sociales, psicológicas y 
económicas adversas. Sin embargo, y a pesar de su importancia, poco se sabe acerca de 
los mecanismos inmunológicos específicos que conducen al desarrollo de alergia o a la 
preservación de la tolerancia. Por ello, es importante realizar estudios que permitan aclarar 
estas cuestiones, así como plantear estrategias innovadoras de intervención en dicha 
respuesta inmune. 
Para intentar dar respuesta a estas interrogantes, la primera investigación realizada 
en la tesis doctoral consiste en un análisis exhaustivo de subpoblaciones celulares del 
sistema inmune y células secretoras de citoquinas en niños con síntomas compatibles con 
la APLV. Las muestras se recolectaron entre 1 y 4 días tras la primera reacción adversa, 
para poder estudiar las alteraciones inmunológicas relacionadas con el establecimiento de 
esta alergia. Los resultados revelaron que los niños que desarrollaron APLV tenían 
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menores recuentos de células T reguladoras, así como niveles más bajos de vitamina D en 
suero. Además, estos parámetros estaban estadísticamente correlacionados y eran 
buenos predictores para distinguir entre controles sanos y niños alérgicos. Por lo tanto,  
estos factores podrían tener una implicación crucial en el inicio del proceso alérgico en los 
niños y ser una diana terapéutica para el tratamiento de esta alergia alimentaria. 
La inmunoterapia oral (ITO) es una de las estrategias actuales más prometedores 
para el tratamiento de la alergia alimentaria, por ello es prioritario que se realicen más 
estudios que arrojen una mayor evidencia científica sobre este tipo de tratamiento. La ITO 
implica la administración de dosis regulares, gradualmente crecientes de la proteína 
alergénica bajo supervisión médica. El objetivo es inducir un primer estado de 
desensibilización, definido como un aumento del umbral de reactividad, pero que requiere 
el consumo continuo del alérgeno para evitar la reaparición de la alergia; y una posterior 
inducción de la tolerancia oral, que significa la falta de respuesta duradera contra el 
alérgeno alimentario. Los estudios piloto han arrojado resultados prometedores, con tasas 
de éxito que superan el 70%. Sin embargo, las diferencias entre los protocolos empleados, 
y la falta de conocimiento sobre los mecanismos inmunológicos responsables de la 
adquisición del estado de desensibilización y de la tolerancia, impiden sacar conclusiones 
definitivas y dificultan la implementación de mejoras para el desarrollo de esta estrategia 
terapéutica. Por otra parte, todavía no hay suficiente evidencia en los biomarcadores que 
reflejen el éxito de la intervención, así como en los que indiquen qué niños podrían ser 
buenos candidatos para el tratamiento y cuáles tienen un riesgo menor de sufrir reacciones 
adversas. 
Durante la realización de esta tesis doctoral se ha evaluado la eficacia clínica y los 
cambios inmunológicos asociados con la ITO para la APLV y la alergia al huevo mediadas 
por IgE en lactantes. El estado inmunológico basal de los niños alérgicos reclutados fue 
comparado con el de una población sana de igual rango de edad y sexo. Se evaluaron 3 
protocolos diferentes de ITO: i) un protocolo rápido de desensibilización al huevo basado 
en una fase rápida de 5 días de duración, con una tasa de éxito (definida como la 
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capacidad de consumir un huevo poco cocido) del 93,8% de los pacientes a los 5 meses 
de intervención; ii) un régimen de larga duración para la desensibilización al huevo que 
permitó que el 60% de los niños comieran el equivalente a un huevo completo (≥ 32 mL de 
clara de huevo pasterizada) en un periodo medio de 11,75 meses; iii) un protocolo de 
desensibilización a la leche de vaca de larga duración que alcanzó un 70% de éxito (≥ 200 
mL de CM) en un tiempo promedio de 18,9 meses. Una característica distintiva que fue 
estudiada en los protocolos de larga duración, es la introducción progresiva en la dieta del 
paciente de alimentos que contenían leche/huevo. Por otra parte, la eficacia de 
desensibilización a largo plazo fue evaluada a los 24-48 meses tras completar el protocolo, 
reflejando que un 70-75% de los niños alérgicos participantes mantenían el consumo de 
huevo o leche de vaca como parte normal de su dieta. 
Tras el análisis de los resultados inmunológicos subyacentes a los estudios de ITO, se 
observó una disminución en los niveles séricos de IgE alérgeno-específica a lo largo de la 
terapia, acompañada de un aumento en la IgG4 específica a alérgenos. Dado que los 
mecanismos sobre los cuales actúa la ITO incluyen la modulación de respuestas de las 
células T, las células mononucleares de sangre periférica de las muestras de sangre  
fueron aisladas y estimuladas con ovoalbúmina (OVA) o β-caseína (β-CN) para medir la 
secreción de citoquinas asociada a la respuesta de linfocitos T colaboradores Th2, Th1 y 
células T reguladoras (Treg), así como la expresión de los genes maestros controladores 
de las correspondientes diferenciaciones de dichas células T (GATA3, T-bet y FoxP3). Los 
resultados obtenidos mostraron una disminución de la respuesta alérgica Th2 en niños 
desensibilizados satisfactoriamente, con una menor producción de interleucina (IL)-13 e IL-
5. No se observaron cambios significativos en la expresión génica en ninguno de los genes 
estudiados. Los resultados indican que, niveles más elevados de IgE específica a 
alérgenos al inicio podrían servir para predecir una respuesta clínica negativa al 
tratamiento.  
En resumen, los principales hallazgos de esta tesis señalan que la cantidad de células 
Treg circulantes y los niveles séricos de vitamina D podrían tener un papel crucial en el 
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establecimiento de la APLV en los niños. El protocolo rápido de inmunoterapia oral se 
mostró muy eficaz a la hora de inducir la desensibilización a las proteínas del huevo en 
pocos días, con una protección que se mantuvo a largo plazo. El éxito en la 
desensibilización se asoció con reducciones significativas de IgE específica a alérgenos, 
con aumentos de la IgG4 específica y con una disminución en las citoquinas Th2 
asociadas con los procesos alérgicos. 
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ABBREVIATIONS 
 
 
DBPCFC: Double blind placebo controlled food challenge 
CM: Cow’s milk 
CMPA: Cow’s milk protein allergy 
EW: Egg white 
IL-: Interleukin- 
IFN-γ: Interferon-γ 
LZ: Lysozyme 
OIT: Oral Immunotherapy 
OM: Ovomucoid 
OVA: Ovalbumin 
PBMCs: Peripheral blood mononuclear cells 
ROIT: Rush Oral Immunotherapy  
sIgE: Specific Immunoglobulin E 
sIgG4: Specific Immunoglobulin G4 
SPT: Skin prick test 
TNF-α: Tumor necrosis factor-α 
Treg: Regulatory T cell 
α-LA: α-Lactalbumin 
β-CN: β-Casein 
β-LG: β-Lactoglobulin 
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1.1. FOOD ALLERGY IN THE PEDIATRIC AGE 
1.1.1. Food allergy ‒ an immune mediated adverse reaction to food  
There is no universally accepted definition for food allergy. The expert panel of the 
National Institute of Allergy and Infectious Diseases of USA (NIAID) defines food allergy as 
“an adverse health effect arising from a specific immune response that occurs reproducibly 
on exposure to a given food and is distinct from other responses to food, such as food 
intolerance, pharmacological reactions, and toxin-mediated reactions” (Boyce et al., 2010). 
Thus, we can roughly define food allergy as an immune-mediated adverse reaction to food. 
This immune response can be classified into IgE-mediated, non-IgE-mediated or a mixture 
of both (Muraro et al., 2014) (Figure 1). While IgE-mediated food allergy are responsible 
for most food allergic reactions and is characterized by the presence of food-specific serum 
IgE antibody to a food allergen, non-IgE mediated food reactions are associated with cell-
mediated mechanisms or antigen-specific antibodies other than IgE (Valenta et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Overview of adverse reactions to food. 
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1.1.2. Dietary proteins ‒ main food allergens 
An allergen is defined as the antigenic molecule giving rise to an allergic response and 
is virtually always proteinaceous in nature. Many factors may contribute to the overall 
allergenicity of any given protein (Huby et al., 2000; Bannon, 2004). Some, such the 
presence of epitopes with allergenic potential, may be essential. Others, such us the 
glycosylation status, resistance to proteolysis, and enzymatic activity, may play a subsidiary 
but nevertheless critically important role (Benedé et al., 2013). In view of that, and despite 
none of these factors is unique, a food allergen possesses three distinct molecular 
properties; the property to bind IgE antibodies, the property to elicit an allergic reaction and 
the property to sensitize an individual (Aalberse, 2000).  
Although more than 170 foods has been identified as triggers of allergic responses, 
those causing most of the significant allergic reactions include peanut, tree nut, egg, milk, 
fish, shellfish, wheat and soy (Sicherer and Sampson, 2010), being cow’s milk and egg the 
most common offending foods in children from continental Europe (Nwaru et al., 2014). 
Additionally, the number of identified incriminating foods continue to increase, which could 
either be the result of the globalization and thereby the introduction of new food containing 
potential new allergenic proteins (Van Putten et al., 2006). Since no single characteristic of 
a dietary protein is sufficient for predicting its allergenic potential, to develop an improved 
allergy risk assessment strategy for this novel proteins is a priority action for the research 
community. Advancing in research for factors influence the intrinsic ability of proteins to act 
as allergens, as digestibility and/or intestinal abortion, identification of allergenic epitopes 
and effects of the food matrix and processing on allergenicity are needed (Martos et al., 
2013; Benedé et al., 2014). 
 
1.1.3. Immunologic basis of IgE mediated food allergy 
 
Aalthough the immunological changes involved in food allergy have not been yet 
clearly understood, it is known that depends on a complex network of communicating 
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immune cells, which are the focus of intensive research. The primary immune cell lineages 
involved in the initiation and progression of the response include dendritic cells (DCs), mast 
cells, basophils, eosinophils, T cells and B cells.  
Allergic sensitization to proteins involves the induction of an IgE response of sufficient 
magnitude to facilitate the elicitation of an inflammatory reaction following subsequent 
exposure to the same (or a cross-reactive) allergen. When sensitization occurs via oral 
route, the main site to exposure to food allergens is the gastrointestinal tract. This means 
that for food allergens to initiate allergic sensitization, they must first overcome the normal 
gut barriers, including acidity, digestion, motility, mucin, layers and tight junction of the 
enterocytes that prevent passage of macromolecules (Rescigno, 2011).  
Two phases can be distinguished in the early pathogenesis of the IgE mediated food 
allergy; a sensitization and an effector phase (López-Expósito et al., 2013) (Figure 2). 
Briefly, a primary contact with the dietary protein where oral tolerance induction fails or is 
abrogated, leads to initiate the immune mechanisms when allergen activates antigen 
presenting cells (APC) (DCs are the major APC population involved) and other immune 
cells to enhance innate signals which instruct the differentiation of naïve CD4+ T cells 
preferentially into allergen-specific effector Th2 cells. These innate signals may include 
membrane bound ligands expressed on DCs, such as OX40L and Jagged (Blázquez and 
Berin, 2008), that interact with their respective receptors on T cells, as well as soluble 
mediators from other cells, such as IL-4, IL-25, IL-33 or TSLP. This differentiation and 
clonal expansion of naïve CD4+ T cells into allergen-specific effector Th2 cells producing 
IL-4 and IL-13 is followed by the induction of antibody class switching in B cells which are 
primed to become IgE secreting plasma cells. Allergen-specific IgE (sIgE) binds to the high-
affinity receptor FcεRI on the surface of mast cells and basophils and, thus, patient’s 
sensitization results. Effector phase occurs upon a subsequent contact with the allergen 
when cross linking of the FcεRI-bound IgE on sensitized basophils and mast cells activates 
them and undergoes degranulation and release of mediators responsible for the classical 
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symptoms of the immediate phase, such as histamine, cytokines and proteases. (Akdis and 
Akdis, 2015; Cabrera and Urra, 2015). 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overview of mechanisms leading to allergic reaction. 
 
1.1.4. Antigen-specific T-cell responses 
Naïve T cells are a pluripotent population capable of differentiating into a number of 
distinct phenotypes upon primary immunization and activation by APC. Effector T cells, 
upon activation in the primary response, secrete cytokines, proteins or peptides that 
stimulate or interact with other leukocytes, playing a role in orchestrating the immune 
response to the allergen (Berin and Shreffler, 2008). Some of these primed effector T cells 
develop into effector memory T cells (TEM), which upon re-encounter with antigen can 
rapidly produce a response to confer immediate protection in peripheral tissues. However, 
according to the duration of antigenic stimulation and the type and amount of cytokines 
present during priming, some differentiating T cells will become central memory T cells 
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(TCM) with a low activation threshold, which will be maintained for long periods 
predominantly in lymph nodes, from where they will be ready to expand and differentiate on 
a future exposure to the same antigen (Sallusto and Lanzavecchia, 2001).  
Different signals are necessary for T-cell activation and distinct effector T helper (Th) 
populations can be defined generally based on their respective cytokine profile. Activated 
allergen-specific Th2 cells produce IL-4, IL-5, IL-9 and IL-13, considered to drive the 
allergic response, through the maintenance of allergen-specific IgE (sIgE) levels, 
eosinophilia, recruitment of inflammatory cells to inflamed tissues, induction smooth muscle 
contraction and mucus secretion (Akdis and Akdis, 2009). As a consequence of these 
events, the more severe clinical manifestations of allergy, such as allergic rhinitis, atopic 
dermatitis, and in extreme cases, systemic anaphylactic reactions appear. Differentiated 
Th1 cells express high levels of IFN-γ which promote clearance of intracellular pathogens 
and their presence may counterbalance a dominant Th2 response. In response to allergic 
stimuli, naïve T cells have also been shown to express high levels of GATA3 and low levels 
of T-bet, master transcriptional regulators for many Th2 and Th1 genes, respectively 
(Grogan and Locksley, 2002). 
Failure of an immune deviation from an allergen-specific Th2 response to a Th1 
immune response has been proposed as the mechanism responsible for allergic disease. 
However, evidence suggests that dysregulation in the immune system involved in allergy 
cannot be explained simply by the Th1/Th2 dichotomy, and other effector T cell subsets 
can contribute to ongoing allergic reactions, such as Th17, Th9 and Th22 (Akdis et al., 
2011). Furthermore, in addition to the mentioned effector Th cell subsets, T cells with 
immunoregulatory properties exist and these are broadly referred as regulatory T (Treg) 
cells. Treg cells are characterized by the expression of the forkhead transcription factor 
FoxP3. Functional allergen-specific Treg cells have been demonstrated to have a pivotal 
role in inducing and maintaining immune tolerance through different mechanisms such as 
the suppression of mast cells, basophils, and eosinophils; the suppression of inflammatory 
dendritic cells and induction of tolerogenic dendritic cells; the suppression of allergen-
specific Th2 cells, hence preventing the provisional of survival factors for these allergy 
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effector cells; and the blocking and reduction of IgE production with an early induction of 
IgG4. All these mechanisms can be mediated via the secretion of IL-10 and/or TGF-β, or 
through cell contact-dependent suppression. IL-10 and TGF-β suppress IgE production by 
B cells, and meanwhile, IL-10 induces IgG4. (Palomares et al., 2010; Akdis and Akdis, 
2014).  
 
1.1.5. The immune response in the early childhood 
Several studies demonstrate that there are great differences, in terms of the 
characteristics and functionality of the immune system, between children and adults 
(reviewed in Simon et al., 2015). The immature immune system in early life is rapidly and 
continuously renewing and producing new cells (mainly T cells developed in the thymus) 
which make more adaptive responses against a specific antigen than those in adults.  
Neonates contain far fewer T cells than adults and it is known that function of early-life 
T cells is different from adults, reflecting the fetal life, where exposure to foreign antigens is 
largely restricted (Adkins, 1999). Foreign antigen activation of late fetal or neonatal T cells 
appear initially skewed towards Th2 immunity which is reinforced by neonatal DCs and 
epigenetic features (Holt, 2004). Therefore, a maturational deficiency in Th1 function 
seems to occur, but it tends rapidly to modify during infancy and consolidate presumably 
through influence of other antigenic exposure. One of the major sites that impacts on the 
development of the immune system is the gut. Gut environment and bacteria that colonize 
the gut have a profound influence on the response to many possible antigens (Rescigno, 
2014). Other different feature in the newborn immune system is the ability to form and 
expand new immunological memory comprising memory T and B cells, which becomes 
increasingly important as it have not yet encountered and established a memory bank to 
many pathogens (Simon et al., 2015).   
This immature scenario might be of special relevance in Treg cells which play a key 
role immune homeostasis of neonates (Correa-Rocha and Muñoz-Fernández, 2011). 
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Giving their suppressive nature, Treg cells are crucial in maintaining maternal-fetal 
tolerance and their values are increased during the pregnancy (Kahn and Baltimore, 2010). 
These values persist for an extended period of time giving the early-life immune response 
an anti-inflammatory profile. A dysfunction in Treg subset, either as a consequence of the 
immune system’s immaturity in childhood or by alterations in the generation of the 
repertoire of Treg, could be implicated in certain pathologies that occur in childhood as 
allergies, autoimmune diseases or immunodeficiency (Correa-Rocha et al, 2012).  
 
1.1.6. Epidemiology of food allergy  
Food allergy constitutes a major public health problem while their prevalence and 
persistence is increasing throughout the world. Allergic reactions can be life threatening 
and have far-reaching implications on affected patients and their families, not only upon 
safety but also on quality of life due to emotional and social restrictions and a remarkable 
healthcare spending. 
On the basis of numerous studies, the true prevalence of food allergy remains unclear 
because factors such as allergy definitions, study populations, methodologies, geographic 
variations, ages and dietary exposure, among others, influence the estimates (Sicherer, 
2011). More recent estimates indicate that food allergy affects 3.5%–5% of adults and 5%–
8% of children in Western countries (Chafen et al., 2010; Nwaru et al., 2014; Sicherer and 
Sampson, 2014). Although, knowledge about the epidemiology of food allergy is limited and 
there are global variations, evidence highlights that the prevalence of food allergy is rising 
in developed countries, with cow's milk, egg and peanut allergy representing most of the 
burden (Boyce et al., 2010).  
 
1.1.7. Causes of food allergy onset 
The causes of food allergy are still unknown and a plethora of risk factors are 
proposed to influence their development, including race, genetics, dietary and 
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environmental factors and characteristic of food allergens (Cochrane et al., 2009; Lack, 
2012). Besides these questions, it is generally assumed that the increase in prevalence of 
allergic reactions concur with aspects of the westernized lifestyle such as changes in air 
pollution, indoor exposure to allergens and a lack of early childhood exposure to infectious 
agents. Such theory, collectively known as the ‘hygiene hypothesis’, argues that extreme 
cleanliness and a lack of early childhood exposure to pathogens, symbiotic harmless 
organisms in the gut, skin and elsewhere and parasites increases susceptibility to allergic 
diseases by suppressing natural development of the immune system. It means that children 
need contact with the microbial biodiversity from the environment for the proper maturation 
and development of the immune system (Wills-Karp et al., 2001; Okada et al., 2010).  
Genetic predisposition seems to be an important determinant; however, no accurate 
markers associated with food allergy have been identified, suggesting that multiple genes 
and important gene-environmental interactions have implication for development of food 
allergy (Hong et al., 2009; Lack, 2012).  
The gut microbiota is also likely to be a crucial factor and may help explain why allergy 
prevalence is increasing. Differences have been found in microbiota between allergic and 
non-allergic children (Abrahamsson et al., 2012), suggesting certain changes in the pattern 
of intestinal colonization and microbes may be more important to sensitization than others 
(Azad et al., 2015; Bunyavanich et al., 2016). Other factors, which may simultaneously 
influence the gut microbiota, are suggested to contribute for the development of allergy: the 
age at which solid food is introduced, breast versus formula feeding, degree of 
gastrointestinal infection, intestinal permeability, mechanisms and site of intestinal antigen, 
absorption and adjuvant effects (Cochrane et al., 2009).  
The marked changes in diet over the past several decades have been also suggested 
as influential factors; vitamin D insufficiency, reduced consumption of omega-3 fatty acids, 
reduced consumption of antioxidants and the inflammatory state triggered by obesity 
(Sicherer and Sampson, 2014). Within this context, vitamin D raises a particular interest 
since that there is a growing body of literature linking vitamin D status in the regulation of 
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immune function. More recently variations in vitamin D status and intake have been 
considered it for epidemiological and immunological studies on allergies (Reinholz, et al, 
2012). Nowadays, it is known that several tissues in the body possess receptors for the 
active form of vitamin D, 1α,25-dihydroxyvitamin D3, and that immune cells including 
macrophages, epithelial cells and DCs, are capable of converting the circulating inactive 
form 25-hydroxyvitamin D (25(OH)D) to the active metabolite (Chambers and Hawrylowicz, 
2011). This inactive 25(OH)D represents the main circulating vitamin D metabolite and is 
the most reliable parameter to define human vitamin D status (Heaney, 2012). The active 
form of vitamin D is an important immune system regulator showing direct effects on naïve 
and activated Th cells, Treg, activated B cells and DCs (Jones et al., 2012). Between the 
main immunomodulatory properties of vitamin D, its impact on Treg has been largely 
proposed. Several studies demonstrated that vitamin D contribute significantly to the 
induction, survival and preservation of the Treg population (Penna et al., 2005; Chambers 
and Hawrylowicz, 2011; Vijayendra et al., 2015). Additionally, numerous studies showed a 
relationship between decreased values of vitamin D, in both mother and infant, and a 
higher incidence of allergy (Chiu et al., 2015; Jones et al., 2015; Vijayendra et al., 2015). 
Because of the growing interest, this is a priority area for future research and studies will be 
crucial to further understand the potential link between vitamin D status and Treg induction 
and function. 
 
1.1.8. Diagnosis of food allergy 
Several diagnostic tools are available for the diagnosis of food allergy (Sicherer and 
Sampson, 2010; Sampson et al., 2014). First evaluation requires a thorough history and 
physical examination to determine the possible causal food or food and reaction 
consistency. To arrive at a diagnosis, specifically whether the food-induced allergic disorder 
is likely IgE mediated, the clinician should consider appropriate testing that can be 
evaluated in the context of these prior probability estimates. Serum immunoassays to 
determine food sIgE antibodies and skin prick tests (SPT) are rapid means to detect 
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sensitization (Sporik et al., 2000; García-Ara et al., 2001; Heinzerling et al., 2013). 
However, the appropriate diagnosis became more complicated by the fact that symptoms 
representative of IgE mediated food allergy may appear in patients without detectable 
levels of sIgE as well as detection of sIgE does not necessarily correlate with clinical 
symptoms (Sampson et al., 2014). To confirm diagnosis, an oral food challenge (OFC) is 
often used, in which the potential allergen is gradually fed in increasing doses under 
supervision to determine tolerance or clinical reactivity. The gold standard test for the 
diagnosis of food allergy is the double-blind, placebo-controlled OFC (DBPCFC) as 
minimizes biases (Bindslev-Jensen et al., 2004). However, there is yet to be universal 
standardization of the interpretation of challenge results, particularly in research setting. 
Authorities, the European Academy of Allergology and Clinical Immunology (EAACI) and 
the American Academy of Asthma, Allergy & Immunology, have published a consensus 
report on the standardization of DBPCFC (Sampson et al., 2012) and a recent framework 
for improved documentation and harmonized interpretation of DBPCFCs has been reported 
(Grabenhenrich et al., 2016). 
 
1.1.9. Treatment of food allergy and future directions 
There are no approved interventional treatments for food allergy. The only currently 
accepted treatment for food allergy is complete avoidance of the offending allergen which 
can be difficult and has a negative impact on patient and families quality of life.  
Considering that, a number of novel therapeutic strategies are under investigation. The 
therapies undergoing the most extensive research are oral and sublingual immunotherapy, 
where doses of the dietary protein are given in progressively increasing quantities toward a 
steady dose, for induction of desensitization. Other food allergen-specific strategies include 
subcutaneous and epicutaneous immunotherapy (Tordesillas et al., 2017); peptide 
immunotherapy (Yang et al., 2009; Rupa and Mine, 2012) together the development of 
peptide-based hypoallergenic derivatives of major food allergens (Lozano-Ojalvo et al., 
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2016); and gene therapy using bacterial plasmid DNA. Allergen non-specific strategies 
include recombinant vaccines; strategies through via antibodies (Berin and Mayer, 2013); 
the administration of probiotics and prebiotics to manipulate the gut microbiota (Simonyte 
Sjödin et al., 2016); epigenetics with allergy candidate gene-specific changes in DNA 
(Hong and Wang, 2014); Chinese herbal medicine called food allergy herbal formula; and 
the use of anti-cytokines and toll-like receptor agonists (Berin and Sicherer, 2011; Nowak-
Wegrzyn and Sampson, 2011; Wood, 2016). 
Future challenge is to understand the mechanisms responsible for establishment of 
food allergy along with restoration of natural or induced tolerance which would enable to do 
a most accurately diagnosis, prevention, treatment and management of food allergies 
(Sampson, 2016). In this context, oral immunotherapy attracts considerable attention as 
successful desensitization has been demonstrated in multiple exploratory trials. However, 
despite the clear progress and interest toward this therapy, there are still many questions to 
be answered and parameters to accurately define before OIT becomes an accepted option 
outside of the research setting (Bégin et al., 2014). 
 
1.2. FOOD ORAL IMMUNOTHERAPY  
1.2.1. What is oral immunotherapy? 
Oral immunotherapy involves mixing an allergenic food into a vehicle and consuming it 
in gradually increasing doses (Burbank et al., 2016). Protocols vary in the type of food and 
vehicle substance used for OIT, whit some using commercially available foods in their 
natural forms (e. g. liquid milk, ground peanuts) whereas others use prepared products 
such as defatted peanut flour or dehydrated egg white (EW).  
 
 
 
24 |   Introduction 
 
1.2.2. Regimens and phases in OIT 
Most food OIT protocols include 2 phases, a first induction phase which is followed by 
a maintenance phase (Figure 3).The induction phase, also called build up phase, often 
includes an initial escalation stage done over a single day with a fast up-dosing, opening 
from a very small dose that is gradually increased. If well-tolerated, the dose is escalated 
incrementally during a buildup period (usually biweekly or weekly) until a target 
maintenance dose is reached. This phase must be performed in a setting monitored by 
health professionals, as most reactions occur, and the purpose is to safety begin OIT in a 
subthreshold starting dose and identify a permissible daily dose for home administration. 
Generally, the initial doses are in microgram quantities of allergenic protein, often requiring 
liquid preparation/dilution, and can be advanced to the solid OIT product in the range of 
several milligrams by the end of this phase. Maintenance therapy continues with daily 
administration in the home, with a variable duration of months or even years (Nowak-
Węgrzyn and Albin, 2015).  
A distinction should be made between approaches that induce desensitization versus 
those in which oral tolerance is achieved. If this maintenance dose is successfully 
achieved, the patient is said to be desensitized, that is, an increase in the threshold for 
reactivity is reached but in a desensitized state the protective effect requires continued 
consumption of the allergenic protein to prevent the reappearance of reactivity. Therefore, 
after that, the maintenance dose may be discontinued for a pre-specified amount of time 
and the patient again undergoes a challenge with the offending food. If the subject does not 
react, he or she has been said to have achieved oral tolerance, which is referred to 
“sustained unresponsiveness” (Burks et al., 2012; Kobernick and Burks, 2016). This is the 
ultimate aim of OIT, the ability to tolerate the food after discontinuing ingestion of the 
allergen for a period of at least 4-12 weeks (Rolinck-Werninghaus et al., 2005). Although a 
number of studies have demonstrated that the majority of patients treated with OIT can be 
desensitized successfully to a particular food, sustained unresponsiveness is achieved less 
commonly (Nowak-Węgrzyn and Albin, 2015). To date, it is unclear whether permanent 
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tolerance is a function of the duration of OIT and may be achieved in any allergic individual 
if the OIT is continued long enough or whether some allergic individuals will never become 
truly tolerant. In view of that, evaluation of immune changes that occur during 
immunotherapy becomes relevant to gain insight into the mechanisms of allergic 
sensitization and regulation of tolerance to food allergens.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Typical protocol for food oral immunotherapy. 
 
1.2.3. Immune response to food allergens during OIT 
There is little current knowledge regarding the immunological changes and 
mechanisms subjacent to OIT. In humans, the examination of the immunological 
mechanisms of oral desensitization for food allergy has hampered by several problems. 
First, unpredictable allergic reactions in patients have resulted in desensitization courses 
that vary from months to years. In addition, blood samples volumes are small within 
children and food-specific T cells constitute a very small fraction (< 1%) of peripheral T cell, 
being difficult to study.  
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In the early stages, active suppression of immune responses seems to occur with an 
increase in food-specific IgG4 (sIgG4) (Burks et al., 2012; Vickery et al., 2013) and 
decreased and mast cell and basophil responsiveness (Thyagarajan et al., 2012). Allergen 
sIgG4 antibodies are thought to capture the allergen before reaching the effector cell-bound 
IgE, and thus to prevent the activation of mast cells and basophils and inhibit the release of 
mediators. Allergen sIgE levels increase initially and then gradually decrease, and some 
studies have shown that OIT alters the binding pattern of antigen to IgE, possibly through 
changes in the diversity of epitope recognition or altered antigen affinity (Wang et al., 2010; 
Vickery et al., 2013). This outcomes agree with a meta-analyses of 21 controlled trials that 
associate desensitization with a significant reduction in sin prick test responses to the 
relevant food (mean difference -2.96 mm) and an increase in sIgG4 (mean increase 19.9 
µg/ml), whereas do no report a reduction in allergen sIgE (Nurmatov et al., 2014). The 
evaluation of basophil suppression during OIT has been addressed by several authors. In 
2009, Wanich et al. showed that allergen-specific basophil reactivity and suppression is 
associated with clinical unresponsiveness in children with milk allergy. Results of 
Thyagarajan et al. (2012) also demonstrated that OIT suppress basophil responsiveness in 
a peanut OIT study performing an in vitro stimulation of peripheral blood with peanut 
allergen and supporting the hypothesis that OIT induced a pathway-specific basophil 
anergy. 
Induction of peripheral T-cell tolerance is a crucial step and the allergen-specific 
changes in T-cell phenotype during OIT and seems to occurs with a shift away from Th2 
cytokine production toward a proinflammatory profile characterized by increased production 
of IL-1β and TNF-α (Jones et al., 2009; Blumchen et al., 2010; Varshney et al., 2011). 
However, little information is known about which immune mechanisms or alterations are 
responsible for triggering this inflammatory cascade that develops the onset of allergy and 
the evidence about the specific immune subsets implicated in the process of tolerance is 
very scarce. In a previous study reported by Fuentes-Aparicio et al. (2012), it was 
postulated that OIT highly probable could modify the immune homeostasis and the 
changes would be reflected in the systemic immune populations. It was observed that 
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allergic children have a higher percentage and absolute counts of  peripheral effector-
memory T cells (TEM) than healthy controls, which play a key role in allergy (Tiemessen et 
al., 2004), and after OIT these values returned to levels similar to those of healthy children 
(Fuentes-Aparicio et al., 2012). Moreover, interestingly, it was also found that OIT modified 
values of T cell subsets could being implicated in such origin a marked thymical production 
of a particular subset of new T cells with a hypo-proliferative and non-reactive phenotype 
(CD38/ROneg) (Fuentes-Aparicio et al., 2012). The replacement of TEM by a subset of 
CD38/ROneg cells would ensure a selection of non-reactive T cell clones reducing the 
immune response against the allergen. A similar observation has been recently reported by 
Bégin and Nadeau (2015) with data of a peanut OIT study. Authors sequenced T-cell 
receptors of peanut-proliferative CD4+ T cell, finding a small number of clones consistent 
overt time only in subjects receiving peanut OIT, which suggest a possible mechanism of 
replacement of peanut-proliferative T cells. Ryan et al. (2016) have also recently 
investigated this point performing a single-cell sorting and transcriptional profiling of 
individual T cells collected throughout peanut OIT. Authors showed that sustained OIT 
success, even after immunotherapy is withdrawn, is associated with the induction, 
expansion, and maintenance of peanut-specific memory and naive T-cell phenotypes. 
Thus, an issue of concern in OIT is whether the observed immune changes during the 
therapy results from a reprogramming of existing allergen-specific T cell clones or from 
their replacement by different clones to determine the dominant response. 
Since the immune response to allergens is the result of a balance between Treg and 
effector T cells, in the recent years there has been considerable interest about the role of 
Treg in OIT-mediated desensitization to food. In egg and peanut allergies, OIT protocols 
have been reported with an in vitro increase of Treg from peripheral blood mononuclear 
cells (PBMC) (Jones et al., 2009; Varshney et al., 2011; Urra et al., 2012). In a previous 
egg OIT study, our group also showed the relevance of Treg subset whose frequency and 
absolute numbers was significant increased when egg desensitization was achieved 
(Fuentes-Aparicio et al., 2014). Moreover, going further, we observed that OIT induced a 
profound change in the Treg/TEM ratio, as Treg increase was associated with a decrease in 
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effector immune cells implicated in the allergic process. Interestingly, data of the same 
study also allowed seeing a direct correlation between the frequency of effector Treg 
subset and the number of circulating basophils in egg allergic children.  
Presumed mechanisms of action for OIT involved gut immunity, which affect the 
allergic response through immunomodulation of circulating cells. Oral tolerance is thought 
to originate in the gut, which support the generation of FoxP3+ Treg cells. There is 
evidence relating oral tolerance with the capacity of the mucosal DCs to induce FoxP3+ 
Treg cells in mesenteric lymph nodes. In mouse models, in conjunction with improved 
tolerance to the food, OIT resulted in an increase in CD4+CD25+FoxP3+ cells and IL-10 
and TGF-β-producing Tregs in the lamina propia (Smaldin et al., 2015). The immune 
responses locally in the gut are poorly understood in human. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Oral Immunotherapy-induced immune changes in T cells, B cell responses (IgE and 
IgG4) and basophil activation. 
 
1.2.4. The search for better diagnostic and predictive biomarkers in food allergies 
Novel insights into how the immune system works in response to OIT are pointing the 
way toward development of food allergy biomarkers and therapies.  
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As mentioned above, particular subsets of CD4+ T cells could constitute a marker of 
the development of oral tolerance and, therefore, due the potential importance of 
monitoring T cells during OIT, single-cell approaches and the immune monitoring of 
individuals undergoing OIT may be useful.  Moreover, while peripheral responses of 
effector Th1 and Th2 cell subsets has been addressed during OIT studies, the involvement 
of other effector T cell subsets, such as Th9, Th17 and Th22, are poorly investigated. The 
study reported by Fuentes-Aparicio et al. (2012) described a decrease in the serum 
associated-cytokines to these responses (IL-9, IL-17A and IL-22) of egg allergic children 
desensitized with egg OIT. In a work of Dhuban et al. (2013), Th17 responses to antigen 
stimulation were impaired in peanut allergic children, suggesting the potential use of IL-17 
as biomarker for tolerance to food antigens. However, there is a lack of studies 
investigating the antigen-specificity of such responses to human OIT.  
The possible implication of other allergy-related subsets of cells, as B cells, in 
successful immunotherapy also raises interest. An aforementioned study of our group 
(Fuentes-Aparicio et al., 2012) revealed that the percentage of B cells remained unchanged 
in egg allergic children after OIT.  In a recent report of peanut OIT, an early and transient 
expansion of circulating peanut-specific memory B cells that peaks at week 7 have been 
described (Patil et al., 2015). Moreover, the kinetics of the induced antigen-specific memory 
B cell population demonstrates that the rise in peanut-specific IgA, IgG, and IgG4 begins at 
about the same time as the peak expansion of this population. Thus, one way to address 
the potential relevance of OIT-induced changes is to isolate antigen-specific B cells and 
study them on a clonal level. Moreover, the population of regulatory B cells (Breg), which 
are able to secrete IL-10, are being extensively investigated. The Breg cell subset 
characterized in human blood as CD24+ CD27+ B cells can negatively regulate monocyte 
cytokine production via IL-10 dependent pathways (Iwata et al., 2011). Along these 
preliminary data, B cells and specific Breg subset could be potential biomarkers to study for 
novel allergen-specific immunotherapies (Fujita et al., 2012).  
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While it is expected that allergen-specific OIT reflects changes in allergen sIgG4 and 
sIgE levels, the levels of allergen-specific IgG1 (sIgG1) and IgA are poorly investigated 
(Savilahti et al., 2014a). IgG4 acts as a blocking antibody for sIgE whereas allergen-
specific IgGs inhibit IgE-mediated cell degranulation (Uermösi et al., 2014). Results of a 
recent trial of egg OIT (Sugimoto et al., 2016) suggests that the presence of high serum 
levels of allergen sIgG1 after the build-up phase of OIT and high levels of IgA in longer OIT 
are potentially suitable biomarkers for positive immune responsiveness to OIT.  
A recent work has shown that signals from the skin to the gut may govern the 
perpetuation to allergic reaction to food antigens (Wang, 2016). Epidermal IL-33 and TSLP 
induced after injury, stress, or environmental factors can trigger the onset of allergic 
reactions through activation of DCs with the ability to induce a Th2 cell response. In 
addition, allergic sensitization also results in the increase of intestinal epithelial-derived 
cytokines TSLP, IL-33 and IL-25, which also propagates the allergic response (Wang and 
Liu, 2009). IL-33 also promotes the function and maturation of IL-9-producing mucosal 
mast cells, which increased clinical reactivity to food allergens (Chen et al., 2015; Benedé 
et al., 2016). Further study of these complex pathways will provide the discovery of 
biomarkers and therapeutic targets.   
Emerging evidence also highlight the important influence of commensal gut microbiota 
in oral tolerance, as initially suggested by the observation that mice raised in a germ-free 
environment did not have normal tolerance (Hazebrouck et al., 2009), as well as mice 
treated with antibiotics or whose gut microbiota were compromised. About human studies, 
Bunyavanich et al. (2016) have recently published an association between early-life gut 
microbiota and the resolution of cow's milk allergy, suggesting that bacterial taxa within 
Clostridia and Firmicutes could be studied as probiotic candidates for milk allergy therapy. 
However, it still remains unclear which bacteria (or other microbes), in which numbers and 
combinations, and when during the gut colonization process may prevent allergic diseases 
(Simonyte Sjödin et al., 2016). 
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1.3. COW'S MILK ORAL IMMUNOTHERAPY 
1.3.1. Cow's milk protein allergy overview 
Cow's milk protein allergy (CMPA) is the most common food allergy among infants in 
Europe, with prevalence rates estimated in the range of 2% and 3% (Boyce et al., 2010). 
Although spontaneous resolution generally occurs in most infants (at around 50%) with IgE-
CMA within the first 3-6 years (Elizur et al., 2012; Wood et al., 2013), studies suggest 
varying results (19-79%) to the rate of resolution during childhood (Skripak et al., 2007; 
Santos et al., 2010).  
Unfortunately, the first line treatment of CMA is the total avoidance of milk to prevent 
adverse reactions, which can be life-threatening. Nevertheless, milk exclusion involves a 
wide dietary restriction, which leads to negative nutritional, social, psychological and 
economic consequences. Moreover, because of cow´s milk (CM) ubiquity, avoidance 
cannot be always guaranteed and accidental reactions may occur (Boyano-Martínez et al., 
2009).  
 
1.3.2. Mayor allergens in cow's milk 
Cow's milk contains around 3 to 3.5% of proteins and the main characteristics that 
should be emphasized are the multiplicity and diversity of proteins that may be involved in 
allergic sensitization, which include approximately 20 different proteins (Herz, 2008).  
Moreover, polysensitization to several proteins most often occurs, and the milk proteins of 
different mammalian species as goat and ewe, become to be potential allergens (Järvinen 
and Chatchatee, 2009; Rodríguez del Río et al., 2012). 
 Between cow’s milk protein, caseins (CN, Bos d 8), which constitute 80% of the total 
milk proteins are described as the most allergenic ones, followed by β-lactoglobulin (β-LG, 
Bos d 5) and α-lactalbumin (α-LA; Bos d 4), are the major allergens from the remaining 
whey protein fraction (Monaci et al., 2006). However, proteins present in very low 
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quantities, such as bovine serum albumin (BSA, Bos d 6), immunoglobulins, and especially 
lactoferrin, also appear to be important, since some authors have reported even 35%-50% 
sera from allergic patients respond to those proteins and sometimes to those proteins only 
(Wal et al., 1995). 
The effect of industrial processing (pasteurization, ultra-high-temperature-heating, or 
dry blending for cow's milk proteins biological activity is minimal (Nowak-Wegrzyn and 
Fiocchi, 2009). However, in these considerations not only the temperature and time of 
heating have implications but also the possible interactions within the food matrix could 
affect (Nowak-Wegrzyn et al., 2008).  
 
1.3.3. Cow's milk Oral Immunotherapy Trials 
As in any other food OIT protocol, cow´s milk oral immunotherapy (CM-OIT) involves 
administering small, increasing doses of cow´s milk during a build up phase followed by a 
maintenance phase with regular intake of a maximum tolerated amount (around 200 mL) 
(Brożek et al., 2012; Martorell et al., 2014). Methods and protocols vary, together with 
patient’s characteristic (age, severity or the reactions and level of sensitization), and thus, 
the results between studies are difficult to compare. In order to put into context how 
scientific literature on CM-OIT answers some of the most relevant questions on this field, 
the key features of some of the most relevant CM-OIT studies are summarized below in 
Table 1., listed in chronological order. In the conventional protocols, the initial build up 
phase is performed over weeks to months (Figure 3). In contrast, an alternative build up 
phase consists of doses which are doubled and given several times a day over a few days 
period (commonly 1- to 5-days period) is also reported for cow's milk allergy (Bauer et al., 
1999; Martorell et al., 2007; Staden et al., 2008; González-Jimenez et al., 2013), as well as 
the combination of a rush desensitization followed by a conventional procedure (Longo et 
al., 2008).  This attempt of rush oral immunotherapy (ROIT), tries to be capable to rapidly 
desensitize patients to allergens, confirming safety and improving the compliance with 
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therapy. Other additional measures also tries to minimize the rate of adverse reactions, as 
initiating therapy with sublingual immunotherapy (SLIT) followed by OIT (Keet et al., 2012; 
Frichmeyer-Guerrerio et al., 2014) or performing the build up phase in combination with 
anti-IgE monoclonal antibodies (omalizumab) (Nadeau et al., 2011). 
Previous studies have shown desensitization rates of 30-92% after a wide array of 
protocols, but it still has to be established whether a true tolerance with long-lasting effect is 
achieved and it is possible that the observed very large effects of immunotherapy on 
achieving tolerance of cow’s milk were due to naturally acquired unresponsiveness (Wood 
et al., 2013). So far, no uniform protocol has been developed and the results are somehow 
controversial because of the uncertainty of the immunological mechanisms reflected. 
Desensitization status, that is, an increasing in the threshold dose which triggers 
symptoms, has a positive benefit in patient’s nutrition and quality of life, allowing patients to 
eat a wide range of products that contain CM and protecting them against reactions on 
accidental exposure. However, daily consumption of CM seems to be needed to be 
maintained and is not known for how long the regular intake must be followed, which is the 
minimum dose and minimum time interval between single doses (days or weeks) 
necessary to maintain desensitization and whether the elimination diet may even increase 
the chance for developing more severe allergic reactions when the ingestion is 
reintroduced (Niggemann et al., 2006). Regarding this issue, Pajno et al. (2013) showed in 
their CM-OIT trial that the achieved tolerance to CM can be maintained with milk given 
twice weekly, without a mandatory daily. From today’s perspective, CM-OIT has pros and 
cons and there is still a lack of sufficient evidence for introduced it in the common clinical 
practice (Yeung et al., 2012; Kostadinova et al., 2013). The disadvantages are the 
following: risk of and adverse reaction, parent’s fear, low compliance, poor accessibility to 
allergist, and distance to the hospital. In contrast, the benefits observed were dietary 
improvement and the general subjective perception of a better quality of life.  
Before starting the protocol, it is important to thoroughly consider clinical predictors for 
favorable outcomes in order to identify which patients might represent those for whom 
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therapy is more appropriated. Children with low to moderate sIgE levels (Staden et al., 
2007; Sicherer et al., 2010; García-Ara et al., 2013), low initial starting dose and those who 
not require adrenaline during induction (Álvaro et al., 2012; Levy et al., 2014) would be 
expected to respond better to OIT and they are the less likely of spontaneous tolerance 
(Wood et al., 2013). Nevertheless, these high risk patients would probably be those with 
the greatest benefit since they are more likely to have persistent food allergy and their 
reactions can be life threatening.  
It remains to be elucidated why some children succeeded in CM-OIT and others do 
not. Currently, there is little knowledge regarding the immunological changes and 
mechanisms subjacent to CM-OIT, and therefore, it is crucial to propose predictors to 
accurately define the efficacy and the risk of adverse reactions. In general, the different 
studies performed have highlighted an increase in the levels of allergen sIgG4 (Skripak et 
al., 2008; Pajno et al., 2010; Keet et al., 2012; Savilahti et al., 2014a; Savilahti et al., 
2014b; Salmivesi et al., 2016),  together with a decrease in allergen sIgE response (Longo 
et al., 2008; Martorell et al., 2011; Álvaro et al., 2012; Keet et al., 2012; González-Jimenez 
et al., 2013; Vázquez-Ortiz et al., 2013; Savilahti et al., 2014a; Savilahti et al., 2014b; 
Salmivesi et al., 2016), although in the case of this sIgE response the results between 
studies are somehow controversial (Meglio et al., 2004; Zapatero et al., 2008; Pajno et al., 
2010; García-Ara et al., 2013). Moreover, CMA resolution involves not only sIgE and Ig4 
but also IgG1 and IgA (Savilahti et al., 2014a). In the last years, the diversity and affinity of 
IgE and IgG4 binding to epitopes on CM proteins have been study in children undergoing 
CM-OIT and several authors suggest it may help because of such epitope binding 
correlates with severity of allergic symptoms and the natural development of tolerance in 
CMA (Savilahti et al., 2014b; Martínez-Botas et al., 2015).  
The balance between Treg and promoting Th2 T cells appears to be decisive and 
whether T cell response and expression of key cytokines are associated with 
desensitization of milk allergic patients is poorly investigated. To the best of our knowledge, 
there is only one report available characterizing the CM-specific T-cell response of milk 
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allergic patients before and after a CM-OIT protocol (Bedoret et al., 2012). Trying to go 
deeply in this line, Salmivesi et al. (2016) have reported the changes in the Th-2 type 
cytokines IL-4 and IL-5, together with IL-10 involves in Treg response, in the serums of CM 
allergic patients during a six month CM-OIT intervention. The presumed mechanism of 
action for CM-OIT through which dendritic cells induce and maintain Th2 allergen-specific 
cells has been also addressed by Frichmeyer-Guerrerio et al. (2014). Authors showed that 
CM-OIT reduces CM-induced Th2 cytokine responses by CD4+ T cells when co-cultured 
with plasmacytoid dendritic cells.  
Summarizing and taking all of this evidence together, larger clinical studies are needed 
to verify these findings and a future greater understanding of the immune responses and 
mechanisms that contribute to the effectiveness of CM-OIT will enhance the efficacy and 
safety of these therapies made it possible its application as a common CM treatment in the 
clinical practice.  
 
  
CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Meglio et al. 
(2004) with follow-up  
Meglio et al., (2008) 
 
N=21 
 
Aged 5-10 years 
 
Non-randomized, non-controlled 
 
Build up: mean of 201 days, 
target  200 ml of CM 
 
Follow-up: 5 years and 8 months 
 
 
 
Desensitization: 
71.4% totally desensitized 
(N=15) 
14.3% partially 
desensitized (40-80 ml) 
(N=3) 
 
Follow up: N=20 
70% tolerated CM 
 
Changes OIT between baseline and desensitization: 
↓ SPT to CN and α-LA 
n.s. in CM-sIgE, CN-sIgE and β-LG-sIgE  
 
Changes OIT between baseline and long follow up: 
↓ CN-sIgE  ↓  α-LA-sIgE  and ↓ SPT to CN and  α-LA 
 
Changes between post desensitization and long follow up: 
↓ α-LA-sIgE 
 
Martorell et al. 
(2007) 
 
N=4 
 
Aged 19 months- 5 
years 
 
Rush protocol.  
Non-randomized, non-controlled 
 
Build up: 5 d, target 200 ml of 
CM 
 
Maintenance: 200 ml of CM 
daily 
 
Follow up: 1, 6 months and 1, 2, 
3 years 
 
Desensitization: 100% 
Only 1 case of risk of 
anaphylaxis solved with 
medication in few min 
 
Long follow up: 100% 
taking CM with good 
tolerance 
 
During OIT: 
↓ CN-sIgE progressively during longer time of following (not detectable 
at 3 years) 
 
Staden et al. 
(2007) 
 
N=25 OIT group 
N=20 Control group 
 
Aged 1-3 years 
 
Randomized, controlled 
 
Build up: median of 7 months 
(70 days - 12 months), target 
250 ml of CM.  
Planned in 67 days 
 
Maintenance: medium of 9 
months (7- 15 months), ≥ 100 ml 
of CM daily.  
 
Desensitization 
OIT group: 
36% (N=9) full tolerance 
(250 ml)  
12% (N=3) tolerant with 
regular intake 
16% (N=4) partial 
tolerance 
 
Control group: 
35% (N=7) tolerant 
 
OIT group vs Control group (baseline): 
n.s. in sIgE 
 
During OIT in OIT group: 
↓ sIgE in the group of desensitized children following OIT (N=16) 
n.s.  in sIgE in children who fail desensitization (N=9) 
 
During OIT in Control group: 
↓ sIgE in the group of children who become tolerant following OIT 
(N=7) 
n.s. in sIgE in children who maintain the allergic status (N=13) 
  
 
CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Longo et al. 
(2008) 
 
N= 30 (OIT group) 
N= 30 (Control group) 
 
Aged 5-17 years 
 
Rush protocol. 
Randomized, single-blind, 
placebo-controlled 
 
Build up: rush phase 10 d, target 
20 ml of CM with progressive 
increase at home with target 150 
ml 
 
Maintenance: ≥ 150 ml CM daily 
 
 
Desensitization: 
30% rush phase in 10 d 
0% control 
 
Maintenance (12 months): 
36% completely  and  
54% partially (OIT group) 
0% Control 
 
OIT group: 
↓ CM-sIgE 
(baseline-6 months 
(baseline -12 months) 
 
Control group: 
CM-sIgE essentially unchanged in control group, it is only observed a 
slight reduction in N=3 
 
Skripak et al. 
(2008) with follow up 
by Narisety et al. 
(2009) 
 
N=13 OIT group 
N= 7 placebo group 
with N=6 subsequently 
open label-treated 
 
Aged 6-13 years 
 
 
Double-blind, placebo- 
controlled 
 
Commercial dry nonfat 
powdered milk 
 
Build up: 10 weeks, target 500 
mg (15 ml CM) 
 
Maintenance: 500 mg daily  If 
tolerance ≥ 2500 mg (23 weeks) 
in DBPCFC continue protocol 
 
Desensitization: 
92% OIT 
Median threshold dose 
with DBPCFC was 
increased to 5.140 mg 
compared with 40 mg for 
placebo 
 
Open label-treated group: 
after OIT the median 
threshold dose with 
DBPCFC was increased 
to 8.140 mg (baseline 40) 
 
 
 
 
 
 
 
During OIT: 
↑ CM-sIgG, particularly sIgG4 but suggesting that other IgG subclasses 
are implicated. (OIT group) 
↓ SPT to CM (OIT group) 
↓ SPT to CM (Placebo group) 
n.s.in CM-sIgE 
 
Open label-treated group: 
↑ CM-sIgG4  and ↓ SPT to CM  
 
 CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Zapatero et al. 
(2008) 
 
N=18 
 
Aged ≥ 4 years (mean 
of 5 years) 
 
Non-randomized, non-
controlled, prospective 
 
Build up: median of 14 weeks 
(9-32 weeks), target of 250 ml of 
CM  
Planned in 10 weeks 
 
Maintenance: normal diet with 
milk drunk freely 
 
Desensitization: 
88.8% totally desensitized 
(N=16) 
5.5% partially 
desensitized (40 ml) 
(N=1) 
 
Follow up: 6 months 
 
Long follow up: 100% of 
totally desensitized 
children (88.8%) 
continued a diet without 
restriction of milk (8 
months-1 year) 
 
 
Changes OIT between baseline and the end of desensitazion: 
↓ SPT to CM 
↓ CN-sIgE 
n.s. CM- α-LA- and β-LG sIgE 
 
Changes OIT between baseline and 6 mo follow up: 
↓ SPT to CM 
↓ CN-sIgE 
n.s. CM- α-LA- and β-LG sIgE 
 
 
Pajno et al. 
(2010) 
 
N=15 (OIT group) 
N=15 (Placebo group) 
 
Aged 4-10  years 
 
Randomized, singe-blind, 
Placebo-controlled 
 
CM (OIT) 
Soy milk (placebo) 
 
Build up: 18 weeks, target 200 
ml 
 
Maintenance: 200 ml of CM 
daily 
 
 
 
 
Desensitization: 
67% OIT group 
0% Control group 
 
 
Maintenance: 67% (6 
months) 
 
OIT vs Placebo: 
↑ CM- specific IgG4 (18 weeks) 
n.s.: CM-specific IgE (transient decrease at early build up) 
 
During OIT: 
↑ CM-specific IgG4 (baseline-18 weeks) (12 weeks -18  weeks) 
n.s.: CM-specific IgE 
  
CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Martorell et al. 
(2011) 
 
N= 30 OIT group 
N=30 Control group 
 
Aged 2-3 years 
 
Randomized, controlled, 
parallel-group, 
multi-center. 
 
Build up: 6-12 months, target 
200 ml of CM 
 
Maintenance: 12-17 months in 
OIT and 12-15 in Control with ≥ 
200 ml CM daily and dairy 
products  without restrictions 
 
 
Desensitization: 
90% OIT group 
23% Control group 
 
Follow up: 90% following 
a dairy diet without 
restrictions (12 months) 
 
OIT from baseline to 12 months: 
↓ CM-sIgE ↓ CN-sIgE (OIT group) 
↓ SPT to CM (OIT group) 
n.s.  in any markers (Control group) 
 
 
OIT vs Control: 
↓ CM-sIgE and ↓ CN-sIgE (12 months) 
↓ SPT to CM (12 months) 
n.s. changes at baseline 
 
 
Nadeau et al. 
(2011) with 
immunologic changes 
in 
Bedoret et al. 
(2012) 
 
N=11 
 
Aged 7-17 years 
 
Non-randomized, non-controlled 
 
Dried nonfat powdered CM 
 
Build up: 7-11 weeks in 
combination with omalizumab, 
target 2 g daily (60 ml CM) 
 
Maintenance: 2 g with 
omalizumab until week 16. 
Dose-increase to  ≥8 g daily 
(≥240 ml CM) week 24 
 
Desensitization: 
81.8 % (7-11 weeks) 
 
Maintenance: 81,8%  
passed DBFC to 8 g and 
took ≥8 g/d (≥240 ml CM) 
 
OIT (N=5) 
CM-specific CD4+ T cell proliferation ↓↓1 week from baseline and 
persisted during build up (8-16 weeks) but ↑ maintenance phase at 3-4 
months  
 IL-10 / TGF-β producing Treg cells not are involved in ↓ CM-
specific CD4+ T cell proliferation  (10-14 weeks) 
 Anergy could be involved in ↑ CM-specific CD4+ T cell proliferation 
after desensitization 
 
OIT (N=10) 
↑ IFN-γ / IL-4 ratio (weeks 36-52) in fully desensitized patients 
↓ CM-sIgE (weeks 36-52) 
↑ CM- sIgG4 (weeks >24) 
↓ SPT to CM (weeks 52) 
↓CM basophil activation markers CD203c+ CD63+ (weeks 24-52) 
 
 
 
 CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Sánchez-García et al.  
(2011) 
 
N=105 
 
Aged 2-15 years 
 
Non-randomized, non-controlled 
 
Build up: mean of 19 weeks, 
target of 200 ml of CM 
Planned in 16 weeks  
 
Maintenance: ≥ 200 ml of CM 
daily. Other dairy products were 
allowed except cheese of other 
species. 
 
 
Desensitization: 
81.9 % (N=86) totally 
desensitized 
19.1% (N=19) failed 
 
 
Desensitization vs failure (baseline): 
↓ CM- and CN-sIgE  
n.s.: SPT to CM; α-LA- and β-LG sIgE 
 
NR Changes during CM-OIT 
 
Álvaro et al., 
(2012) 
 
N= 44 allergic 
anaphylactic during 
DBPCFC at baseline 
N=22 allergic non-
anaphylactic 
N=21 negative 
DBPCFC at baseline 
(tolerant) 
 
Mean age of 8.1 years 
 
Non-randomized, non-controlled 
 
Build up: 26.4 weeks in 
anaphylactic group and 23.1 
weeks in non-anaphylactic, 
target 150 ml of CM  
 
Maintenance: ≥ 200 ml daily 
 
Desensitization: 
Anaphylactic 
Totally (≥150 ml): 79.5% 
(N=35) 
Partially (5-149 ml): 
15.9% (N=7) 
 
 
Non-anaphylactic 
Totally: 72.7% (N=16) 
Partially: 27.3% (N=6) 
 
Anaphylactic patients vs tolerant (baseline): 
↑ CM- and CN-sIgE  
 
 
Anaphylactic patients vs non-anaphylactic  (baseline) 
↑ CM- and CN-sIgE  
 
 
OIT in anaphylactic patients: 
↓ CM- and CN-sIgE  
 
 
OIT in non-anaphylactic patients: 
↓ CM- and CN-sIgE  
 
 
 
 
 
  
CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Keet et al. 
(2012) 
 
N= 10; SLIT 
N=10; SLIT + OIT(B) 
N=10; SLIT + 
OIT(A) 
 
Aged 6-21 years 
 
Double-blind, placebo-controlled 
 
Aqueous CM extract (SLIT) 
Powdered CM 
 
Build up: 
SLIT / Median 10 weeks, target 
7mg daily 
SLIT+OIT(B) 
Median 28 weeks, target 1000 
mg daily 
SLIT+OIT(A) 
target 2000 mg daily 
 
Maintenance: 60 weeks 
Avoidance: 1 week.  
 
Maintenance: ≥60 weeks 
10% SLIT 
60% SLIT+ OIT(B) and 
80% SLIT + OIT(A) 
passed OFC (8 g of CM) 
 
Tolerance: 
10% SLIT 
30% SLIT+ OIT(B) and 
50% SLIT + OIT(A) 
passed OFC (8 g of CM) 
 
 
Outcomes from baseline to 60 weeks (desensitization): 
In both groups SLIT and SLIT + OIT(A+B) 
↑ CM- specific IgG4 
↓ SPT to CM 
↓ CD63 CD203c basophil markers 
 
Only in SLIT + OIT(A+B) group: 
↓ CM-specific IgE 
↓ spontaneous histamine release 
 
 
 
 
 
García-Ara et al. 
(2013) 
 
N= 36 OIT group, 
subgroups according 
baseline CM-specific 
IgE 
-OIT1 (0.35-3.5 KU/L) 
-OIT2 ( >3.5-17 KU/L) 
-OIT3 (>17-50 KU/L) 
N= 19 Control group  
 
Aged 4-14 years 
 
Non-randomized, non-controlled 
 
Build up: median of 3 months, 
target 200 ml of CM twice a day 
Completed build-up in <3 
months: 90% OIT1, 50% OIT2, 
30% OIT3 
 
Maintenance: 200 ml of CM 
twice a day and free diet 
 
Follow up: 1, 6 and 12 months 
 
Desensitization: 
92% (N=33) OIT group  
(100% OIT1; 88% OIT2; 
88% OIT3) 
 
 
Maintenance: 88. 8% 
(N=32) 20% had 
experienced adverse 
events at 6 and 12 
months of follow up. 
 
Control group: 5.26% 
(N=1)  
 
OIT from baseline to 6 months of follow up: 
↓ Total IgE and CN-sIgE (OIT group) 
n.s.: CM- α-LA- and β-LG sIgE (OIT group) 
n.s. in any marker (Control group) 
 
OIT from baseline to 12 months of follow up: 
↓ Total IgE, CM- and CN-sIgE (OIT group) 
n.s.: α-LA- and β-LG sIgE (OIT group) 
↓CN-sIgE (Control group) 
 
Predictors:  
Children with low or moderate levels of CM-sIgE had a better evolution 
and less severe symptoms.   
Children who tasted goat’s or sheep’s milk cheese had symptoms. 
 CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
González Jiménez et 
al. 
(2013) 
 
N=18 
 
Aged 3-14 years 
 
Rush protocol.  
Non-randomized, non-controlled 
multi-center 
 
Build up: 5 days, target 200 ml 
(6.600 mg CM protein) 
without premedication 
 
Maintenance: 200 ml daily. 
 
Desensitization:  
39% totally desensitized 
(200 ml of CM) 
61% Partially (mean of 
103 ml of CM) 
 
Long follow up: 72% 
consuming CM without 
restriction (24 months) 
 
 
During OIT: 
↓ CM-sIgE (24 months) 
↓ αLa-sIgE (24 months) 
↓ CN-sIgE (6, 12,  24 months) 
n.s.: βLg sIgE 
 
Salmivesi et al. 
(2013) with changes in 
biomarkers in 
Salmivesi et al. 
(2016) 
 
N= 18 OIT group 
N=10 placebo group 
(subsequently open 
label-treated) 
 
Aged 6-14 years 
 
Double-blind, randomized, 
placebo-controlled 
 
Pasteurized 2.5% fresh milk 
(OIT) 
Oat, rice or soy milk (placebo) 
 
Build up:162 d, target 6400 mg 
 
Maintenance OIT group+ 
placebo through an open-label 
OIT, 6400 mg CM protein daily 
 
 
Desensitization: 
89% OIT group 
 
Maintenance: 81% 
consumed CM or milk 
products 6400 mg CM 
protein/d (12 months) and 
79% (3-3.5 years) 
 
Open label-treated group: 
100% desensitized 
 
OIT vs Placebo: 
↑ serum IL-6 (6 months) 
↑ serum IL-10 (6 months) 
 
 
During OIT (N=28 after completed CM-OIT): 
↓ Blood eosinophils 
↓ serum total IgE 
↑ allergen-sIgG 
↑ allergen-sIgG4 
↑ serum IL-4 
↑ serum IL-6 
↑ Leptin and resistin (inflammatory adipocytokines) 
 
 
 
 
 
 
  
CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Vázquez-Ortiz et al. 
(2013) 
 
N=81 (recruited 
throughout 5 years) 
 
Aged 5-18 years 
 
Non-randomized, non-controlled 
 
Build up: 16 weeks, target 200 
ml of CM 
 
Maintenance: 200 ml daily 
(median 25 months) 
 
Desensitization: (25 mo) 
71.6% totally desensitized 
(200 ml of CM) 
Partially desensitized 
20.9% (mean of 103 ml of 
CM) 
 
OIT from baseline to 24months: 
↓ CM-sIgE  
↓ SPT to CM  
 
Predictors: 
CM-sIgE ≥50 KU/l and SPT ≥ 9 mm at baseline are related with 
frequent and persistent adverse reactions during CM-OIT 
 
Frichmeyer-
Guerrerio et al. 
(2014) 
 
 
N=8; SLIT 
N=8; SLIT + OIT(A) 
N=8 SLIT + 
OIT(B) 
 
 
Aged 6-17 years 
 
Open label,  randomized 
 
Aqueous CM extract (SLIT) 
Powdered CM (OIT) 
 
Build up: 
SLIT 
median of 10 weeks, target 7mg 
daily 
SLIT+OIT(B) 
Median of 28 weeks, target 1000 
mg daily 
SLIT+OIT(A) 
target 2000 mg daily 
 
Maintenance: ≥60 weeks 
 
1 week avoidance + OFC after 5 
weeks (6 months total) 
 
Maintenance: ≥60 weeks 
0% SLIT passed OFC 
62.5% SLIT+ OIT passed 
OFC (8 g of CM) 
 
Tolerance after 
avoidance: 
31.25% SLIT+ OIT (6 
months) (N=5) 
 
 
 
Treatment of pDCs and mDCs with CM extract: 
not  induce significant IL-6 or TNF-α, IL-10 (very lows levels of IL-6 and 
not detectable IL-10) 
 
OIT impacts primary on pDCs whereas SLIT affects mDCs 
 
TLR responses in DC during OIT between desensitized and tolerant 
(baseline- 6 months): 
↓TLR9-induced pDCs IL-6 responses  (both groups) 
↓ TLR2- and ↓TLR7/8 induced mDCs IL-6 responses  (tolerant) 
 
TLR responses in DC-Tcell co-cultures during OIT between SLIT and 
SLIT+OIT (baseline- 6 months): 
↓TLR7-induced pDC-T IL-13 responses  (OIT group) 
↓TLR7/8-induced mDC-T IL-13 responses  (OIT group) 
↓TLR7-induced pDC-T IL-10 responses  (OIT group) 
 
Cytokine secretion in DC-Tcell co-cultures in response to CM: 
↓ IL-5 and IL-13 by CD4+ T cells in pDC-Tcell (OIT)  
n.s.  in IFN-γ and IL-10  
 
 CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Savilahti et al. 
(2014a) 
 
N= 40 
 
Aged 6-17 
 
Non-randomized, non-controlled 
 
Build up: median of 191 days, 
target ≥ 200 ml of CM 
 
Maintenance: 200 ml daily 
 
 
 
Desensitization: 
80% success OIT 
20% discontinued OIT 
 
Maintenance: 95% 
consuming CM but 25% 
with occasional adverse 
reactions 
 
Predictors of failure at baseline: 
↑ CM- sIgE, sIgA,s IgG, sIgG1, sIgG4 
 
Children who success OIT 
↑ CM- sIgA, sIgG, sIgG1, sIgG4 
↓ CM-sIgE 
 
Children who discontinued OIT 
↑ CM- sIgG, sIgG1, sIgG4 
n.s.: CM- sIgE, sIgA 
 
 
Savilahti et al. 
(2014b) 
 
N= 32 OIT group 
 
Aged 6-17 years 
 
Non-randomized, non-controlled 
 
Build up: median of 186 days 
(range 167–458) , target  
200 ml of CM daily 
 
Maintenance: 200 ml daily  with 
follow-up at 3 months 
 
Desensitization: 
81% success OIT 
19% discontinued OIT 
(failure) 
 
Success vs Failure: 
↓ CM-sIgE (baseline and final OIT) 
↑ CM-sIgG4 (baseline) 
 
During OIT: 
↓ CM-sIgE and ↑ CM-sIgG4 
↓ IgE binding to CM epitopes and ↑ IgG4 binding 
 
Predictors: 
↑Overlap in IgE and IgG4 binding to CM peptides.  It is relevant to 
favorable outcome the capacity of IgG4 to bind the same epitopes that 
IgE. 
 
Children who discontinued OIT had IgE and IgG4 antibodies that 
bound to CM peptides with greater intensity, broader diversity and 
greater affinity than in children who successfully completed OIT 
 
↑ sIgE/sIgG4 ratio in CM peptide binding predictor  of failure 
 
  
 
Table 1. Summary of some of the most relevant trials on cow's milk oral immunotherapy. 
Abbreviations: DBPCFC, double-blind placebo-controlled food challenge; α-LA, α-Lactalbumin; β-LG, β-Lactoglobulin; CM, cow’s milk; CN, casein; n.s., no 
significant change; mDCS, myeloid dendritic cells; NR, not reported; OFC, oral food challenge; pDCs, plasmacytoid dendritic cells; SLIT, sublingual 
immunotherapy; sIgE, specific-IgE; sIgG1, specific IgG1; sIgG2, specific IgG2; sIgG4, specific IgG4; SPT, skin prick test 
  
CM-OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Martinez-Botas et al. 
(2015) 
 
N= 25 OIT group 
N=7 Control group 
 
Aged 4–7 years 
 
Non-randomized, controlled 
 
Build up: median of 8 weeks, 
target 200 ml of CM 
 
Maintenance: 24 months  with ≤ 
200 ml of CM daily on a free diet 
 
Follow up: 6, 12, 24 months 
 
Desensitization: 
32% ≤ 8 weeks 
48% > 8 weeks and > 7 
allergic reactions or 
premedication 
20% >7 allergic reactions 
+ premedication 
 
Maintenance: 100% 
 
Good correlation between sIgE and sIgG4 binding peptides of five 
major CM proteins and clinical outcomes. (αS1-CN, αS2-CN, β-CN, κ-
CN, β-LG) 
 
Number and intensity of IgG4-binding peptides increased continuously 
during 24 months CM-OIT. 
 
Slow and continuous decrease in number and intensity of IgE binding 
peptides with statistical significance at 24 mo. 
 
Authors identified two sets of 16 IgE-binding peptides at baseline 
suggested as predictors. 
 
Early age of starting CM-OIT may be an important factor in the 
achievement of oral desensitization. 
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1.4. EGG ORAL IMMUNOTHERAPY 
1.4.1. Egg allergy overview 
Egg, typically represented in our setting by hen's egg, is considered a substantial food 
while constitutes a primary protein source in our diet and it is included in a wide range of 
cooked and manufactured foods. After cow's milk allergy, egg allergy becomes the second 
most common form of food allergy in pediatric patients in Europe, especially in the first 
years of life, affecting approximately 1-3% of children (Nwaru et al., 2014; Xepapadaki et 
al., 2016). In Spain, egg allergy is the most frequent food allergy in young children, with a 
reported incidence of 2.4-2.6 % in the first 2 years of life (Martorell et al., 2013). Most of the 
egg allergy reactions show specific IgE positivity against egg proteins and clinical 
symptoms could compromise the patient’s life, having into account that the lowest observed 
egg protein dose capable of eliciting a reaction may be as low as 2 µg (Morriset et al., 
2003). In fact, egg allergy is one of the most common causes of severe anaphylaxis 
(Caubet and Wang, 2011). Although egg allergy is associated with a high rate of natural 
tolerance with resolving within the first 6 years of life, the development of this process is not 
well understood and egg allergy persist in about 50% of children at this age (Sicherer et al., 
2014), suggesting the increasing of the clinical disorder in the adulthood.  
As other food allergies, the standard treatment of egg allergy is based on the 
avoidance of egg protein intake. However, due to the broad presence of egg derived 
components in cooked or manufactured food products, maintaining a strict egg avoidance 
diet is not easy and dietary failures are relatively frequent, leading to a substantial decrease 
in the quality of life of both patients and their families (Boyano-Martínez et al., 2012). To 
overcome the inadvertent transgressions, together with the risks of nutritional deficiencies 
derived from not consuming egg proteins, in the last few years there has been an 
increasing numbers of studies focused in the treatment of egg allergy.  
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1.4.2. Mayor allergens in egg 
Most of the allergenic egg proteins are found in EW. Four proteins, ovomucoid (OM) 
(11%), ovalbumin (OVA) (55%), ovotransferrin (12%) and lysozyme (LZ) (3%), named from 
Gal d 1 to Gal d 4, respectively, have been identified as the major ones. Although OVA is 
the most abundant protein comprising EW, OM has shown the highest allergenic activity in 
egg (OM, OVA LZ in this regard) (Benhamou et al., 2010).  
In addition, other minor proteins such as ovomucin, ovoflavoprotein, avidin and 
ovoinhibitor have also been identified. The yolk has various proteins such as apovitelines, 
phosvitins and livetins which may also be allergenic, although to a lesser extent (Mine and 
Yang, 2008). 
 
 
1.4.3. Egg Oral Immunotherapy Trials 
As a promising strategy for treating egg allergy, the aim of egg OIT is to induce a 
permanent tolerance or alternative desensitization, in order to allow patients to eat this food 
(or small, hidden doses) without risk of allergic reaction. Based on positive results, egg OIT 
has been actively researched and a growing number of studies have been performed, 
especially in the last 10 years. However, as occurs in cow’s milk OIT, there are many 
methodological differences in published studies which prevent us from drawing robust 
conclusion, such as the study design, the number of patients included, the marked 
variability between protocols, the extracts used, the time when response treatment is 
assessed, the varying definition of success, the long-term maintained effectiveness, etc. 
(Bégin et al., 2014; Praticò et al., 2014; Ibánez et al., 2015; Peters et al., 2016). The key 
characteristics of some of the most relevant egg OIT studies, including the immunological 
outcomes and the latter follows-up reported, could be found at the end of this section, 
summarized in chronological order in Table 2. 
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OIT protocols are performed in IgE-sensitized patients, with history of allergic reactions 
after ingestion of egg proteins and in most part of the cases with a positive DBPCFC.  
Although the treatment can be administered at any age, even during the first years of life, 
most studies tend to be performed in patients older than 6 years with less chance of 
outgrowing their egg allergy (Sicherer and Sampson, 2014). It has special interest the 
duration of the build-up phase which range from 1 day to more than 300 days, with different 
schedules, amount of egg, maximum preprogramed dosage and material used (whole egg, 
EW; raw, pasteurized, dehydrated, undercooked, hard-boiled or foods that contain egg). 
Such differences among protocols, equivalences between the doses administered and 
variances owing to the allergenic potential of the material employed make interpretation 
and comparison between several egg OIT protocols very difficult. 
Maintenance phase usually lasts from 6 to 12 months, but it can be prolonged for 
years and in some cases it is not defined. The maintenance dose is usually the target dose 
for the build-up phase and most protocols establish the amount equivalent to 1 egg.  The 
administration interval also varies from once daily to every 2-3 days depending on the 
previously established target. Patients maintain desensitization only if they consume eggs 
regularly during this phase, therefore in many studies patients are lost to follow-up owing to 
poor adherence. Moreover, whether patients maintain this unresponsiveness by following 
an egg exclusion diet is the relevant question concerned OIT. It is the ultimate goal and few 
studies have analysed successfully reintroduction of egg into the diet after a period of 
avoidance (Vickery et al., 2010; Burks et al., 2012; Caminiti et al., 2015; Escudero et al., 
2015). 
Randomized placebo control studies are considered the “gold standard” in egg OIT 
since can reduce the influence of unknown or baseline variables, together with the 
possibility that the observed effects of intervention are due to spontaneous development of 
tolerance or different treatment settings. However, it can lead to ethical issues, hinder 
design and procedures complications and make difficult the adherence to the protocol for 
both children and parents. Thus, only a few studies compared OIT to a placebo (Burks et 
al., 2012; Caminiti et al., 2015), besides neither were randomized nor controlled (Vickery et 
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al., 2010; Itoh et al., 2010; García Rodríguez et al., 2011; Sugimoto et al., 2016). Although 
limited, rush desensitization protocols over days have been also reported. The most 
relevant reports performed a rapid desensitization schedule with a several daily dose 
increases include those published by Itoh et al. (2010) and García Rodríguez et al. (2011). 
The immunological mechanisms involved in the clinical changes observed during egg 
OIT are not entirely clear and data reported by egg OIT studies are limited, while 
contradictory. The majority of studies report allergen sIgE and IgG4 serum antibody 
changes and basophils and mast cell responses by increased positivity on skin prick 
testing. A decrease in the dimensions of the wheal produced by skin prick testing with EW 
is commonly observed (Vickery et al., 2010; Burks et al., 2012; Dello Iacono et al., 2013; 
Fuentes-Aparicio et al. 2012; Escudero et al., 2015). It is also generally accepted that 
levels of egg sIgG4, OVA sIgG4 and EW sIgG4 increase over the time and at early stages 
(Itoh et al. 2010; Vickery et al., 2010; Escudero et al.; 2015; Sugimoto et al., 2016) even 
some authors point at egg sIgG4 as a predictor of desensitization (Caminiti et al., 2015). 
Nevertheless, differences in desensitized children when comparing baseline EW sIgE and 
egg allergen sIgE values with those observed during treatment are not entirely clear. Some 
OIT protocols display lower allergen sIgE levels at the end of the immunotherapy (Vickery 
et al., 2010; Dello Iacono et al., 2013; Meglio et al., 2013; Caminiti et al., 2015; Escudero et 
al., 2015; Sugimoto et al., 2016), also studies with a ROIT protocol (Itoh et al., 2010; García 
Rodríguez et al., 2011), but, on the contrary, no significant changes in IgE levels during OIT 
have also been reported (Burks et al., 2012; Fuentes-Aparicio et al., 2012). 
Very few studies have addressed the production of Th1, Th2 and/or Treg egg protein-
specific cytokines which reflect the allergen-specific changes in T cells during egg OIT. In 
their OIT study, Vickery et al. (2010) observed a statistically significant reduction in the egg-
specific production of IL-13/IFN-γ ratio from 96 hours-stimulated PBMC at 18 months of 
treatment, whereas such ratio were increasing as egg OIT was prolonged (18-24 months). 
Same authors also reported an increase in the egg-specific IL-10 levels at 12 months of 
egg OIT.  
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In a previous study of Fuentes-Aparicio et al. (2012), a broad panel of cytokines was 
quantified in serums of 19 children egg allergic children before and after egg OIT. A marked 
reduction in different Th1 and Th2 cytokines were observed after desensitization 
achievement (IL-2, IL-5, IFN-γ and TNF-α). In the same way, serum IL-10 levels also 
suffered a reduction after OIT. It is important to highlight that, although there was no 
significant difference in IL-13 after treatment, it was the only cytokine showed an increasing 
tendency. Meglio et al. (2013) quantified serum levels of IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, 
IFN-γ and TNF-α, but without could not demonstrate any significant differences for the 
cytokines tested at 6 months of their egg OIT study, apart from a slightly significant 
increase of serum IL-5. Itoh et al. (2010) also did not found differences for the serum IL-4 
and IFN-γ levels at either 6 months or 12 months of their egg ROIT study, albeit observed 
that IL-10 significantly decreased and TGF-β1 increased at both times points of the 
treatment. Thus, the mentioned studies showed contradictory data for secretion of IL-10, 
since no change (Meglio et al., 2013) until an increase (Vickery et al., 2010) or even a 
decrease (Itoh et al., 2010; Fuentes-Aparicio et al., 2012). 
The changes that OIT could reflect in peripheral blood by the presence of modified 
values of immune subsets have scarcely been studied to date. We previously described 
that OIT in egg allergic children modifies values of T cell subsets decreasing the 
percentage and absolute counts of effector-memory CD4+ T cells (TEM) (Fuentes-Aparicio 
et al., 2012). TEM cells have immediate effector function and can rapidly produce 
inflammatory mediators, such as Th2-associated cytokines IL-4 and IL-5 (Sallusto and 
Lanzavecchia, 2001). In addition, we observed in all desensitized children a marked 
increase in a particular subset of CD4+ T cells whit a hypo-proliferative and non-reactive 
phenotype (CD4+ CD38+ CD45RO- HLA-DR- cells). Since these cells are probably newly 
generated in the thymus, we hypothesized that egg OIT induces changes in the immune 
homeostasis that increases the replenishment by the thymus of the CD4+ pool with this 
subset of cells, which ensures the selection of non-reactive clones, acquiring this non-
reactive phenotype and reducing the immune responses against egg allergens. 
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Additionally, in vitro experiments identified CD4+ CD38+ cells as great IL-13-secreting T 
cell subset (Scalzo-Inguanti and Plebanski, 2011) and it is known that interleukin 13 
induces IgG4 production and favors class switching to IgE in B lymphocytes (Punnonen et 
al., 1993). 
Other known marker as FoxP3+ Treg cells has been also investigated by Urra et al. 
(2012). Authors reported that unlike controls, children undergoing the egg desensitization 
protocol showed significantly increased CD4+ FoxP3+ cells in egg white stimulated cells. In 
agreement with the authors, a previous study in 19 allergy children following an OIT 
protocol with egg reported an increase in the frequency and absolute counts of Treg 
associated with egg desensitization (Fuentes-Aparicio et al., 2014). Moving beyond, 
different phenotypes of these Treg were measured, finding that the increase in the Treg 
number was more significant for the effector-Treg subset. Thus, the egg OIT could be 
favoring the generation of peripheral antigen-specific Treg without increasing the 
differentiation or activation of effector CD4+ T cells. 
  
  
EGG OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Itoh et al.  
(2010) 
 
N=6 
 
Aged 7-12 years 
 
 
 
 
 
Rush protocol.  
Non-randomized, non-controlled 
 
Powdered egg / scrambled 
egg 
 
Rush build up: median of 12 d 
(9-18), target 1 scrambled egg 
(60g, 1 whole egg of medium 
size) 
 
Maintenance: at least 1 heated 
egg twice/week. 
 
Desensitization: 100% 
 
Maintenance: 50% did 
not tolerated 1 g of 
powdered egg at 9-12 
months   
 
 
100% keeping M dosage 
without symptoms after 
16-21 months 
 
 
 
↓ EW- and OM- sIgE  
↑ EW- sIgG4 
(0-12 months) 
 
↓ Th1/Th2 ratio 
(0-6 months) 
 
↓ serum IL-10 
↑ serum TGF-β1 
(0-6 months and 0-12 months) 
 
n.s.: serum IL-4 and IFN-γ, SPT 
 
 
Vickery et al. 
(2010) 
 
N=8 
 
Aged 3-13 years 
 
 
 
 
 
Non-randomized, non-controlled 
 
Powdered EW 
 
Build up: median of 174 d, 
target of 300 mg  
 
Maintenance: mean of 33.8 mo 
of OIT with a median dose of 
2.4 g/d (300 mg - 3.6 g)  
 
1 months of avoidance  
 
Desensitization: 75% 
(300 mg) 
 
62.5% tolerated 3.9 g in 
OFC at 4 months 
 
75% keeping dosage at 
33 months  
 
Tolerance after 
avoidance: 75%  
 
 
 
↓ SPT  to EW  
↓ EW-sIgE 
↓ OM-sIgE  
↑ EW-sIgG4 
↑ OM-sIgG4 
(0-final build up) 
The reduction in IgE production is allergen-specific 
 
Egg protein-specific cytokines after stimulation PBMCs 
↑ IL-10 (0-12 months) 
↑ TGF-β (0-6 months) 
↓IL-13/IFN-γ (0-18 months) 
 
n.s.: CD24+ CD25+ T cells 
 
 
 
  
EGG OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
García Rodríguez et 
al. 
(2011) 
 
N=23 
 
Aged 5-17 years 
 
 
 
Rush protocol. 
Non-randomized, non-controlled 
 
Pasteurized raw EW / cooked 
egg 
 
Rush build up: 5 d, target 1 
whole cooked egg + 8 ml of 
raw EW 
 
Maintenance: 1 cooked egg 
(24 h first 3 months; 48 h 3-6 
months;  72 h after 6 months) 
 
Build up: 60.9% ≤ 5 d  
26% 5-10 d  
 
 
Maintenance: keeping 
dosage after 6-14 mo. 1 
patient became 
symptomatic owing to 
poor adherence 
 
 
↓ SPT 
↓ EW- sIgE 
(0-6 months) 
↑ EW- sIgG 
(0-3 weeks, 0-3 months and 0-6 months) 
 
↑FoxP3+ Treg (Urra et al, 2012) 
 
Differences in SPT, EW-, and OM-sIgE between patients completed 
Build-up phase ≤ 5 d and those > 5 d 
 
Burks et al. 
(2012) 
 
N=40 OIT group  
N= 15 Placebo group 
(10 months) 
 
Aged 5-11 years 
 
Double-blinded, randomized, 
placebo- 
controlled 
 
Dehydrated EW 
 
Build up: 10 months, target 2 g 
 
Maintenance: 22 months, up to 
2 g/d 
 
4-6 weeks of avoidance diet 
 
 
 
 
Desensitization: 55% 
OIT vs.  0% placebo 
(5 g in DBPCFC at 10 
months) 
 
75% tolerated 10 g in 
DBPCFC at 22 months 
 
Tolerance after 
avoidance: 28% (10 g at 
24 months) 
 
Long follow-up: 25% 
asymptomatic at 36 
months  
 
OIT vs. placebo: 
↓ SPT   
↓ Egg CD63+ basophils 
↑ Egg-sIgG4 
n.s.: Egg-sIgE 
 
Differences between patients OIT were desensitized and those 
were not:  
Egg-sIgG4 at 10, 22, 24 months from baseline 
Egg-sIgE at 22 months 
 
Predictors:  
Egg-sIgG4 predicted desensitization at 10, 22, 24 months from 
baseline 
SPT predicted desensitization at 22, 24 months from baseline 
 EGG OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Fuentes-Aparicio et 
al. 
(2012) with 
Treg outcomes in 
Fuentes-Aparicio et 
al. 
(2014)  
 
N=19 OIT group  
N= 22 Control group 
 
Aged 3-14 years 
 
 
Controlled 
 
Dehydrated egg  
 
Build up: mean of 9.7 weeks, 
target 10 g (1 egg) = Tend 
 
Maintenance: follow up a 6 
and 12 months. 
Recommended normal diet 
 
Desensitization: 84.2% 
(N=16) 
 
 
 
 
Desensitized OIT group (N=16) (T0-Tend) 
 
↓ SPT to EW, OVA an OM 
↑ EW sIgG 
↓ TNF-α, IFN-γ, IL-2,  IL-5, IL-10, IL-9, IL-17A, IL-22 
↑% and absolute counts effector-memory CD4+ T cells 
↑% absolute counts CD4+ CD45RA+ CD31+  T cells, recent thymic 
emigrants  (TEM) 
↑% absolute counts CD4+ CD38+ CD45RO-  T cells 
↑% and absolute counts of Treg 
↑ absolute counts of TEM Treg 
↑↑ counts of Treg/ TEM ratio 
 
Positive correlation EW sIgG/ CD4+ CD38+ CD45RO-  
Negative correlation absolute counts of Treg  and % of Treg TEM  
Positive correlation % of Treg TEM  and absolute counts of basophils 
 
n.s.: % and absolute counts of CD4+ T cells, CD8+ T cells, B cells, 
Natural Killer cells, monocytes, basophils, neutrophils, eosinophils   
Total IgE and EW, OVA, OM sIgE   
IL-12, IL-4, IL-13, IL-1β 
 
OIT vs. control (T0): 
↑% and absolute counts TEM 
↓% and absolute counts CD4+ CD38+ CD45RO- 
 
OIT vs.control (Tend): 
n.s.: TEM, CD4+ CD38+ CD45RO- 
 
  
EGG OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Dello Iacono et al. 
(2013) 
 
N=10 OIT group  
N= 10 Control group 
 
Aged 5-11 years 
 
 
 
Randomized, 
controlled, 
home-based 
 
Raw EW 
 
Build up: not reported time, 
target 40 ml (1 small egg 
approx.)  
 
Maintenance: 6 months, 10-40 
ml/d 
  
 
Desensitization: 0% 
total, 90% partial OIT vs. 
0% Control (6 months) 
 
Median dose tolerated 
20 ml. No patients 
reached maintenance 
dosage of 40 ml  
 
OIT group: 
↓ EW-sIgE 
↓ SPT to EW 
(0-6 months) 
 
Control group:  
n.s. of any biomarker  
 
 
 
Meglio et al. 
(2013) 
 
N=10 OIT group  
N= 10 Control group 
 
Aged 4-14 years 
 
 
Randomized, controlled, 
home-based 
 
Raw EW 
 
Build up: mean of 215 d, target 
25 ml (3.1 g of egg proteins) 
 
Maintenance: 6 months, raw 
EW at least 3times/week or 
foods containing same quantity 
 
 
Desensitization: 80% 
OIT vs.  20 % Control (at 
6 months) 
 
 
 
 
OIT group: 
↓ SPT to EW  
↓ OM-sIgE  
↑ OVA-sIgE 
↑ serum IL-5 
n.s.: serum IL-4, IL-6, IL-10, IL-12, IL-13, IFN-γ, TNF-α 
(0-6 months) 
 
Control group:  
n.s.  of any biomarker 
 
 
 
 
 
 EGG OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Caminiti et al. 
(2015) 
 
N=17 OIT group  
N= 14 Placebo group 
(4 months) 
 
Aged 4-11 years 
 
 
 
Randomized,  
placebo-controlled 
 
Dehydrated EW / Cooked or 
boiled Eggs 
 
Build up: 4 months, target 4g 
(EW contained in 1 egg) 
 
Maintenance: 6 months, 2-3 
egg/week 
 
3 months of avoidance diet 
 
 
 
 
Desensitization: 94% 
OIT vs 0% placebo 
 
Tolerance after 
avoidance: 29% OIT vs 
7% placebo  
 
OIT vs. placebo (0-4 months): 
↑ Egg- sIgG4 
n.s.: SPT to egg and sIgE 
 
OIT group: 
↓ SPT to egg (0-4 months and 0-10 months) 
↑ Egg- sIgG4 (0-4 months and 0-10 months) 
↓ Egg- sIgE (0-10 months) 
↑ SPT  to egg ↓ Egg- sIgG4 and  ↑ Egg- sIgE patients who lost 
tolerance after maintenance + avoidance 
 
Control group: 
n.s.  of any biomarkers 
 
Predictors: 
Egg-sIgG4 predicted desensitization (14 months) 
 
Escudero et al. 
(2015) 
 
N=30 OIT group  
N= 31 Control group 
 
Aged 5-17 years 
 
 
 
Randomized, controlled 
 
Dehydrated EW /Undercooked 
egg (fried, scrambled or 
omelette) 
 
Build up: median of 32.5 d, 
target 2.8 g  
 
Maintenance: 3 months, 1 
undercooked egg/48 hours 
1 months of avoidance diet 
 
Desensitization: 93% 
OIT 
 
Tolerance after 
avoidance: 37% OIT vs 
3% placebo 
 
Long follow-up: 37% 
asymptomatic at 36 
months  
 
 
 
OIT vs. placebo (0-4 months): 
↓ SPT to OVA and OM 
↑ OVA-sIgG4 
 
OIT group (0-4 months): 
↓ SPT to EW, OVA and OM 
↓ OVA-sIgE and ↑ OVA-sIgG4 
↓ EW-, OVA-, OM-sIgE (3 months) between patients who passed 
DBPCFC 4 months and those were not 
 
Predictors: 
EW- and OM-sIgE predict the DBPCFC result at 4 months 
  
 
Table 2. Summary of some of the most relevant trials on egg oral immunotherapy.  
Abbreviations: d, days; DBPCFC, double-blind placebo-controlled food challenge; EW, egg white; n.s.:, no significant change; OFC, oral food challenge; OM, 
ovomucoid; sIgE, specific-IgE; sIgG1, specific IgG1; sIgG2, specific IgG2; sIgG4, specific IgG4; SPT, skin prick test  
 
 
 
EGG OIT STUDIES 
Study / Subjects 
Design, material and 
intervention 
Efficacy Immunological outcomes 
 
Sugimoto et al. 
(2016) 
 
N=26 
 
Aged >5 years 
 
 
Non-randomized, non-controlled 
 
Hard-boiled egg 
 
Build up: mean of 17 d (8-38) 
target 1 hard-boiled egg 
 
Maintenance: 1 hard-boiled 
egg/24 hours 
 
 
 
Desensitization: 100% 
 
Maintenance: 80.8% 
keeping dosage after 1 
year  
2 groups:  
high desensitization 
(HD) and low 
desensitization (LD) 
 
↓EW-, OVA- , and OM- sIgE  
(0-3 months, 0-6 months and 0-12 months) 
 
Fast ↑EW-sIgG1, sIgG2, sIgG4 and sIgA (0-1d) and remain at 
12mo 
 
HD vs. LD (at baseline): 
↑EW-, OVA- sIgA 
↓OM- sIgG2  
 
HD vs. LD (OIT): 
↑EW-sIgA, OVA-sIgA (0-3 months, 0-6 months  and 0-12 months) 
↑EW-sIgG1 (0-1d) 
 
↑EW-sIgG1  at 1d could be a useful biomarker 
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Food allergy, defined as an immune-mediated adverse reaction to food, is an important 
health concern since constitutes a potentially life-threatening condition and its prevalence 
and persistence are undergoing an increase in the last years. Cow's milk is one of the first 
foods introduced into an infant’s diet and, accordingly, is one of the first and most common 
causes of food allergy in early childhood. Cow's milk protein allergy (CMPA) is associated 
with a high rate of natural tolerance, disappearing within the first years of life. However, this 
allergy often precedes the development of other IgE-mediated food allergies, such as the 
allergy to egg proteins which, similarly, is one of the most frequent food allergies in 
pediatric patients in Europe. The reason why CMPA appears in some children and not in 
others, and which are the immune alterations responsible of their establishment in infants 
are not well understood. Immune system of children significantly differs to those in adults, 
since it is largely still developing and hence immature, but also has a great plasticity in 
response to antigens or therapies. Evidence on cow's milk allergy and its appearance 
would be relevant for the better understating and control of food allergies in the infancy. 
 Notwithstanding all efforts, there is still no suitable therapy available against food 
allergy except avoidance, which involves a wide dietary restriction, with negative nutritional, 
social, psychological and economic consequences. Oral immunotherapy (OIT), which 
involves giving regular, gradually increased oral dosages of the allergenic protein, is 
nowadays one of the most studies approaches toward a treatment for food allergy. 
Although the results are promising, the immune mechanism or alterations subjacent to the 
process are poorly understood. In the last years many groups have reported on their 
experience with food OIT, but there are still many methodological differences in published 
studies which prevent us from drawing robust conclusion, such as the study design, the 
number of patients included, the allergenic extracts used, the parameters measured to 
evaluate immune changes, the time when response treatment is assessed, the varying 
definition of success, the long-term maintained effectiveness, etc.  
Under this context, the main purpose of this work is to elucidate the immune 
mechanisms responsible of the establishment of food allergy in children, why some children 
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naturally outgrow their food allergy and which are the immune mechanisms by which 
desensitization occurs in allergic children during an oral immunotherapy treatment.  
To this aim, the following secondary concrete objectives are stablished: 
-  To investigate which immune alterations constitute differential factors between allergy 
and tolerance, and hence could be implicated in the establishment of cow's milk allergy in 
infants; elucidating if these crucial factors are good diagnostic or predictive markers, 
whether they could be behind the establishment of the disorder in the adulthood, and even 
if they could constitute a good therapeutic target for prevention and/or treatment of cow's 
milk allergy. 
- To investigate which are the immune mechanisms involved in the acquisition of oral 
desensitization by allergic children during a process of cow's milk or egg oral 
immunotherapy; identifying biomarkers of tolerance induction, clarifying why some children 
succeeded in cow's milk and egg oral immunotherapy and others do not; and proposing 
predictors to accurately define the efficacy and the risk of adverse reactions during cow's 
milk and egg oral immunotherapy. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
3. MATERIALS AND METHODS 
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3.1. Ethics statements 
All human samples and procedures were obtained and performed with written consent 
from the next of kin, caretakers, or guardians on the behalf of the minors/children involved 
in the performed studies. All experiments were conducted according to the principles 
expressed in the Declaration of Helsinki. The Bioethics Committees from the Consejo 
Superior de Investigaciones Científicas (CSIC), Spain, and the Hospital Universitario La 
Paz, Madrid, Spain, approved the studies of OIT performed in the Hospital Infanta Sofía of 
Madrid. Similarly, the Bioethics Committee of the Hospital Infantil Universitario Niño Jesús, 
Madrid, and the Hospital General Universitario Gregorio Marañón, Madrid, did the 
appropriate revision of all procedures within the studies performed in such Hospitals.  
 
3.2. Human peripheral blood samples collection and separation of fractions  
Peripheral blood samples were obtained from participants (allergic and non-allergic 
children) in all performed studies at hospital, at corresponding Division of Allergy or 
Urgencies, after the informed consent from legal guardians according to ethics statements. 
The amount of blood was drawn based on minimum requirements and always accordingly 
to child's age, less than 3 ml of blood in children under 2 years of age and a maximum of 5 
ml in older patients. 
Blood samples were collected into blood collection tubes treated with ethylenediamine 
tetraacetic acid (EDTA) as anticoagulant. Samples stored for a no longer period of 8 h were 
laboratory processed performing methods as described below: human sera were analyzed 
for total and allergen-specific IgE and IgG4 antibodies and vitamin D testing and human 
blood cells were used for cell culture and stimulation, flow cytometry analysis and study of 
gene expression. 
Samples from participants in all performed studies were centrifuged at 150g for 15 min 
at 20ºC to separate sera from the whole blood samples. Sera were placed in cryotubes 
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stored at -20ºC until serological test for measure total and allergen-specific IgE and IgG4 
antibodies were done and a density gradient with Ficoll-Paque Plus media (GE Healthcare, 
Barcelona, Spain) were used to separate Peripheral Blood Mononuclear Cells (PBMCs). 
For that procedure, blood was diluted 1:1 with Phosphate Buffered Saline (PBS) without 
Ca
2+/
Mg
2+
 and gently layered onto a conical tube with Ficoll. After centrifugation at 500g for 
30 min at 20ºC with slow acceleration and without deceleration to prevent mixing of the 
phases, the layer containing the PBMCs was aspirated from the plasma-Ficoll interface 
with a disposable transfer pipet, transferred into a new conical tube and washed twice by 
centrifugation with PBS at 300g for 10 min at 20 ºC. The resulting cell pellet was used for 
cell-culture or flow cytometry assays.  
 
3.3. Measurement of serum total and allergen-specific IgE and IgG4 antibodies by 
ImmunoCAP 
Levels of total serum IgE and serum allergen-specific IgE and IgG4 were analyzed by 
ImmunoCAP System (Thermo Fisher Scientific, Waltham, MA, USA). Whole EW (allergen 
code on CAP platform (f1)), OM (nGal d1 (f233)) and OVA (nGal d2 (f232)) were specific 
IgE and IgG4 checked in serum of participants in egg OIT studies, whereas whole cow’s 
milk (f2) and total CN (nBos d8 (f78)), α-LA (nBos d4 (f76)) and β-LG (nBos d5 (f77)) were 
the allergens measured in CM OIT. ImmunoCAP test is designed as a classic “sandwich” 
immunoassay. Allergen ImmunoCAP covalently bound on a cellulose solid-phase is 
incubated with 20 μl of serum in the platform. After washing away non-specific IgE or IgG4 
bindings (depending on test), enzyme labelled antibodies against IgE or IgG4 are added to 
form a complex. Following incubation, unbound enzyme-anti-antibody is washed away and 
the bound complex is then incubated with a developing agent to stop the reaction. The 
fluorescence of the eluate is measured by the own equipment and the response for the 
patient samples is transformed to concentrations with the use of a calibration curve. The 
software analyses and calculates the results.  
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3.4. Chemiluminiscence assay for vitamin D testing in serum samples 
Vitamin D was quantified as 25-hydroxyvitamin D in serum samples to study its 
potential role in the CMA establishment in infants. Quantification was performed by 
chemiluminiscence assay at Hospital General Universitario Gregorio Marañón employing 
the LIASON 25-OH-Vitamin D Total Assay in a LIASON XL analyser (DiaSorin, Stillwater, 
MN, USA). Values were expressed as ng/mL. 
 
3.5. In vitro cell-culture and allergen-specific stimulation of PBMCs 
Isolated PBMCs of samples from the Hospital Infanta Sofía were cultured in vitro (2 × 
10
6
 cells/mL) with OVA or β-CN, egg OIT or cow’s milk OIT respectively (both with 200 
μg/mL; Sigma-Aldrich, St Louis, MO, USA), in AIM-V medium for 7 days at 37ºC in 5% 
CO2. Similar in vitro OVA-stimulation of PBMCs were performed in samples from the 
Hospital Infantil Universitario Niño Jesús but prolonged for only 72 hours. Medium alone 
was used as negative control and the mitogen phytohemagglutinin (PHA) (4 μg/mL) 
(Sigma) as a positive control. All experiments were performed in 24-well plates (Corning, 
Corning, New York) with a final volume of 1ml of medium. After allergen-specific 
stimulation, the plates were centrifuged at 1100 rpm for 10 min, supernatants frozen at -
80ºC until cytokine analysis and cell pellets in Lysis Buffer RA1 (Macherey-Nagel, Duren, 
Germany) and β-mercaptoethanol (Sigma-Aldrich, St Louis, MO, USA)  or Trizol® reagent 
(Life Technologies, Carlbad, CA, USA) before RNA isolation. 
 
3.6. Cytokine profile and immune cells subsets by flow cytometry analysis 
3.6.1. Cytokine profile analyses by flow cytometric bead array 
PBMCs culture supernatants after allergen-specific stimulation were analyzed for the 
presence of IL-5, IL-13, IL-10, IFN-γ and TNF-α (pg/ml) by using a multiplex flow cytometric 
bead array (CBA) (BD cytometric bead array; BD Biosciences, San Diego, CA, USA) 
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according to manufacturer`s instructions. All cytokines were measured under the same 
conditions and at the same time with 25 μl of culture supernatant, after being captured with 
the commercial beads conjugated with specific antibodies and the detection reagents, 
mixture of phycoerythrin (PE)-conjugated antibodies. We designed a Bead Flex Set where 
sandwiches complexes (capture bead + recognized cytokine + detection reagent) were 
formed and these complexes were measured by acquiring samples in The Gallios™ flow 
cytometer (Beckman Coulter, France) and analyzed by Beckman Coulter Kaluza and FCAP 
Array v3 (BD Biosciences) Software. Each capture bead has a known size and 
fluorescence, making it possible to detect it using flow cytometry, and the detection reagent 
provides a fluorescent signal in proportion to the amount of bound cytokine. The cytokines 
concentrations detected were calculated using 10-points standard curves of each of the 
human cytokines (0-2500 pg/mL). Results are expressed as the amount of cytokine 
detected after the stimulation with OVA minus the amount of cytokine detected after in vitro 
stimulation with the negative control.  
 
3.6.2. Percentage of CD4+CD25+Foxp3+ Treg cells in allergen-specific stimulated 
PBMCs  
Percentage of CD4+CD25+Foxp3+ Treg cells was measured after stimulation with OVA for 
72 hours of PBMCs from samples of the Hospital Infantil Universitario Niño Jesús. PBMCs 
were separated, cell surface stained for CD4/CD25 (BD Biosciences) and next fixed and 
permeabilized with the Fixation/Permeabilization Solution Kit (BD Biosciences) according to 
the manufacturer’s instruction, prior to the intracellular staining for transcription factor 
FoxP3 (BD Biosciences). Isotype controls were included in any antibody staining. Samples 
were acquired in a Gallios™ flow cytometer (Beckman Coulter, France) and percentages of 
CD4+CD25+Foxp3+ Treg cells were analyzed by Beckman Coulter Kaluza (BD 
Biosciences) Software. 
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3.6.3. Percentage and absolute counts of immune cell subsets in lysed whole blood 
The study of the percentage and absolute counts of immune cell subsets could be 
implicated as biomarkers in CM allergy were performed at the Instituto de Investigación 
Sanitaria Gregorio Marañón, Madrid, Spain.  
The percentage and absolute counts of total T lymphocytes, B lymphocytes and 
basophils, as well as different subset thereof, were determined by flow cytometry in a 
Gallios™ flow cytometer (Beckman Coulter, France). We performed two multicolour flow 
cytometry panels staining a precise volume of 100 μl from whole blood sample for different 
cell surface markers. After incubation for 30 min in the dark at room temperature, red blood 
cells were lysed in a TQ-Prep™ Workstation (Beckman Coulter) and, immediately prior to 
acquisition on the flow cytometer, 100 μl of Flow-Count Fluorospheres (Beckman Coulter) 
were added to samples in order to determine the absolute numbers of the cell subtypes 
(cells/μl).  
To characterized T lymphocytes, we designed a first flow cytometry panel for which 
samples were stained with CD3 (T cells), CD4 (CD4+ T cells) and CD8 (CD8+ T cells), 
including markers for the following subsets: naïve (CD45RA+CD27+), activated (HLA-
DR+), central memory (CD45RA−CD27+), effector memory (CD45RA−CD27−). Absolute 
counts of regulatory T (Treg) cells in total blood were quantified measuring 
CD3+CD4+CD25+CD127low cells.  
Percentage and absolute counts of B cells (CD19+CD3−) were determined by a 
second flow cytometry panel, including naïve (CD27−IgD+), memory non-switch 
(CD27+IgD+), memory switch (CD27+IgD−) and regulatory B (Breg) cells 
(CD24highCD27high) phenotypes. Basophils (CD45lowCD123+IgE+) including activated 
basophils (CD63+) were also measured. 
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3.6.4. Percentage of CD4+CD25+Foxp3+Treg and cytokine secreting cells in non-
specifically stimulated PBMCs 
PBMCs of blood samples from the Hospital Universitario Gregorio Marañón were 
isolated by density gradient separation using Ficoll-Paque media (GE Healthcare, 
Barcelona, Spain) as previously described in section 3.3.  
A multicolor flow cytometry panel was designed to investigate the percentage of total 
and subsets of interest of CD4+CD25+Foxp3+ Treg cells.  Approximately 10
6
 PBMCs were 
separated and firstly incubated with Human FC block (BD Biosciences, San Diego, CA, 
USA) for 15 min at 4ºC to block non-specific binding of antibodies to FC receptors. Cell 
surface marker staining were done for 30 min in the dark at 4ºC for terminally differentiated 
effector cells (TemRA) (CD45RA+CD27−), and recent thymic emigrants (RTE) 
(CD45RA+CD27+CD31+) subsets of CD25+Foxp3+ Treg cells. Percentage of Treg cells 
(CD3+CD4+CD25+Foxp3+) were analysed by Foxp3 intracellular staining with the Anti-
Human Foxp3 Staining Set (eBioscience, San Diego, California) according to the 
manufacturer’s instructions. Briefly, after the staining of cell surface antigens, cells were 
washed, incubated with a fixation/permeabilization solution for 30 min in the dark at 4ºC, 
washed again twice and stained for intracellular cytokines for another 30 min at 4ºC. 
Analysis of cytokine-secreting CD4+ T cells was performed in PBMCs non-specifically 
stimulated with phorbol 12-myristate 13-acetate (PMA) (50 ng/ml) and Ionomycin (Io) (1 
μg/ml) (both from Sigma-Aldrich, St. Louis, MO) for 5h at 37ºC in 5% CO2 and including the 
presence of GolgiStop protein transport inhibitor (0.7ul/ml) (BD Biosciences, San Diego, 
CA, USA). PBMCs were surface stained for 30 min in the dark at 4ºC with markers 
including activation (CD69+), Th1 response (CXCR3+), Th2 response (CCR4+CCR6-) and 
Th17 response (CCR4+CCR6+CXCR3-). Viability was assessed by labelling dead cells 
with fixable viable dye (eBioscience) Intracellular staining of IFN-γ (Th1 response), IL-4 
(Th2 response), and IL-17 (Th17 response) was done following the instructions of the 
Cytofix/Cytoperm Kit (Beckton Dickinson). Frequency of cytokine-secreting cells was 
calculated in total CD4+ T cells. 
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3.7. Relative gene expression 
3.7.1. Separation and quality assessment of total RNA  
Total RNA from in vitro cultured and allergen-specific stimulated PBMCs was extracted by 
using the Total RNA Isolation NucleoSpin
®
 RNA II Kit (Macherey-Nagel, Duren, Germany) 
in samples from the Hospital Infanta Sofía, or iPrep™ Trizol® Plus RNA Kit (Life 
Technologies, Carlbad, CA, USA) in samples from the Hospital Infantil Universitario Niño 
Jesús, according to the manufacturer´s instructions. The RNA template was qualitatively 
assessed and quantified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo 
Alto, CA, USA) and a NanoDrop ND1000 instrument (Thermo Fisher Scientific), 
respectively. 
 
3.7.2. Quantitative Real-Time Polymerase Chain Reaction 
Reverse transcription reactions were performed following the manufacturer’s 
instructions with the Transcriptor First Strand cDNA Synthesis Kit (Roche, Manheim, 
Germany). RT-qPCR was performed in a ViiA™ 7 Real-Time PCR System (Applied 
Biosytems) using a total of 6 ng of transcribed cDNA and TaqMan® Gene Expression 
Assay for the transcription factors: GATA3 (Human Assay ID Hs00231122m1), T-bet (ID 
Hs00203436m1) and FoxP3 (ID Hs01085834m1), according to manufacturer´s 
recommendations. The hypoxanthine guanine phosphoribosyl transferase (HPRT) (ID 
Hs02800695m1) was used as reference gene. The amplification program used was: 1 
cycle of 10 min at 95 °C, 40 cycles of 15 s at 95 °C and finally 1 cycle of 1 min at 60 °C. All 
reactions were performed in triplicate. The mean value of the replicates for each sample 
was expressed as the quantification cycle (Cq). The relative gene expression values (RQ) 
of a gene between two times of treatment were calculated as reported by Livak and 
Schmittgen (2001). A RQ value of sample higher than 2 or lower 0.5 was established to be 
considered a relevant change (RQ=1 showed no change). 
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3.8. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 5 software (San Diego, CA, 
USA) and SPSS software (IBM, New York, USA). Shapiro-Wilk test was used for assessing 
normality of variables. Non-parametric Mann–Whitney test was used for comparison a 
variable of interest between two independent groups of participants, and Wilcoxon test 
when comparing a variable between to related samples to analyse differences during OIT. 
Correlation between variables was established by Pearson correlation (PC) test. Capacity 
of discrimination between groups for the different variables was analyzed by ROC’s curves. 
P-value <0.05 by 2-sided test was considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
4. RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
4.1. The establishment of cow's milk protein 
allergy in infants 
 
 
This study aimed to investigate the immune alterations which constitute 
differential factors between allergy and tolerance in pediatric cow's milk protein 
allergy, and hence could be implicated in its establishment in infants.  
The results reported in this section have been published in the reference: 
[Perezabad, L., López-Abente, J., Alonso-Lebrero, E., Seoane, E., Pion, M., 
Correa-Rocha, R. (2017). The establishment of cow's milk protein allergy in 
infants is related with a deficit of regulatory T cells (Treg) and vitamin D. 
Pediatric Research. doi: 10.1038/pr.2017.12]. 
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4.1.1. RESULTS 
Participant selection, samples and follow up 
Infants younger than 9 months, with symptoms compatible with cow's milk protein 
allergy (CMPA), such as vomiting or skin eruptions after cow’s milk (CM) ingestion were 
recruited at Pediatric Allergy Division or Urgencies of the Hospital General Universitario 
Gregorio Marañón (Madrid, Spain). The confirmation of CMPA diagnosis was performed by 
Oral Food Challenge (OFC) (unless contraindicated by severe clinical profile), as well as 
considering the total and CM-specific IgE values, physical examination and family history. 
Patients with a diagnosis of non-IgE mediated CMPA, cow's milk intolerance, allergic 
proctocolitis, or enterocolitis, were excluded from the study. Egg allergy, which is also 
frequent at this age, was discarded in all patients. As follows, after applying the inclusion 
and exclusion criteria, the children enrolled in the study were distributed in two groups: 1) 
infants with a confirmed diagnosis of CMPA (CMPA group) by immediate symptoms after 
OFC (N=15); and 2) age-matched non-allergic controls (Control group) (N=13) with a 
negative result for the OFC, and subsequent ingestion of milk at home without developing 
symptoms.  
Peripheral blood samples were obtained between 1 and 4 days after the first CM 
adverse reaction and just before the oral challenge test and the diagnosis of the infants. 
Samples were processed immediately as described in Material and Methods (section 3.2).  
Patients included in the CMPA group were clinically followed along a year to determine 
whether they became tolerant to milk. A patient was considered tolerant by the absence of 
allergic reaction after a controlled exposition to milk and confirmed if the patient was able to 
consume CM in a normal quantity without adverse reactions. 
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Patient's demographics and specific IgE response 
Twenty-eight participants were enrolled, divided into two groups. There were no 
significant differences in sex and age between groups, being the mean age in Control and 
CMPA groups 6.18 and 6.43 months, respectively. As expected, total and specific IgE to 
CM, α-LA, CN and β-LG were increased in the CMPA group but not in the Control group. 
Values are registered in Table 3. 
 
 
 
 
 
Table 3. Demographics and specific IgE response of children included in Control and CMPA 
groups. Values are presented as mean ± SEM. * P-value <0.05 in non-parametric Mann-
Whitney test comparing Control and CMPA values. Plasma values of IgE are expressed as 
kU/L. 
 
Extensive analysis of immune subsets and cytokines  
Percentage and absolute counts (cells per μL of total blood) of a wide range of 
immune cell subsets were compared between children with CMPA and Controls (Table 4). 
Interestingly, there were very few differences between the values observed in CMPA and 
control children, and percentages and absolute counts for CD4+ and CD8+ T cells, 
including subsets naïve (CD45RA+CD27+), central memory (CD45RA-CD27+), effector 
memory (CD45RA-CD27-) and activated (HLADR+); B cells (CD19+CD3-) covering naïve 
(CD27-IgD+), memory switch (CD27+IgD-), memory non-switch (CD27-IgD+) and Breg 
(CD24highCD27high); and basophils (CD45lowCD123+IgE+) including activated basophils 
 Control (N= 13) CMPA (N= 15) P-value 
Age (months) 6.18 ± 0.62 6.43 ± 0.46 0.747 
Gender (% male) 53.85 % (7/13) 60.0 % (9/15) 0.747 
Total IgE 8.90 ± 2.87 65.35 ± 27.63 0.005* 
CM specific IgE 0.10 ± 0.04 4.71 ± 1.77 0.000* 
α-LA specific IgE 0.01 ± 0.01 1.67 ± 0.69 0.003* 
CN specific IgE 0.06 ± 0.03 1,00 ± 0.44 0.003* 
Β-LG specific IgE 0.05 ± 0.03 4.36 ± 2.15 0.000* 
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(CD63+) were comparable between both groups. Significant differences were only found for 
naïve CD8 T cell counts, which were lower in CMPA children than in controls. 
 
 
Percentage Cells/μL 
Control 
(N= 13) 
CMPA 
(N= 15) 
P-
value 
Control 
(N= 13) 
CMPA 
(N= 15) 
P-
value 
Total 
Lymphocytes  
      
CD4+ T cells  46.54 ± 2.97 49.81 ± 2.89 0.345 3056 ± 220 2632 ± 212 0.420 
CD8+ T cells 12.41 ± 1.16 12.69 ± 1.17 0.534 798 ± 81 642 ± 46 0.123 
B cells 24.89 ± 2.18 24.64 ± 1.69 0.872 1669 ± 192 1304 ± 113 0.123 
       
CD4+ T cells       
Naive 82.60 ± 1.75 79.04 ± 3.71 0.884 2530 ± 197 2151 ± 210 0.332 
Central 
Memory 
9.37 ± 1.19 10.03 ± 1.07 0.872 279 ± 32 236 ± 16 0.084 
Effector 
Memory 
0.56 ± 0.10 1.63 ± 1.08 0.533 17.3 ± 3.6 19.8 ± 5.0 0.982 
Activated 1.02 ± 0.13 1.72 ± 0.68 0.927 31.2 ± 3.8 30.6 ± 4.0 0.565 
       
CD8+ T cells       
Naive 84.32 ± 3.54 77.35 ± 6.04 0.497 671 ± 82 477 ± 45 0.023* 
Central 
Memory 
8.73 ± 1.70 12.17 ± 2,38 0.300 67.0 ± 13.5 80.8 ± 20.2 0.596 
Effector 
Memory 
1.87 ± 0.98 2.60 ± 1.46 0.712 14.5 ± 7.0 22.2 ± 13.4 0.982 
Activated 2.68 ± 0.78 6.58 ± 2.85 0.420 21.4 ± 6.3 48.0 ± 22.9 0.836 
       
B cells       
Naive 91.41 ± 0.91 90.55 ± 0.74 0.357 1534 ± 184 1118 ± 129 0.069 
Memory 
switch 
0.99 ± 0.17 1.09 ± 0.14 0.447 15.2 ± 2.2 13.3 ± 1.8 0.534 
Memory 
non-switch 
6.09 ± 0.80 6.77 ± 0.66 0.357 95.0 ± 12.3 86.2 ± 9.6 0.662 
Breg 1.48 ± 0.17 1.72 ± 0.30 0.765 22.4 ± 2.3 21.2 ± 3.0 0.420 
       
Basophils 
Total 
 
0.60 ± 0.03
a
 
 
0.65 ± 0.08
a
 
 
0.982 
 
58.3 ± 3.5 
 
57.1 ± 7.3 
 
0.475 
Activated 40.11 ± 4.73 38.13 ± 4.73 0.695 23.8 ± 3.6 23.0 ± 5.0 0.504 
 
Table 4. Values of percentages and absolute counts (cells per μL of total blood) for immune cell 
subsets in Control and CMPA children enrolled in the study. Values are given as mean ± SEM. 
*: P <0.05 in non-parametric Mann-Whitney test comparing groups. Percentage for each subset 
is calculated regarding the total of the corresponding population (Total Lymphocytes; CD4+ T 
cells; CD8+ T cells; B cells or Basophils). 
a 
percentage of basophils in total leucocytes (CD45+). 
 
PBMCs from CMPA infants were non-specifically stimulated in vitro with PMA and 
ionomicine, and the percentage of Th1, Th2 and Th17 cytokine-secreting CD4+ T cells 
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analysed. There were no differences neither in the frequency of IFN-γ secreting CD4+ T 
cells (Th1) (Mean ± SEM CMPA=3.51 ± 2.09; Control=1.82 ±0.34; P=0.742), nor in the 
frequency of IL17-secreting CD4+ T cells (Th17) (CMPA=0.14 ±0.03; Control=0.10 ± 0.02; 
P=0.727). However, the frequency of IL4-secreting CD4+ T cells (Th2) was significantly 
higher in CMPA children (Figure 5) (CMPA=0.69 ± 0.13; Control=0.43 ± 0.06; P=0.037). 
Between the different variables studied here, the higher frequency of IL4-secreting 
CD4+ T cells (IL4-TCD4) seems to be the only differential immune factor in CMPA children 
that could be associated with the appearance of symptoms and the development of this 
allergy. 
 
 
 
 
 
 
Figure 5. Percentage of IL4-secreting CD4+ T cells measured by intracellular staining in PMA + 
Io stimulated PBMCs. Median with interquartile range in both Control and CMPA groups are 
represented. *: P<0.05 in non-parametric Mann-Whitney test comparing Control and CMPA 
values. 
 
Values of regulatory T cells and immune homeostasis 
It was expected that increased frequency of (effector) IL4-secreting CD4+ T cells 
would promote the expansion/activation of Treg cells in CMPA patients. The percentage of 
Treg cells into the CD4+ T cell population, which is a relative measure that can be 
influenced by the expansion or depletion of other CD4+ T cell subsets, was comparable 
between Control and CMPA groups of children (Figure 6A; P=0.433). However, when 
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absolute counts of Treg cells (cells per μL of total blood) were measured, significantly lower 
Treg numbers in the CMPA group were found compared with Controls (Figure 6B; 
P=0.040). 
 
 
 
 
 
 
Figure 6. Values of Treg cells. Percentage (A) and absolute counts (cells per μL of total blood) 
(B) of Treg cells. Median with interquartile range in both Control and CMPA groups are 
represented. *: P<0.05, n.s.: non-significant differences in non-parametric Mann-Whitney test 
comparing Control and CMPA values. 
 
After analysing the phenotype and the differentiation stage of these Treg cells, the 
absolute counts of all the Treg subsets were lower in the CMPA group in comparison to 
controls (Table 5), and this deficiency was significant for the central memory (CD45RA-
CD27+) (Figure 7A; P=0.040) and terminally differentiated effector cells (TemRA) 
(CD45RA+CD27−) (Figure 7B; P=0.022) Treg subsets. Additionally, only in the CMPA 
group, a negative correlation between the frequency of IL4-TCD4 cells and naïve 
Foxp3+CD25+ Treg cells (PC=−0.783; P=0.003) was observed, together with a positive 
correlation with the frequency of activated Treg (PC=0.881; P=0.000). In other words, a 
high frequency of IL4-TCD4 cells is associated with a decrease in the proportion of naïve 
Treg and an increase in the proportion of activated Treg, which could reflect an active 
differentiation of Treg cells from a naïve to an activated phenotype in response to the 
increased frequency of IL4-TCD4 cells. 
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Percentage Cells/μL 
Control 
(N= 13) 
CMPA 
(N= 15) 
P-
value 
Control 
(N= 13) 
CMPA 
(N= 15) 
P-
value 
Treg Cells
a
 7.51 ± 0.44 6.97 ± 0.54 0.433 227.9 ± 21.0 174.8 ± 16.4 0.040* 
  Naïve
b
 69.73 ± 2.86 64.89 ± 3.67 0.528 157.3 ± 14.3 120.0 ± 13.4  0.081 
  Central 
     Memory
b
 
19.26 ± 2.74 19.52 ± 1.57 0.982 43.12 ± 5.60 32.68 ± 3.99 0.040* 
  Effector 
    Memory
b
 
1.20 ± 0.35 1.91 ± 0.83 0.311 2.89 ± 0.97 2.38 ± 0.47 0.945 
  Activated
b
 3.52 ± 0.34 4.10 ± 0.98 0.534 7.95 ± 0.96 6.37 ± 1.34 0.117 
  TemRA
b
 0.57 ± 0.21 0.09 ± 0.01 0.027* 1.28 ± 0.45 0.16 ± 0.02 0.022* 
 
Table 5. Values of percentages and absolute counts (cells per μL of total blood) for Treg and 
Treg subsets. Values are given as mean ± SEM. *: P<0.05 in non-parametric Mann-Whitney 
test comparing Control and CMPA values. 
a
 Percentage of Treg cells in the total of CD4+ T 
cells; 
b
 Percentage of Treg subsets in the total of Treg cells. 
 
 
 
 
 
 
 
Figure 7. Values of Treg cells. Absolute counts of Central memory (C Mem) Treg cells (A) and 
terminally differentiated effector cells (TemRA) Treg cells (B). Median with interquartile range in 
both Control and CMPA groups are represented. *: P<0.05 in non-parametric Mann-Whitney 
test comparing Control and CMPA values. 
 
We also analysed the ratio between Treg and IL4-TCD4 cells, which is an indicator of 
the balance between immune tolerance and immune reactivity. The ratio was lower in the 
CMPA group than controls, reflecting a Treg imbalance in CMPA patients. The differences 
in the Treg/IL4-TCD4 ratio were significant in both cases, when percentage (P=0.036) or 
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absolute counts (P=0.027, Figure 8) of Treg and IL4-TCD4 cells were used to calculate the 
ratio between these subsets. The Treg/IL4-TCD4 imbalance and the deficit in the number 
of circulating Treg cells in CMPA infants could result in an inadequate control of effector T 
cells, and could explain the increased frequency of IL4-TCD4 cells. In fact, in the CMPA 
group but not in controls there was a negative correlation between Treg absolute counts 
and IL4-TCD4 cells. The lower was the quantity of circulating Treg the higher was the 
frequency of IL4-TCD4 cells (PC=−0.614; P=0.019). 
 
 
 
 
 
 
 
Figure 8. Ratio between Treg and IL4-secreting CD4+ T cells (IL4-TCD4) absolute counts. 
Median with interquartile range in both Control and CMPA groups are represented. *: P<0.05 in 
non-parametric Mann-Whitney test comparing Control and CMPA values. 
 
Mechanisms of Treg cells deficit. Thymic function and Vitamin D levels 
There are different mechanisms that could explain the decreased Treg numbers 
observed in the CMPA group. Because Treg cells is a subset of CD4+ T cells, which is also 
generated in the thymus, a deficiency in the thymic production of Treg cells could be 
related with the reduced number observed in periphery. The expression of CD31 within the 
pool of Foxp3+CD25+ Treg cells were analysed, a marker which is only expressed in 
recent thymic emigrants (RTE) and it is considered an indirect indicator of thymic 
production (Kimmig et al., 2002). The results showed that there are not any significant 
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differences in the frequency (P=0.703) and absolute counts (P=0.560) of RTE Treg 
(CD45RA+CD27+CD31+) between the CMPA and control group (Figure 9A, 9B), and 
hence, a possible defect in the thymic production as the reason of Treg deficiency can be 
discarded. 
Other mechanism that could be implicated in a deficit of Treg cells is the serum levels 
of 25-hydroxyvitamin D. Values of vitamin D, quantified as 25(OH)D (ng/mL), were 
significantly lower in the CMPA group than in control children (CMPA=35.3 ± 3.5; 
Control=47.9 ± 3.7; P=0.041) (Figure 9C). Moreover, a direct correlation between plasma 
levels of Vitamin D and absolute counts of Treg were observed (PC=0.390; P=0.027). 
Serum 25(OH)D values lower than 30 ng/mL are considered insufficient in children 
(Muehleisen and Gallo, 2013). Even if the median values of vitamin D in the CMPA group 
are higher than this cut-off, we observed that the only four children with values lower than 
30 ng/mL all belonged to the CMPA group (Figure 9D). In addition, children included in the 
CMPA group were those with lower vitamin D values and lower Treg counts (orange dots, 
Figure 9D), supporting the hypothesis that the deficiency in vitamin D could be related with 
the deficit of Treg cells and the subsequent increased Th2 immune responses. 
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Figure 9. Percentage (A) and absolute counts (cells per μL of total blood) (B) of recent thymic 
emigrants (RTE) Treg cells. (C) Serum concentration of 25(OH)D (ng/ml) measured by 
chemiluminiscence. Median with interquartile range in both Control and CMPA groups are 
represented. n.s.: non-significant differences *: P<0.05 in non-parametric Mann-Whitney test 
comparing Control and CMPA values. (D) Correlation of Vitamin D levels and absolute counts of 
Treg cells (cells per μL of total blood). Control: grey squares; CMPA: orange dots. Pearson 
coefficient= 0.390; P=0.027.  
 
Treg counts and serum Vitamin D levels can discriminate between Controls and 
CMPA children 
Blood samples were obtained from patients with a suspicion of CMPA before the OFC 
and the definitive diagnosis of CMPA. Therefore, we analysed whether the three variables 
differentially expressed in CMPA children could be good predictors of the result in the oral 
challenge test and the clinical diagnosis of this allergy. The receiver operating characteristic 
(ROC) curve is widely utilized to evaluate the performance of diagnostic tests. The area 
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under the ROC curve (AUC) is a summary index commonly used to determine the quality to 
predict an event by different variables (Yao et al., 2015). ROC-curves were calculated to 
provide information on the sensitivity and specificity of these variables to discriminate 
between healthy Controls and CMPA children. The analysis of the data indicates that low 
serum 25(OH)D levels (AUC=0.754; 95% confidence interval (95CI)=0.553-0.955; 
P=0.041); low absolute number of Treg (AUC=0.728; 95CI=0.538-0.918; P=0.040) and a 
high frequency of IL4-TCD4 cells (AUC=0.747; 95CI= 0.547-0.946; P=0.037) are good 
variables to discriminate between CMPA and Control children (Figures 10a-c, 
respectively). The Treg/IL4-TCD4 counts ratio was also a good predictor (AUC=0.756; 
95CI=0.536-0.946; P=0.027) to distinguish between CMPA and control children (Figure 
10d). 
 
 
 
 
 
 
 
 
 
 
Figure 10. ROC Curves and predictive value of analysed variables: serum concentration of 25-
hydroxyvitamin D (μg/L) (a); total Treg counts (cells per μL of total blood) (b); frequency of IL4-
secreting CD4+ T cells (IL4-TCD4) (c); and the Treg/IL4-TCD4 counts ratio (d) were good 
discriminators between healthy and CMPA children.  
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Basal Vitamin D level was associated with the achievement of spontaneous 
tolerance to cow's milk in the first year.  
Infants included in CMPA group were 1 year follow up to determine which patients 
spontaneously become tolerant to cow’s milk. Seven out of 15 patients (46.6 %) remained 
allergic to cow’s milk whereas 8 out of 15 (53.3 %) became tolerant or desensitized to 
cow’s milk within the first year following the diagnosis. Interestingly, the vitamin D levels 
measured 1-4 days after the first adverse reaction to milk and before of CMPA diagnosis 
were good predictors of patients who spontaneously acquire tolerance or remain allergic. 
The presence of basal levels of vitamin D lower than 40 ng/mL predicted in our cohort 
those patients that remained allergic after 1 year, with a sensitivity of 87.5% and a 
specificity of 80% (AUC=0.850; 95CI: 0.608-1; P=0.040) (Figure 11).  
 
 
 
 
 
 
 
Figure 11. ROC Curve and predictive value of basal 25-hydroxyvitamin D levels (μg/L). Values 
of Vitamin D were a good predictor of those patients that did not acquire spontaneous tolerance 
to cow’s milk along the first year after CMPA diagnosis. 
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4.1.2. DISCUSSION 
In this study we performed an analysis of biomarkers which may elucidate immune 
alterations related with the establishment of cow's milk allergy in children. For that purpose, 
15 infants with symptoms compatible with CMPA after cow's milk ingestion were recruited 
and the results compared with that of a group of 10 control patients from the same age-
range. Samples were collected between 1-4 days after the first adverse reaction in CMPA 
children and therefore, we could study the immune system just after the onset of the 
allergic process.  
Almost no difference was found in the frequency and absolute counts of the different 
immune cell subsets or in the phenotype of these populations between controls and CMPA 
children. It is noteworthy that the frequency of antigen-specific cells in peripheral blood is 
very low (allergen-specific T cells are typically less than 0.01%) (Wambre et al., 2014) and 
thus, the changes in allergen-specific cells were unlikely reflected in the values of cells we 
observed in peripheral blood. We did not analyze antigen-specific cells because the goal of 
our study was to identify immune markers easily measurable in peripheral blood that could 
be implemented in the clinical routine for the follow-up of these patients. 
 We observed a lower absolute number of naïve CD8+ T cells in CMPA children. 
Previous studies demonstrated a reduced percentage of CD8+ T cells in children with 
CMPA (Järvinen et al., 1998; Osterlund and Suomalainen, 2002), but they do not quantify 
the absolute counts of these cells. Because CD8+ T cells are one of the subsets 
responsible for the IFN-γ production, the reduced pool of naïve CD8 T cells in CMPA 
patients could be related with the decreased production of IFN-γ observed in patients with 
CMPA or other atopic diseases (Järvinen et al., 1998; Osterlund and Suomalainen, 2002). 
However, the role of CD8 T cells in food allergy is unclear with conflicting evidences of 
pathogenic or protective functions for this subset (Huber and Lohoff, 2015), and further 
studies must be conducted to clarify the function of CD8 T cells in CMPA allergy. 
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At the light of our results, a deficit in the number of Treg cells seems to be one of the 
determining factors related with the establishment of CMPA. Although the activation and/or 
differentiation of Treg cells appears to be correctly occurring in CMPA children, the 
frequency of IL4-TCD4 cells remains increased, probably as a consequence of the deficit in 
the number of circulating Treg cells that we observe in the CMPA group. In the context of 
food allergy, evidence from animal models and humans studies demonstrate how Treg 
cells can prevent allergic sensitization (van den Elsen et al., 2013) and induce oral 
tolerance (Karlsson et al., 2004; Fuentes Aparicio et al.,2013) and, thus, how Treg cells 
play a crucial role in the allergic disorders (Palomares et al., 2010). Our results indicate that 
the Treg deficiency is already present in the first 1 to 4 days after the first adverse reaction. 
Therefore, decreased Treg values could constitute a factor that predispose for the 
acquisition of an atopic phenotype and more concretely for the establishment of CMPA in 
infants. To definitively confirm this fact, it would be necessary to measure Treg values 
before the first ingestion of cow's milk, with difficulty in the large cohort of healthy infants 
should be enrolled for this kind of study as it will be unknown which children become 
allergic. 
Regarding to the potential reasons for the Treg deficit in these infants, it is interesting 
to note that decreased numbers of Tregs are not due to the immaturity of the immune 
system at this age. Previous studies have demonstrated that neonates already have high 
Treg values (Correa-Rocha et al., 2012). In fact, controls infants of the present study 
showed Treg counts around 200 cells per μL, which are markedly higher than values 
observed in healthy children around 3 years old (Ferrando-Martínez et al., 2014) or 9 years 
old (Fuentes-Aparicio et al., 2013). We also found that, impairment in the thymic production 
of Treg cells can be discarded as responsible for the decreased Treg values. RTE Tregs 
were not different, and naïve Treg values were also comparable in both groups. That 
means that the deficit of Tregs are consequence neither of the level of thymic production 
nor of the arrival of these naïve Tregs to the periphery. Between the different Treg 
phenotypes, only the number of central memory and TemRA Treg cells was significantly 
reduced. These results indicate that the production, activation and differentiation to effector 
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cells in the Treg subsets seem to develop correctly in CMPA children. Indeed, we observed 
in the CMPA group that children with the highest values of circulating Treg cells were also 
those with lower frequencies of IL4-secreting CD4+ T cells, which reflects a suitable 
suppressive function of Tregs in these children. The fact that central memory and TemRA 
subsets of Treg cells (which are the most advanced steps of differentiation) are the most 
affected, could reflect a inaccuracy in the survival of these cells or in the mechanisms to 
maintain this pool after the antigenic stimulus.  
Several studies demonstrate that vitamin D contributes significantly to the induction, 
survival and preservation of the Treg population (Penna et al., 2005; Chambers and 
Hawrylowicz, 2011; Ferrando-Martínez et al., 2014). Furthermore, numerous studies find a 
relationship between decreased values of vitamin D, in both mother (Chiu et al., 2015; 
Vijayendra Chary et al., 2015) and infant (Jones et al., 2015), and a higher incidence of 
allergy. The lower vitamin D values found in CMPA children and the direct correlation 
observed between vitamin D and the quantity of circulating Treg cells support the 
hypothesis that the impaired survival of Treg cells could be influenced by the deficit of 
vitamin D. 
Our results show that IL4-secreting CD4+ T cells are the only population increased in 
periphery during the first phases of CMPA. Treg cells have been proved to specifically 
prevent an excessive expansion of CD4+ T cells at the mucosa that could lead to an 
allergic inflammatory response (Curotto de Lafaille et al., 2008). A great deal of evidence 
has also demonstrated that Tregs deficiency in the periphery is sufficient to evoke chronic T 
cell-mediated autoimmunity and immunopathology (Sakaguchi et al., 2008). Therefore, the 
deficit of Treg cells found in CMPA children could be enough to facilitate the persistence of 
IL4-producing cells, which could initiate and maintain the inflammatory cascade responsible 
for the allergic symptoms. A recent study also reports that Treg cell reprogramming toward 
a Th2-cell-like lineage can promote food allergy (Noval Rivas et al., 2015). The fact that the 
most differentiated subsets of Treg cells are notably decreased could also reflect a switch 
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of these cells to a Th2-like phenotype that will contribute to their increased frequency in 
CMPA children. 
In summary, we hypothesized that after the introduction of cow’s milk proteins in the 
diet, in those children with adequate immune homeostasis, Treg cells can prevent the 
inadequate expansion of IL4-producing CD4+ T cells. However, in children with a deficit of 
vitamin D probably Treg cells exerts its function initially, but without the appropriate 
stimulus (such as vitamin D) Tregs could have a reduced survival and become exhausted. 
In this scenario, the ratio of Treg/effector cells decreases and the inadequate suppression 
of effector cells will lead to the increased presence of IL4-secreting CD4+ T cells and the 
development of the allergic symptoms to these proteins. The demonstration that vitamin D 
sufficiency is an important protective factor for food allergy in the first year of life (Allen et 
al., 2013), supports the hypothesis that restoring the survival Tregs could be a potential 
strategy to prevent the establishment of CMPA in infants. 
Finally, the statistical analysis indicates that low vitamin D values and decreased Treg 
numbers are good predictors to distinguish between controls and CMPA infants. The fact 
that these altered values are present few days after the first adverse reaction to the milk, 
prior to the definitive diagnosis of CMPA, support the utility of these values as diagnostic 
markers of CMPA. In addition, these parameters were good predictors of the results in oral 
challenge test. Thus, Treg values and serum vitamin D levels, which are easily measurable 
in a blood analysis, can be markers to discriminate between CMPA positive and negative 
and it could replace the use of oral challenge in those patients where these tests would 
involve a high risk. Finally, basal insufficiency of vitamin D was also a good predictor of 
those patients that will not achieve spontaneous tolerance in the first year, constituting also 
an interesting predictive marker of the clinical progression of these patients. 
Further studies in larger cohorts of infants must be performed to confirm the quality of 
these markers, and whether Treg and vitamin D values in peripheral blood could constitute 
useful markers for the clinical follow up of CMPA patients.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
4.2. Cow's milk and egg oral immunotherapy in 
children 
 
 
Oral immunotherapy is nowadays one of the most promising approaches toward 
a treatment for food allergy. This work aims to investigate which are the immune 
mechanisms involved in the acquisition of oral desensitization by allergic 
children during a process of cow's milk or egg oral immunotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
4.2.1. Oral long-course desensitization to cow's milk: 
Open-label, non-randomized, non-controlled study of 
cow's milk oral immunotherapy.  
 
This study aimed to evaluate the safety and efficacy to induce clinical 
desensitization to cow's milk in a pediatric population following an open-label, 
non-randomized, non-controlled oral immunotherapy protocol based on an 
individualized up-dosing and characterized by a progressive introduction of 
milk-containing foods. In addition, the immune responses against β-casein of 
peripheral blood mononuclear cells from the allergic patients were evaluated 
before and after the protocol and compared to a non-allergic population. 
The results reported in this section have been published in the reference: 
[Perezabad, L., Reche, M., Valbuena, T., López-Fandiño, R., Molina, E., López-
Expóxito, I. (2017). Oral Food Desensitization in Children With IgE-Mediated 
Cow's Milk Allergy: Inmunological Changes Underlying Desensitization. Allergy, 
Asthma & Immunological Research. 9:35-42]. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral long-course desensitization to cow's milk   | 97 
 
 
4.2.1.1. RESULTS 
Patient characteristics and description of protocol 
Twenty children (7 females and 13 males) aged between 1.5 and 11 years (mean 4.3 ± 
0.54) and 15 non-allergic children (8 females and 7 males) aged between 5 and 14 years 
(mean 8.7 ± 1.05) were enrolled in the study (Table 6). Subjects were recruited from the 
Allergy Service at Infanta Sofia Hospital (Madrid, Spain).  
All the CMPA patients enrolled were diagnosed through a compatible clinical history, 
positive SPT (≥ 3 mm of negative control) with CM, CN, α-LA and β-LG (performed with 5 
mg/mL in all cases) and positive CM-, CN-, α-LA-, and/or β-LG-sIgE. The baseline average 
sIgE levels of the allergic group were 27.38 ± 6.97 kU/L (0.4-100 kU/L) for CM, 26.45 ± 
7.45 kU/L (0.1-100 kU/L) for CN, 20.53 ± 5.98 kU/L (0.1-94.1 kU/L) for α-LA and/or 14.18 ± 
5.0 kU/L (0.5-82.3 kU/L) for β-LG. In addition, all the subjects had experienced a positive 
reaction during a single blind food challenge (SBFC) with commercial semi-skimmed ultra-
high temperature treated (UHT) pasteurized CM (3.3% protein) the month before the 
beginning of the study. Fifty five percent of the CMPA patients were allergic to other foods. 
Also, 45% of them had a past or current history of atopic dermatitis, 40% of asthma and 
30% of allergic rhinitis (Table 6). Non-allergic children have no detectable IgE against a 
broad panel of the most common allergens. There were not statistically significant 
differences regarding sex or age between any of the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Demographics, anamnesis, and response to CM-OIT in cow's milk-allergic patients. 
Abbreviations: AD, atopic dermatitis; AS, asthma; CM; cow's milk; FA, other food allergies; NA, not applicable; OIT, oral immunotherapy; RN, allergic 
rhinitis; SBFC: single blind food challenge  
 
Patient 
Age 
(years) 
Sex FA AD RN AS 
SBFC 
Symptom 
SBFC 
dose 
(mL CM) 
Medicatio
n 
before OIT 
OIT 
Symptoms 
OIT 
duration 
(months) 
Visits to 
the Unit 
(number) 
Tolerance 
after OIT (mL 
CM) 
1 1.5 F No No No No Skin 120 No Yes 24 10 ≥ 200 
2 5.9 F No No Yes Yes Anaphylaxis 15 No No 11 21 ≥ 200 
3 3.5 M Yes No No No Anaphylaxis 4 Yes Yes 20 37 ≥ 200 
4 2.4 M No No No No Skin 64 No Yes 14 27 ≥ 200 
5 3.8 M Yes Yes No No Anaphylaxis 2 No No 22 35 ≥ 200 
6 3 F No No No No Skin 90 No No 10 14 ≥ 200 
7 3.9 F Yes Yes Yes No Anaphylaxis 0.3 Yes No 18 42 ≥ 200 
8 3.1 M No No No No Skin 70 No No 6 16 ≥ 200 
9 7 M Yes No Yes Yes Anaphylaxis 0.3 Yes Yes 24 21 ≥ 200 
10 4 F Yes Yes Yes Yes Skin 1 Yes Yes 24 46 ≥ 200 
11 3.5 M Yes Yes Yes Yes Anaphylaxis 4 Yes Yes 24 43 ≥ 200 
12 3 F No No No No Digestive 30 Yes Yes 24 44 ≥ 200 
13 2.5 M Yes Yes No Yes Anaphylaxis 4 No No 20 24 ≥ 200 
14 4 M Yes No No Yes Anaphylaxis 3 Yes Yes 24 10 ≥ 200 
15 3.9 M Yes Yes No No Anaphylaxis 0.1 Yes Yes 24 37 60 
16 3 M Yes Yes No No Anaphylaxis 1 Yes Yes 24 44 35 
17 3.1 M No No No No Respiratory 2 No Yes 24 32 55 
18 11 F No No Yes Yes Anaphylaxis 4 Yes Yes 24 48 80 
19 10 M Yes Yes No Yes Anaphylaxis 10 No No NA NA NA 
20 4.1 M No Yes No No Skin 30 Yes Yes NA NA NA 
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The OIT protocol was carried out at the Allergy Day Unit under the direct supervision of 
the medical and nursing staff, and with all the equipment and material required for the 
treatment of possible allergic reactions that could occur during the procedure. CM-OIT 
protocol was performed with commercial semi-skimmed UHT CM, as described in Table 7. 
The starting dose of the OIT protocol was the previous one to the highest tolerated dose 
during the SBFC. Once the patients were able to tolerate 4 mL of undiluted CM without 
symptoms, an open challenge with baked goods containing milk was performed. Similarly, 
after tolerating 10 mL, patients were challenged with milk-containing cold meat, with milk 
chocolate after 15 mL, liquid fermented milk (Actimel
®
) after 60 mL, yogurt after 100 mL, 
cow´s cream cheese after 120 mL and, finally, with goat and ewe´s milk cheeses after 200-
240 mL. Between visits, patients were advised to daily ingest at home the maximum dose 
tolerated during their last visit to the unit.  
When needed, premedication with oral antihistamines was given to those patients that 
developed adverse reactions during the protocol, in order to control the symptoms. 
Reaction severity was assessed according to Clark and Ewan (2003). In the case of 
moderate reactions, these were pharmacologically treated and the protocol was restarted 
on the following week at the previously tolerated dose. Hence, the length of the protocol 
was increased stepwise depending on the severity of the reactions experienced by each 
patient. In the case of repeated severe reactions (anaphylaxis) the desensitization protocol 
was interrupted. Patients were considered to have successfully completed the OIT protocol 
if they were able to tolerate a minimum of 200 mL of CM in less than 24 months.  
Once the patients completed the OIT protocol they maintained, during 1 year, a 
daily ingestion of 200 mL of commercial semi-skimmed UHT CM. If after 1 year the clinical 
desensitization was sustained, the patients were authorized to have a non-restricted diet. 
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Table 7. Cow´s milk oral immunotherapy protocol (CM-OIT). Once the patients were able to 
tolerate 4 mL of undiluted CM without symptoms, an open challenge with baked goods 
containing milk was performed. Similarly, after tolerating 10 mL of CM, patients were challenged 
with milk-containing cold milk, with milk chocolate after 15 mL, liquid fermented milk after 60 mL, 
yogurt after 100 mL, cream cheese after 120 ml and, finally, with goat and ewe´s cheese after 
240 mL.  
 
 
Efficacy and safety of desensitization 
The median threshold dose resulting in an allergic reaction during the SBFC was 4.0 
mL (0.1-120 mL), with 60% of the patients developing anaphylaxis, 30% skin-related 
reactions, 5% digestive disorders and 5% respiratory complications (Table 6). Among the 
20 patients included in the study, 14 (patients 1 to 14 in Table 6) tolerated more than 200 
Day 
CM 
dilution 
Dose 
(mL) 
Challenge (% milk protein) 
1 1/10 0.1 Commercial semi-skimmed UHT CM 
8  0.2  
15  0.4  
22  0.8  
29 Undiluted 0.1 Commercial semi-skimmed UHT CM 
36  0.2  
43  0.4  
50  0.8  
57  1  
64  2  
71  4 11 g baked goods (1.2% w/w) 
78  10 15 g cold meat (2% w/w) 
85  15 40 g milk chocolate (0.6% w/w) 
92 
99 
106 
113 
120 
127 
135 
142 
149 
156 
163 
170 
177 
185 
 20 
25 
30 
40 
50 
60 
70 
80 
100 
120 
150 
180 
210 
240 
 
 
 
 
 
66 mL liquid fermented milk (3% w/w) 
 
 
100 g yogurt (3.3% w/w) 
75 g cow´s cream cheese (5.3% w/w) 
 
 
 
25 g goat and ewe´s cheese (30% 
w/w) 
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mL of CM, as well as goat´s and ewe´s milk cheeses, in an average period of 18.9 months 
[interval: 6-24 months], with 27.8 visits to the clinic of [interval: 10-46 times]. 57.14% of 
them experienced mild dermatologic reactions during the desensitization protocol, with the 
most common symptoms being mouth itching and perioral erythema.  
Four patients (patients 15 to 18 in Table 6) tolerated between 35 and 80 mL of CM 
after 24 months of treatment and 40 visits (interval: 32-48 times) to the clinic, on average. 
At the end of the 24 month period, established as a time limit, this group was able to 
consume other foods containing milk as baked goods, cold meat and milk chocolate without 
developing adverse reactions. The reactions during desensitization of this particular group 
of patients were more severe, reporting strong abdominal pain and anaphylactic reactions. 
These children were considered partially desensitized. Two patients (patients 19 and 20 in 
Table 6) left the study for parental decision.  
Thus far, patients have been keeping medical visits to assess their clinical status. 
After 36-48 months of follow up, with regard to patients completed the CM-OIT protocol, 
only one patient has shown severe adverse reactions, losing desensitization and being 
forced to eliminate dairy products completely from the diet. Between partially desensitized 
patients; one of them reached daily ingestion of 200 mL of CM and is following a dairy-free 
diet; other patient continues with partial tolerance (40 mL of CM and a half of yogurt); two of 
them stopped the desensitization protocol due to serious adverse reactions and are 
following a CM restricted diet. Taken together, nowadays, 70% of patients are following a 
free dairy diet and 5% have substantially increased the threshold dose, tolerating the 
equivalent dose of 40 mL of CM and a half of yogurt without developing negative 
symptoms.  
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Baseline status of cow´s milk allergic vs. non-allergic children 
The immunologic status of the CM allergic children enrolled was initially assessed and 
compared with that of the group of non-allergic children of the same age range. As 
expected, CM allergic patients displayed levels of CM-, CM-, CN-, α-LA-, and/or β-LG-sIgE 
(baseline average sIgE levels are previously described) whereas almost non-existing sIgE 
levels were noticed in non-allergic subjects. Concerning the allergen-sIgG4 values, 
although non-statistically significant, a trend toward lower concentration of CN-sIgG4 was 
found in the allergic group (Mean ± SEM Allergic=2.15 ± 0.54; Mean ± SEM Control = 3.64 
± 1.29). CM-, αLA- and β-LG-sIgG4 data were not reported.   
As presented in Figure 12, significant higher production of β-CN-specific Th2 
cytokines (IL-13 and IL-5) was seen in the CM allergic patients compared with non-allergic 
children. In addition, a statistically significant increase was found for β-CN-specific IL-10 
levels in the non-allergic group.  Th1-related cytokines, IFN-γ and TNF-α were not 
detected. 
 
 
 
 
 
Figure 12. Cytokine production by (β-CN-stimulated PBMCs. Levels of (A) IL-13, (B) IL-5 and 
(C) IL-10 (pg/mL) before (orange blocks) and after (blue blocks) the OIT protocol in CM allergic 
patients that tolerated at least 200 mL of CM (n=14). Yellow blocks represent baseline cytokine 
production by β-CN-stimulated PBMCs in non-allergic children (NA; n=15). Bars represent mean 
± SEM. ***: P<0.001, **: P<0.01,*: P<0.05. 
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Immunologic outcomes during OIT (CM-OIT outcomes) 
CM-OIT outcomes: Specific antibody response 
As depicted in Figure 13A, in patients that successfully completed the CM-OIT 
protocol (N=14) a significant drop, of at least 4 fold, in their CM-, α-LA-, β-LG- and CN-sIgE 
levels was detected once the protocol was finished. Moreover, a significant increase from 
baseline was reached in the serum casein-sIgG4 concentration after the CM-OIT treatment 
(Mean = 1.77 ± 0.49 vs. 28.85 ± 12.42) (Figure 13B).  
 
 
 
 
 
 
 
 
 
Figure 13. Antibody response in CM-allergic patients. Serum-specific (A) IgE (kU/L) and (B) 
IgG4 (µg/L) to CM, α-LA, β-LG and CN before (orange blocks) and after (blue blocks) the OIT 
protocol in patients that tolerated at least 200 mL of CM (N=14). Bars represent mean ± SEM. 
***: P<0.001, **: P<0.01.  
 
 
CM-OIT outcomes: β-CN-specific cytokine production by PBMCs  
Regarding the cellular response, no statistically significant difference was found in IL-5 
(P=0.094) (Figure 12B), whereas a marked decrease in IL-13 (P=0.022) (Figure 12A) and 
IL-10 (P=0.002) (Figure 12C) were found between baseline and desensitization time 
points. Th1-related cytokines, IFN-γ and TNF-α were not detected.  
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Interestingly, the differences observed between allergic and non-allergic children in IL-
13 (P=0.018) and IL-5 (P=0.000) before CM-OIT were no longer found once the protocol 
was completed (Figure 12A and 12B). IL-10 production by β-CN-primed PBMCs from non-
allergic donors was significantly higher (P=0.004) than that from CMPA patients at the end 
of the protocol (Figure 10C).  
 
CM-OIT outcomes: Gene expression in β-CN-stimulated PBMCs 
We analyzed the expression levels of the transcription factors Foxp3, T-bet and 
GATA3 in the successful patients (N=14), before and after the CM-OIT protocol. The 
results did not show any significant changes, resulting in mean RQ values close to 1 of all 
studied genes. (Mean ± SEM and range for FoxP3 = 1.25 ± 0.13 [0.69-2.44]; T-bet = 1.92 ± 
0.50 [0.33-6.28]), GATA3= 1.48 ± 0.30 [0.16-4.51]) (Figure 14). 
 
 
 
 
 
 
 
Figure 14. RQ values of transcription factors in response to intervention in complete number of 
CMPA patients completed CM-OIT (N=14). Black square represents change from baseline to 
successful OIT. RQ value of 1 means no difference in two times. 
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Baseline immunologic status of desensitized cow's milk allergic children vs partially 
desensitized 
 
When comparing baseline CN-sIgG4 levels between patients successfully desensitized 
(N=14) and those that partially complete the protocol (N=4), higher levels were found in the 
second group (Mean ± SEM values: 1.77 ± 0.48 vs 10.12 ± 5.52). Moreover, it was noticed 
that 2 out of 4 of partially desensitized children displayed the highest baseline CN-sIgG4 
levels of the total recruited participants (15.3 µg/L and 23.2 µg/L, patients 17 and 18 
respectively in Table 6) and such values diverged strongly from the others. As a result, 
although without statistical significance, we suggest that high baseline sIgG4 level in CM 
allergic children could have an important clinical significance and maybe it could be 
considering as predictor of negative clinical response to OIT. 
Regarding baseline levels of the different cytokines analyzed, there was a trend 
towards higher IL-5 (Mean ± SEM values: 190 ± 130.6 vs 29.93 ± 22.05) and IL-13 (Mean ± 
SEM values: 527.6 ± 289.4 vs 422.1 ± 209.4) after PBMCs stimulation with β-CN in the 
patients who successfully completed the protocol, albeit neither statistical nor clinical 
significance. IL-10 levels were only detected in one child of the partially desensitized group, 
nor Th1-related cytokines (IFN-γ and TNF-α) in either of the groups had detectable levels.  
 
4.2.1.2. DISCUSSION 
In the present study, CM desensitization (corresponding to a CM consumption ≥ 200 
ml without trigger symptoms) was achieved by 70% of the children with IgE-mediated CM 
allergy enrolled in the study, in an average period of 18.9 months. At 36-48 months follow 
up, 70% of desensitized children were still consuming daily CM in the diet without 
restrictions. The desensitization rate was in the range of previous reports by Meglio et al. 
(2008), González-Jiménez et al. (2013), Vázquez-Ortiz et al. (2013), where 71.4%, 72% 
and 71.6% of the children enrolled were desensitized to CM, with 47% of the positive oral 
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food challenges being graded as anaphylactic reactions. Adverse reactions were usually 
controllable with a rate of occurrences lower than those reported in other CM-OIT protocols 
(Staden et al., 2007; Sánchez-García et al., 2012). In any case, the side effects 
encountered during the treatment considerably lengthened the duration of the protocol, 
compared to what was originally planned (185 days), highlighting the importance of 
adapting the dosing regimen to the patient’s response to the therapy.  
A distinct feature of the reported protocol is the progressive introduction of milk-
containing foods into the patient´s diet: this allowed food diversification and helped to 
improve patient´s quality of life, while reducing the withdrawals from the therapy as the 
patients felt confident with the results of the intervention. It should be mentioned that 
desensitized children were also able to consume goat's and ewe's milk proteins. Several 
case reports of allergy to goat and sheep milk proteins in individuals previously 
desensitized to CM can be found in the literature (Rodríguez del Río et al., 2012; Tripodi et 
al., 2013). In fact, Rodríguez del Río et al. (2012) found, in patients who tolerated CM after 
CM-OIT, that 26% of them were still allergic to goat's and ewe's milk,  
It is worth to mention that there are many methodological differences in the duration of 
the build-up phase between protocols. Rush schedules have demonstrated to be capable 
to rapidly desensitize patients to CM in a few days, confirming safety (Martorell et al., 2007; 
Longo et al., 2008; Staden et al., 2008; González-Jimenez et al., 2013), whereas, in an 
opposite way, some studies have documented that prolonged regimens enhance the 
desensitization effect, suggesting that longer treatment courses are more effective and 
possibly safer (Staden et al., 2007; Narisety et al., 2009; Meglio et al., 2013). Because of 
the length of the protocol and the strong familiar commitment required for CM-OIT, the 
study was open label and uncontrolled. However, the high baseline sIgE levels, as well as 
the adverse reactions observed during the therapy, suggested that spontaneous CMPA 
resolution was very unlikely in the population under study (Fiocchi et al., 2008; Wood et al., 
2013). The absence of a placebo group also is a limitation of the study that could be 
justified by the results obtained in the placebo controlled trials performed by Longo et al. 
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(2008) and Pajno et al. (2010), in which none of the children included in the placebo group 
achieved even partial tolerance once the study had ended. It is likely that, in case that the 
treatment applied had altered the natural course of CM-oral tolerance achievement, it 
would have either anticipated it or increased the threshold dose for those patients that did 
not successfully complete the therapy (Staden et al., 2007; Meglio et al., 2008). While the 
current protocol setting cannot confirm patients were tolerant, as CM was not withdrawn for 
ethical reasons, it should be noted that all the patients considered successfully 
desensitized were on a free diet 36-48 months after completed the CM-OIT protocol.  
Baseline sIgG4 levels increased along the therapy, as previously observed by a 
number of authors in other CM-OIT protocols (Skripak et al., 2008; Pajno et al., 2010; 
Bedoret et al., 2012; Keet et al., 2012; Savilahti et al., 2014a, Salmivesi et al., 2016) as well 
as in patients that spontaneously recover from CMPA (Savilahti et al., 2010; Lee et al., 
2013), confirming the important role of this immunoglobulin in oral tolerance establishment. 
Concomitantly with the increase in sIgG4, a significantly reduced antigen-sIgE production 
was found. Although a decrease in allergen-sIgE production is commonly reported in most 
of the CM-OIT protocols described (Longo et al., 2008; Meglio et al., 2008; Zapatero et al., 
2008; Martorell et al., 2011; Bedoret et al., 2012; Keet et al., 2012; García-Ara et al., 2013; 
Vazquez-Ortiz et al., 2013; Savilahti et al., 2014a) other studies have reported no change 
(Meglio et al., 2004; Skripak et al., 2008; Pajno et al., 2010) which, according to the 
authors, might be explained because of the shorter duration of their treatments. In fact, 
Meglio et al. (2008), followed up after 4 years and 8 months the CMPA children 
desensitized in their previous study (Meglio et al., 2004), reporting that the differences 
between CN- and αLa sIgE pre and post oral desensitization were no significant, whereas 
such differences between the pre desensitization and the long follow-up visit became 
significant for both allergen-sIgE. 
In accordance with previous publications (Tiemessen et al., 2004; Tsuge et al., 2007), 
β-CN-primed PBMCs from CM allergic patients presented a significant Th2-biased 
phenotype when compared with not allergic individuals. In fact, enumeration of β-CN-
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specific IL-4- and IL-13-secreting T cells has been proposed as a promising tool to improve 
diagnosis of CMPA (Michaud et al., 2014). β-CN (27% of the total milk proteins) was 
chosen for PBMC stimulation as it represents a serious health risk to patients with CMPA, 
since 75% of the sera from patients with IgE-mediated CMPA against whole bovine β-CN 
have IgE directed against it (Shek et al., 2005). Furthermore, it is known that PBMCs from 
clinically reactive IgE-mediated CMPA patients proliferate in response to LPS-free αS, β 
and κ-CN, but not β-LG (Sletten et al., 2007). Importantly, baseline significant differences in 
IL-5 and IL-13 levels between CMPA and non-allergic children were no longer found once 
the treatment had finished, demonstrating a transition towards a non-allergic phenotype in 
the patients able to ingest ≥ 200 mL of milk without developing symptoms. To the best of 
our knowledge, there is only one other publication dealing with changes in the cytokine 
response by stimulated PBMCs from milk allergic individuals subjected to CM-OIT. Bedoret 
et al. (2012) found a shift from IL-4 and IL13 to IFN-γ production in the patients 
desensitized to milk. However, in our protocol detectable levels of β-CN-specific IFN-γ were 
not found. Salmivesi et al. (2016) found significant increases in serum IL-4 and IL-6 of CM 
allergic children after took part in a CM-OIT intervention. Same authors also reported no 
significant changes in the serum IL-5 and IL-10 concentrations. In a model of plasmacytoid 
dendritic cells (pDC)-CD4+ T cell co-culture, Frischmeyer-Guerrerio et al. (2014) showed 
reduced secretion of Th2 cytokines (IL-5 and IL-13) in response to CM from CM-OIT 
subjects, whereas secretion of IFN-γ and IL-10 to CM did not predict clinical responses in 
their study.  
As well as other egg (Vickery et al., 2010) or peanut (Jones et al., 2009) OIT studies, 
IL-10 production by allergen-stimulated PBMCs decreased, suggesting, not only a Th2 cell 
impairment, but also a decreased Treg function; as IL-10 production is considered one of 
the main effectors responsible for the suppressive effect of Treg (Akdis et al., 1998; Akdis 
and Akdis, 2014). Interestingly, Bedoret et al. (2012) ruled out a role for allergen-specific 
FoxP3+ regulatory T cells in oral desensitization to CM, suggesting that, at least when high 
doses of antigen are administered, the mechanism subjacent lies on anergy or deletion, 
rather than suppression, of allergen-specific T cells. However, according to Shreffler et al. 
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(2009), allergen-specific and functionally suppressive Treg do play a role in the resolution 
of milk allergy and could be important targets for immune monitoring. These authors 
reported that introduction of milk into the diet causes a decline in the frequency of Treg 
present in the peripheral blood, in parallel with an increase in the IgG4/IgE ratio and a 
reduced basophile response; which they attributed to Treg cells being recruited to the 
gastrointestinal tract by allergen ingestion (Shreffler et al., 2009). Similarly, Varshney et al. 
(2011) claimed that decreased Th2 cytokine production and increased IgG4 and Treg cells 
are the main immunologic changes that accompany clinical efficacy of peanut OIT, even if 
they did not detect significant changes in blood IL-10; which raises the hypothesis that 
blood cytokine levels do not reflect mucosal production of Treg, or that mucosal and 
periphery Treg exert different functions. A further possibility is that induction of Treg is 
transient. Thus, Jones et al. (2009) found, in the course of peanut OIT, an early generation 
of Treg and an associated increased production of IL-10 by PBMCs that eventually 
decreased after 12 months. In this respect, it should be noted that, in our study, the long 
time period required for a successful outcome of the treatment (on average 18.9 months) 
might have masked certain immunological events. On the other hand and in accordance 
with our results, Tiemessen et al. (2004) reported that the CM-specific IL-10 production was 
significantly higher in T-cell clones derived from children with persistent CMPA compared 
with those from non-allergic children. 
The lack of treatment-related changes in the expression of Treg (Foxp3), Th1 (Tbet), 
or Th2 (GATA3) transcription factors, despite the existence of measurable variations in 
cytokine production has been already reported in our studies of egg OIT, as in the study by 
Jones et al. (2009) with peanut OIT.  
In conclusion, this report presents an efficient and safe CM-OIT protocol characterized 
by the progressive introduction of milk containing foods that may improves substantially the 
patient’s quality of life along the treatment course. Successful CM-OIT was accompanied 
by an immune alteration characterized by a significant increase in antigen-sIgG4 levels, as 
well as by a significant reduction in antigen-sIgE concentration and in IL-5 and IL-13 
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production by β-CN stimulated PBMCs, towards a non-allergic phenotype. More research 
needs to be done in order to understand the role of IL-10 in CM-OIT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
4.2.2. Oral rush desensitization to egg: A randomized 
controlled study of egg rush oral immunotherapy 
 
The purpose of this randomized and controlled study was to evaluate the 
clinical and immune responses against egg and main egg allergens in a 
pediatric population with IgE-mediated egg allergy under a rush oral 
immunotherapy protocol based on a first 5-days rapid build up phase. In order 
to determine how these outcomes behave when the treatment is not used, we 
also evaluated such responses in a group of egg allergic children remained in 
egg exclusion diet. In addition, a group of non-allergic children were considered 
in this study, to set up and assess the immunological status of participants. 
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4.2.2.1. RESULTS 
Subject population, inclusion and exclusion criteria 
33 egg allergic children from both sexes, who followed an egg avoidance diet, 
including extensively heated egg, were invited to participate after informed consent from 
legal guardians. They were consecutively recruited between April and May 2012 at the 
Department of Allergy, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, and the 
follow-up was completed in July 2013.   
The inclusion criteria were: 
1- Children between 5 and 18 years old. 
2- Egg allergy diagnosis based on presence of IgE-mediated symptoms: positive SPT 
(mean wheal diameter ≥3 mm compared to negative control) and/or serum sIgE 
levels 0.7 kU/L for egg, egg white (EW), ovalbumin (OVA) and/or ovomucoid 
(OM).  
3- Confirmed egg allergy diagnosis by positive DBPCFC to EW. 
Participants were excluded if they had any of the following criteria:  
 History of anaphylactic shock after egg consumption in the previous year. 
 Severe or not controlled bronchial asthma. 
 Non-IgE-mediated adverse events (AE) to egg. 
 Eosinophilic esophagitis. 
 Immunological diseases or malignant diseases. 
 Any baseline disease contraindicating the use of epinephrine. 
 Allergy to any component of the placebo. 
Additionally, a group of 9 non-allergic children from both sexes and the same age range 
were included in the study.  
SPT were performed and evaluated according to the standard procedures for prick testing 
(Dreborg and Frew, 1993) with egg (5 mg/ml), EW (1 mg/ml), OVA (1mg/ml) and 
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OM (1mg/ml) (Leti, Madrid, Spain). The allergen source used for DBPFC and egg 
ROIT was dehydrated EW (OVO-DES NM®, Nutrición Médica SL, Madrid, Spain) with 
entirely preserved allergenicity (Escudero et al., 2013). According to the manufacturer, 
3600 mg of product is equivalent to one medium-sized EW and its protein content is 78% 
(2808 mg). DBPCFC doses were 4, 20, 50, 100, 225, 450, 900, and 1800 mg of dehydrated 
EW (cumulative dose of 2808 mg of protein).  
 
Generation of study groups and description of protocol 
As shown in Figure 15, 40 candidates for the treatment with a first egg allergy 
diagnosis based on presence of IgE-mediated symptoms (positive SPT and/or allergen-
sIgE levels) were assigned into two groups, active group and control group, using a 
computer-generated randomisation table. Once performing the DBPCFC, after diagnosis 
based on full set of criteria, 33 candidates joined their group: Active group rush oral 
immunotherapy 1 (ROIT1; N=19), included those patients receiving egg ROIT immediately 
after randomization, and control group (CG; N=14) formed by those who were non-treated 
and continued on an egg avoidance diet during the next 5 months. Patients in CG who 
failed a second DBPCFC at 5 months joined to intervention receiving the same egg ROIT 
protocol as ROIT1 group. Thus, both ROIT1 and CG who become active, comprise the total 
number of patients that completed desensitization (N=30), study group named as rush oral 
immunotherapy 2 (ROIT2).   
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Figure 15. Study flow chart according to groups and interventions.  
Abbreviations: BP, build up phase; MP, maintenance phase.  
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Blood samples were withdrawn at 3 different time points throughout the ROIT to 
perform the different analyses (Figure 16): T0: baseline; T1: 15 days from end of BP 
phase, and Tf: 5 months from baseline. Regarding the CG, those participants who failed 
the second DBPCFC at 5 months were enrolled in the ROIT intervention, being followed-up 
at same time points for 5 months. There were no significant differences between groups 
except for respiratory symptoms which were more frequently observed in the CG during 
DBPCFC (P=0.04) (Table8). Blood samples from non-allergic children were also analyzed 
to study the baseline allergic immunological status of all participants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Schematic diagram depicting the time schedule of intervention and analyses 
performed. T0: baseline; T1: 15 days from end of build-up phase; Tf: 5 months from the 
baseline. 
* Baseline of egg ROIT protocol in CG. Subjects who failed a second DBPCFC at 5 months 
joined the intervention and their data combined with ROIT1 to form ROIT2 group. 
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TOTAL 
(N=33) 
CG 
(N=14) 
ROIT1 
(N=19) 
Male; N (%) 18 (54.6) 7 (50) 11 (57.9) 
Age (years); mean (SD) 10,4 (2.6) 9.7 (2.3) 10.9 (2.7) 
Age at first egg reaction (years); 
mean (SD) 12,9 (13.6) 15.5 (20.4) 
 
11 (4.6) 
 
Asthma (%) 57.6 27.3 
 
30.3 
Allergy to other foods (%) 69.7 85.7 57.9 
Previous anaphylaxis (%) 42.4 37.1 31.6 
 
Symptoms at baseline DBPCFC 
(%) 
 
 
 
 Cutaneous 20.9 17.8 23.6 
Angioderma 4.2 6.7 2.0 
Dermatititis 2.1 0 3.9 
 Urticaria 14.6 11.1 17.7 
 Oropharyngeal symptoms 30.21 31.11 29.4 
 Digestive 29.17 26.67 31.4 
 Conjunticvitis 1.04 0 2.0 
 Respiratory 18.8 24.5 13.7 
Rhinitis  14.6 15.6 13.7 
Asthma 4.2 8.9 0 
 Anaphylaxis 0 0 0 
 
Threshold dose at DBPCFC (mg); 
median (range) 
 
 
225 (20-3600) 
225 (20-
1800) 
225 (50-
3600) 
 
Table 8. Baseline clinical characteristics and baseline symptoms at double-blind placebo-
controlled food challenge according to study group. 
 
 
The egg ROIT protocol designed consisted of 5 consecutive days build up phase (BP) 
(Table 9) consuming dehydrated EW on an outpatient basis, starting at the highest 
tolerated single dose in the baseline egg DBPCFC. The median threshold dose during the 
DBSBFC was 225 mg (range, 20-3600 mg) (Table 8). After 1 hour of observation without 
symptoms the subsequent dose was administered. In case of an adverse event, the 
previously tolerated dose was administered as the first dose on the following day. During 
the weekend, patients continued with the in-home daily of the last tolerated dose. Thus, BP 
doses were increasing gradually with a target of 3600 mg of dehydrated EW (2808 mg of 
EW protein; one medium-sized EW).  
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As a continuation of BP, subject continued the protocol until 5 months follow-up in a 
maintenance phase (MP), consisted of eating at home undercooked egg (undercooked 
fried egg, scrambled egg, or omelette) every 48 hours. In addition, children could freely 
take any other food products that contain egg proteins.  
 
 
Table 9. Egg ROIT protocol. 5-day build-up phase. 
a 
:The allergen source used for DBPCFC and ROIT was dehydrated EW (OVODES NM, 
Nutrición Médica SL, Madrid, Spain). The ROIT starting dose was based on the 
eliciting dose threshold, so the build-up phase started with the highest single egg 
dose tolerated in the baseline DBPCFC. When the test result was positive with 4 mg, 
the starting dose was 0.04 mg. Doses were administrated in the hospital at intervals 
of 60 minutes. 
b
: Equivalent to one medium-sized EW. 
 
Efficacy and safety of desensitization 
As shown in Figure 15, seventeen of 19 patients (89.5%) in the ROIT1 group 
completed BP and MP. Desensitization was defined as the patient´s ability to eat one 
Positive DBPCFC 
Dehydrated EW (mg) 
Day of ROIT Number of 
doses 
ROIT-starting dose 
of dehydrated EW 
a
 
(mg) 
EW protein 
(mg) 
4 1 1 0.04 0.03 
  2 0.08 0.06 
  3 0.16 0.125 
  4 0.32 0.25 
  5 0.64 0.50 
 2 6 0.4 0.31 
  7 0.8 0.62 
  8 1.6 1.25 
20  9 4 3.12 
  10 20 15.6 
50 3 11 20 15.6 
100  12 50 39 
225  13 100 78 
450  14 225 175.5 
  15 450 351 
900 4 16 450 351 
1800  17 900 702 
  18 1800 1404 
 5 19 1800 1404 
  20 3600 
b
 2808 
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undercooked egg (fried, scrambled, or omelette) without or mild adverse events. One 
patient did not adhere to the protocol, failing eat more egg at the end of BP, and the other 
failed due to mild recurrent abdominal pain and refusal to eat egg after one month in MP 
(EW-sIgE levels of 25.4 and 112 kU/L, respectively). Thirteen of 14 (92.9%) patients in CG 
remained on an egg-avoidance diet for 5 months. One subject in this group dropped out 
before undergoing the second DBPCFC for fear of adverse events. None of the 13 patients 
in CG passed egg DBPCFC at 5 months (T3) (Figure 16).  
Thus, after the enrolment of controls into the active treatment group (ROIT2; 
ROIT1+CG), we have data of 32 patients who underwent egg ROIT, 30 of whom were 
desensitized at 5 months of intervention (rate of success of 93.8%). 86.7% of the 
mentioned 30 patients completed the BP in 5 days or less (median 3 days; range 1-14 
days). Concerning the safety of therapy, the median number of reactions per child in the BP 
was 2.5 (range, 0-17), being 54.8% of recorded symptoms gastrointestinal, 19.4% 
oropharyngeal symptoms, 11% cutaneous, 7.7% rhinitis, 5.8% bronchospasm, and 1.3% (2 
episodes) anaphylaxis. In the MP most reactions were mild and local (75% oropharyngeal 
symptoms, 21.5% mild abdominal pain). 
In order to evaluate the long-term efficacy, patients were contacted approximately two 
years after the end of study. We got information in 27 of children were desensitized (27/30) 
and, only 4 out of 27 (14.81%), reported any adverse event being not able to continue 
eating egg. Therefore, taking together all available data 24 months later from OIT, 
desensitization was maintained in 76.6% of patients (23/30).  
 
Basal immunological status: egg allergic vs. non-allergic children 
Previously to study the immunological effects of ROIT treatment in egg allergic 
children, a comparative study was perform in order to evaluate the basal immunologic 
status of those patients who completed desensitization (N=30) in comparison with the 
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group of non-allergic (NA) children (N=9). There were not significant differences regarding 
age and sex between the two groups at the inclusion in the study.  
Table 10 shows the cytokine levels found in the supernatants of OVA-stimulated 
PBMCs in both studied groups. Results revealed that egg allergic children displayed a 
diminished Th1 cytokine profile in comparison with non-allergic children. PBMCs from 
allergic patients secreted significantly lower levels of both IFN-γ and TNF-α (P<0.001) than 
NA children. Regarding Th2-related cytokines, a diminished production of IL-5 and IL-13 
was found in NA patients, although the differences did not reach statistical significance.  
The Percentage of peripheral CD4+CD25+FoxP3+ T cells (Treg) were also measured 
in 16 egg allergic children and compared with those of children in non-allergic group (N=9). 
Non-statistically significant differences were found between groups (mean ± SEM: 7.49 ± 
0.99 Vs. 5.20 ± 0.64) (P=0.160). 
 
 
 
 
 
 
 
Table 10. Cytokine levels (pg/ml) after stimulation with OVA of PBMCs from egg allergic 
patients at the inclusion in the study compared with a group of non-allergic participants. Values 
indicate mean ± SEM. P<0.05 by Mann-Whitney 2-tailed test was considered significant.  
 
 
Outcomes between groups: Active Group vs Control Group (ROIT vs. GC) 
ROIT vs. GC: Skin prick testing and specific antibody response 
Values in skin prick tests (SPT) for egg, EW, OVA and OM, as well as from EW- OVA- 
and OM-sIgG4, were significantly lower (P<0.05) in ROIT1 than in CG. However, no 
Cytokine 
Egg allergic 
(N=30) 
Non-allergic 
(N=9) 
P-value 
IL-10 320.32 ± 40.91 232.10 ± 43.78 0.224 
IL-5 5.77 ± 3.18 0.07± 0.07 0.065 
IL-13 25.67 ± 6.53 9.56 ± 2.35 0.176 
IFN-γ 14.70 ± 5.64 594.72 ± 253.40 <0.001 
TNF-α 64.78 ± 21.84 448.02 ± 110.70 <0.001 
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significant differences were found between the 2 groups in sIgE levels to egg, EW, OVA or 
OVM or total IgE. In ROIT1 but not in CG, SPT decreased significantly (Figure 17A) and 
sIgG4 increased (Figure 17B) compared to baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 17. Mean levels of immune markers according to groups: CG and activeROIT1. (A) Skin 
prick tests (SPT) to egg protein fractions (*: P=0.05-0.001) and (B) Serum sIgG4 (sIgG4) to egg 
protein fractions (*: P=0.05-0.001). Mean values, and two-sided test 95% confidence intervals. 
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ROIT vs. GC: OVA-specific cytokine production by PBMCs  
Comparison of cytokine levels in PBMCs cultured supernatants at the beginning of the 
study yielded not significant differences for any of the cytokines evaluated; demonstrating 
the immunological status of both groups of patients at the starting time was similar. On the 
contrary, as shown in Table 11, after 5 months of ROIT protocol, OVA-specific IL-13 
concentration significantly decreased from baseline level (P=0.048) in the active group, 
whereas no changes in the CG patients were observed for OVA-specific IL-13. Levels of 
OVA-specific IL-5, IL-10, IFN-γ and TNF-α did not significantly change in either group.  
Similarly, the percentage of peripheral CD4+CD25+FoxP3+ Treg cells did not showed 
statistically significant differences between baseline and 5 months course, in either ROIT1 
(N=4; mean ± SEM: 6.59 ± 1.93 vs. 3.93 ± 0.94) (P=0.343) or CG subjects (N=6; mean ± 
SEM: 7.86 ± 2.32 vs. 7.52 ± 0.67) (P=0.844).  
 
 
 
 
 
 
 
 
 
Table 11. Changes in the OVA-specific cytokines levels (pg/ml) from PBMCs of egg allergic 
patients included in the study, from baseline (0 months) to 5 months from randomization. CG: 
allergic patients who followed an egg-avoidance diet; ROIT1: allergic patients who received egg 
ROIT treatment. Values indicate mean ± SEM. P<0.05 by Wilcoxon 2-tailed test was considered 
significant.  
 
 
 
 
 
CG (Egg avoidance diet) (N=13) ROIT1 (Egg ROIT) (N=17) 
Cytokine 
 
Baseline 
(0 months) 
At 5 months 
P-
value 
Baseline 
(0 months) 
At 5 months P-value 
IL-10 320.5 ± 55.7 349.8 ± 79.6 0.999 297.7 ± 40.8 335 ± 107.7 0.623 
IL-5 3.1 ± 2.0 6.8 ± 4.2 0.553 7.8 ± 5.4 3.5 ± 3.4 0.313 
IL-13 17.6 ± 5.9 35.1 ± 14.7 0.086 31.9 ± 10.5 17.9 ± 12.4 0.048 
IFN-γ 19.9 ± 8.1 76.5 ± 36.2 0.625 16.1 ± 8.0 9.9 ± 8.9 0.250 
TNF-α 31.4 ± 14.4 351 ± 309.3 0.492 90.3 ± 36.2 126.1 ± 56.6 0.761 
 
Oral rush desensitization to egg   | 123 
 
 
ROIT vs. GC: Gene expression of transcription factors in OVA-stimulated PBMCs 
The expression of the transcription factors FoxP3, T-bet and GATA3 of OVA-
stimulated PBMCs between the baseline and 5 months of study did not showed significant 
changes for neither of the groups, with mean of RQ values very close to 1 (Mean ± SEM 
[range] for ROIT1: FoxP3=0.76 ± 0.11 [0.27-1.96]; T-bet=1.14 ± 0.15 [0.43-2.68]; 
GATA3=1.17 ± 0.14 [0.29-2.60]) (Mean ± SEM [range] for CG: FoxP3=0.80 ± 0.08 [0.42-
1.60]; T-bet=0.77 ± 0.15 [0.31-2.17]; GATA3=0.97 ± 0.14 [0.23-2.09]) (Figure 18).   
 
 
 
 
 
 
 
 
 
Figure 18. RQ values of transcription factors in response to intervention. Active group of egg 
allergic children (ROIT1; N=17) and control group following an egg avoidance diet (CG; N=13). 
Black square represents change from T0 (baseline) to Tf (5 months from baseline). RQ value of 
1 means no difference between two times. 
 
 
Immunologic outcomes during ROIT (Egg ROIT outcomes) 
 
Egg ROIT outcomes: Skin prick testing and specific antibody response 
A significant decrease (P<0.001) in the prick test wheel size was observed for egg, 
EW, OVA and OM for all patients after the ROIT. In addition, a significant increase 
(P<0.001) in the serum-sIgG4 levels to egg protein fractions (EW, OVA, OM) was 
observed, together with a reduction in the serum-sIgE levels to mentioned egg protein 
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fractions (P=0.05-0.001). Specific IgE/IgG4 ratios also decreased significantly in all egg 
protein fractions (P<0.001). The decrease in SPT and sIgE/IgG4 ratio occurred earlier and 
was more significant than the changes in sIgE levels. These data are represented in Figure 
19. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Mean levels of SPT, serum sIgE and serum sIgG4 in all children enrolled in the 
ROIT protocol (ROIT2; N=30) according to different times throughout the treatment. T0: 
baseline; T1: 15 days from end of build-up phase; Tf: 5 months from the baseline. (A) SPT to 
egg protein fractions (*: P<0.001); (B) Serum sIgG4 to egg protein fractions (*: P<0.001); (C) 
Serum sIgE to protein fractions (P=0.05-0.001); (D) Serum sIgE/sIgG4 ratio to egg protein 
fractions (*: P<0.001). Mean values and two-sided test 95% confidence intervals. 
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Egg ROIT outcomes: OVA-specific cytokine production by PBMCs  
The production of cytokines by OVA-stimulated-PBMCs was measured at baseline 
(T0), 15 days of the end of build-up phase (Tf) and 5 months from baseline (T3) in patients 
along the OIT protocol. Table 12 shows the evolution of a panel of 5 allergen-specific 
cytokines during the ROIT treatment. Results revealed a diminished Th2 response when 
desensitization was completed, with a significantly lower concentration of OVA-specific IL-
13 (P=0.098). Regarding Th1 cytokines, no significant changes were observed for OVA-
specific IFN-γ, however, a tendency to lower TNF-α levels was found (P=0.08).  
 
 
 
 
 
 
 
 
 
Table 12. Cytokine levels (pg/ml) after stimulation with OVA of PBMCs from all the allergic 
patients completed desensitization (ROIT2). T0: baseline; T1: 15 days from end of the build-up 
phase; Tf: 5 months from baseline. Values indicate mean ± SEM. P<0.05 by Wilcoxon 2-tailed 
test was considered significant.  
 
 
 
Egg ROIT outcomes: OVA-specific Treg production by PBMCs  
Percentage of peripheral CD4+CD25+FoxP3+ Treg cells was measured in 10 patients who 
completed the desensitization protocol, but statistically significant differences did not occur 
between baseline (T0) and the end of treatment (Tf) (mean ± SEM: 6.59 ± 0.89 Vs. 5.39 ± 
0.66) (P=0.160) (Figure 20). 
ROIT2 (N=30) 
 
Cytokine T0 T1 P T0 Tf P 
IL-10 320.3 ± 40.9 
403.3 ± 
48.3 
0.104 320.3 ± 40.9 
299.7 ± 
62.7 
0.435 
IL-5 7.4 ± 3.5 2.9 ± 1.4 0.376 7.4 ± 3.5 2.7 ± 2.0 0.160 
IL-13 33.2 ± 8.6 34.6 ± 7.2 0.875 33.2 ± 8.6 14.8 ± 7.3 0.098 
IFN-γ 42.2 ± 16.9 66.9 ± 33.0 0.502 42.2 ± 16.9 18.3 ± 10.7 0.99 
TNF-α 
203.2 ± 
134.7 
122.3 ± 
32.6 
0.856 
203.2 ± 
134.7 
114.6 ± 
46.3 
0.080 
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Figure 20. Percentage of CD4+CD25+FoxP3+ Tregs cells after stimulation with OVA of PBMCs 
from 10 allergic-patients who completed desensitization: T0: baseline; Tf: 5 months from 
baseline. Values indicate mean ± SEM. P<0.05 by Wilcoxon 2-tailed test was considered 
significant.  
 
 
          Egg ROIT outcomes: Gene expression in OVA-stimulated PBMCs 
RT-qPCR analysis of the transcription factors FoxP3, T-bet and GATA3 for all the 
comparisons mentioned revealed no significant changes with a mean of RQ values very 
close to 1 in all cases (Mean ± SEM [range] of RQ between T0 and T1: FoxP3=1.12 ± 0.13 
[0.22-4.30]; T-bet=1.35 ± 0.04 [0.49-4.34]; GATA3=1.27 ± 0.99 [0.46-3.77]) (Mean ± SEM 
[range] of RQ between T0 and T3: FoxP3=0.96  ± 0.13 [0.27-3.93]; T-bet=1.25 ± 0.13 
[0.29-3.22]; GATA3=1.13 ± 0.11 [0.38-2.68]) (Figure 21). 
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Figure 21. RQ values of transcription factors in response to intervention in complete number of 
egg-allergy patients completed ROIT (ROIT2; N=30). Black square represents change from T0 
(baseline) to T3 (5 months from baseline); black triangle represents change from T0 to T1 (15 
days from end of build-up phase). RQ value of 1 means no difference in two times. 
 
 
4.2.2.2. DISCUSSION 
The ROIT intervention employed in the present study was clinically effective, with a 
94% of patients desensitized and being able to ingest 1 egg after 5 months of therapy. This 
outcome is similar to the percentage achieved with other published randomized controlled 
egg OIT studies, which also used dehydrated EW as allergenic source (Caminiti et al., 
2015; Escudero et al., 2015). However, this study used a rush desensitization protocol in 
which the BP phase (tolerance of equivalent of 1 EW) was completed in as few as 5 days, 
whereas Escudero et al. (2015) reported a prolonged phase of 30 days. In Caminiti et al. 
(2015) used an equivalent dose of 1 EW, and desensitization was achieved even through a 
longer period (120 days).  
To our knowledge, most published egg OIT studies included a BP of around 60 days 
(Ibáñez et al., 2015) and only a few rush oral desensitization to egg protocols have been 
published (Itoh et al., 2010; García Rodríguez et al., 2011), neither of which included 
randomized design nor a control group. These studies used cooked egg during the MP and 
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results showed a loss of desensitization during this period. There is controversy about the 
impact of using either raw or cooked egg on OTI efficacy (Praticò et al., 2014). In the 
current study, egg was given undercooked (nearly raw) during the MP in order to preserve 
its allergenicity, and the model of intervention was found to be effective, considering that 
96.8 % of children reached MP and were able to continue the maintenance dose at the 
scheduled 5 months. The shorter treatment duration improves the adherence to the 
protocol for both children and parents, and also make easier to differentiate actual effects 
of intervention from natural outgrowth. 
As inclusion criteria, the egg allergic children enrolled in this study showed detectable 
serum sIgE for egg protein, but in order to better assess the baseline immune status of the 
allergic children we also recruited a population of non-allergic children of the same age 
range with which the allergic were compared. In this comparison, egg allergic subjects 
showed a decreased Th1 cytokine response pattern by OVA-stimulated PBMCs with 
significantly lower production of IFN-γ and TNF-α. Therefore, children selected to ROIT 
reported a T-cell response clearly differentiated from non-allergic status, and based on the 
cytokine profile we could predict the allergic status of the participating subjects. 
In this study, the decrease of OVA-specific IgE was very significant in desensitized 
patients. Other egg OIT protocols displayed lower antigen-specific IgE levels at the end of 
the immunotherapy (Vickery et al., 2010; Dello Iacono et al., 2013; Meglio et al., 2013), also 
those studies with a rush protocol (Itoh et al., 2010; García Rodríguez et al., 2011). 
However, no significant changes in IgE levels during OIT have also been reported (Burks et 
al., 2012; Fuentes-Aparicio et al., 2012). This fact, could be explained by the dynamic 
immunologic response of IgE through development OIT. The mechanism by which 
allergen-specific IgE changes are still under investigation. Some studies have shown that 
OIT alters the binding pattern of antigen to IgE, possibly through changes in the diversity of 
epitope recognition or altered antigen affinity (Reviewed in Wood, 2016). On the other 
hand, human IgG consists of four subclasses IgG1-4, which are functionally diverse and 
differentially regulated. In the present study a significant increase in the serum sIgG4 to 
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egg protein fractions (EW, OVA OM) was observed, however, we are conscious of our 
study did not measure other different serum OVA-specific subclasses apart from IgG4 
which are discussed of being relevant in food allergy in recent years (Salmivesi et al., 2016; 
Sugimoto et al., 2016;). In their study of egg ROIT, Sugimoto et al. (2016) suggest that a 
significant rise in allergen-specific IgG1 levels after the rush phase of OIT could be a useful 
biomarker of positive response to egg OIT.  
Although participants in the study might spontaneously outgrow their egg allergy we 
believe this to be unlikely. First, almost all of the egg allergic children formed the CG did not 
pass the oral food challenge at 5 months. Second, none of the children in the CG were able 
to eat a regular serving of egg after 5 months of study, compared to 89.5% of those 
receiving ROIT (ROIT1) and completed desensitization. Third, ROIT resulted in a reduction 
in the OVA-specific IL-13 levels in ROIT1 subject whereas no changes in the CG patients 
were observed for this cytokine, supporting that this changes in OVA-specific IL-13 status 
are as a results of the therapy, but not of spontaneous tolerance. We also proved that there 
were no significant differences between the active group (ROIT1) and the control group 
(CG) in the baseline cytokine profiles (data not shown).   
When immunotherapy with an allergen is effective, it appears to be related with a shift 
from Th2 cytokine production (characteristic of allergic status) toward a Th1 (non-allergic) 
profile (Berin and Shreffler, 2016; Burbank et al., 2016; Wood, 2016). In these T-cell 
responses during the course of OIT is involved an induction of Treg cells (Fuentes-Aparicio 
et al., 2014; Syed et al., 2014; Berin and Shreffler, 2016). Although results of Fuentes-
Aparicio et al. (2014) showed that egg desensitization was related to a significant increase 
in the frequency and absolute counts of Treg cells (measured as CD4+CD25+FoxP3+ T 
cells), in the present study we did not find statistically significant differences in the 
percentage of peripheral Treg cells between baseline and the end of treatment, neither did 
in the OVA-specific IL-10 production in which Treg cells are also involved. Previous studies 
have reported a significant increase of IL-10 levels after successful OIT (Jones et al., 2009; 
Vickery et al., 2010; Syed et al., 2014). However, although it was not significant, in this 
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ROIT protocol OVA-specific IL-10 levels decreased in children completed egg 
desensitization from baseline to 5 months of intervention. This outcome is consistent with 
findings by Itoh et al. (2010) in their protocol of rush egg OIT and it was also reported in 
Fuentes-Aparicio et al. (2012), in which serum IL-10 levels also suffered a reduction after 
OIT. Thus, the role of IL-10 when egg desensitization is induced needs yet to be clarified. 
 Together with IL-10 levels, the release of other key cytokines involved in the Th1/Th2 
balance seems to be an important factor for oral tolerance. Upon allergen-specific 
stimulation, a reduction in the allergen-specific Th2-related cytokines levels (IL-4, IL-13, IL-
5) and a rise in those of specific Th1-related cytokines (IFN-γ TNF-α) is the pattern of 
cytokine levels expected to detect after successful OIT (Berin and Shreffler, 2016). 
However, the conclusions we can extract about this concern from available OIT reports are 
controversial (Jones et al., 2009; Vickery et al., 2010; Varshney et al., 2011; Syed et al., 
2014; Wisniewski et al., 2015; Salmivesi et al., 2016). In the current study, we were able to 
demonstrate a reduction in OVA-specific IL-13 after immunotherapy in patients completed 
desensitization. In addition, changes in OVA-specific IL-13 at 5 months of our egg OIT 
protocol separated the immune response of the egg allergic children in the active group 
(ROIT1) from those in the CG. Nevertheless, apart from a significant decrease of IL-13, we 
could not report any other significant differences for the cytokines tested. We could 
implicate the high inter-individual variation, the undetectable levels of some cytokines at 
baseline and the limitation for collecting data at more times during the curse of OIT.  This 
later point is particularly important due to the potentially transient clinical efficacy of OIT as 
reported by Gorelik et al. (2015) in their peanut OIT.  
This study neither was able to demonstrate changes in the expression of the 
transcription factors FoxP3 (Treg response), Tbet (Th1) and GATA3 (Th2) in response to 
intervention, nor in the expression of control group. There is a lack of studies reported gene 
expression of PBMCs from allergy subjects under allergen-specific stimulation.  
The described approach has certain limitation when confirming tolerance to egg.  The 
efficacy of a OIT protocol depends on the defined endpoint, which could be to induce 
Oral rush desensitization to egg   | 131 
 
 
desensitization alone or a more durable state of clinical tolerance often referred to as 
“sustained unresponsiveness” (Burbank et al., 2016). To support this ultimate aim of the 
food allergy treatment, the ability to tolerate the food after discontinuing ingestion of the 
allergen for a period of at least 4-12 weeks must be confirmed (Rolinck-Werninghaus et al., 
2005). Burks et al. (2012) reported in their randomized controlled study with long-term 
follow-up that, 75% of participants passed the oral food challenge at 22 months (10 g of 
dehydrated EW), but only 28% demonstrated “sustained unresponsiveness” on the re-
challenge, after being on a subsequent avoidance of egg consumption for 6 to 8 weeks. 
Similar outcome is described in Caminiti et al. (2015), where egg desensitization occurred 
in almost all subject while only 1/3 of them passed the food challenge after an egg 
avoidance phase of 3 months. Therefore, to determine the extent to which the protective 
effect requires continued consumption becomes a prime focus of interest in OIT. In the 
present study, efficacy is defined as desensitization achievement, namely patient´s ability 
to eat one undercooked egg (fried, scrambled, or omelette) without or mild adverse events. 
This desensitization procedure is deemed as very successful with a rate of success of 
93.8% (30/32) and the long-term efficacy of this state is also reported two years after the 
end of study in the 76.6% of desensitized patients (23/30), however, “sustained 
unresponsiveness” after a period of egg avoidance and later re-introduction of food is not 
confirmed as patients have not stop eating eggs once desensitized.  
In conclusion, the present study shows that the proposed rush OIT protocol can induce 
desensitization to egg proteins in school age children in few days with high efficacy. The 
results also suggest that the significant decrease in OVA-specific IL-13 at short time of 
immunotherapy could be a useful biomarker of positive response to egg OIT. Although 
further studies involving a higher number of patients and analyzing a wide range of 
biomarkers are needed, we consider that this therapy could replace egg avoidance as the 
therapy for egg allergy. However, to confirm the “sustained unresponsiveness” and the 
development of post desensitization strategies that promote long-term immune tolerance 
become an essential prerequisite. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
4.2.3. Oral long-course desensitization to egg: Open-
label, non-randomized, non-controlled study of egg oral 
immunotherapy.  
 
The purpose of this study was to establish differences in the basal 
immunologic responses between an egg allergic group of children and a 
population of non-allergic children. We also investigated the safety and efficacy 
of a specific egg OIT protocol for inducing clinical desensitization, analyzing the 
associated immune responses too. An open-label, non-randomized, non-
controlled study was designed, characterized by an individualized up-dosing 
with introduction of egg-containing foods into children diet. 
The results reported in this section have been published in the reference: 
[Perezabad, L., Reche, M., Valbuena, T., López-Fandiño, R., Molina, E., López-
Expóxito, I. (2015). Clinical efficacy and immunological changes subjacent to 
egg oral immunotherapy. Annals of Allergy, Asthma & Immunology. 114:504-
509]. 
 
. 
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4.2.3.1. RESULTS 
Patient characteristics and description of protocol 
Twenty egg allergic patients (11 males and 9 females) aged between 5 and 15 years 
(mean ± SEM= 10.8 ± 0.71 years) and 15 non-allergic children (7 males and 8 females) 
aged between 5 and 14 years (mean ± SEM= 8.7 ± 1.05 years) were enrolled in the study. 
Subjects were recruited from the Allergy Service at Infanta Sofia Hospital, San Sebastian 
de los Reyes, Madrid.  
All the children enrolled in the egg allergic group were patients diagnosed through a 
compatible clinical history, positive SPT (≥ 3 mm of negative control) with egg (5 mg/mL), 
EW (5 mg/mL), OVA (5 mg/mL), OM (5 mg/mL) and LZ (10 mg/mL) and positive sIgE for 
EW, yolk, OVA, OM and/or LZ.  In addition, all the subjects had a positive reaction during a 
SBFC with pasteurized liquid EW (8.3% protein; Huevos Guillén, Valencia, Spain) during 
the month before the beginning of the study. The average dose of pasteurized EW that 
elicited allergic reactions during the SBFC in the egg allergic group was 1.56 mL [range: 
0.001-8.0 mL], with 45% of the patients developing skin-related reactions, 30% anaphylaxis 
and 25% digestive symptoms. None of the recruited children experienced respiratory 
problems during the SBFC (Table 13). All but 3 egg-allergic subjects had allergies to 
environmental aeroallergens. Also, a 65% of them were allergic to other foods different 
than egg. Egg allergic patient's demographics and anamnesis are described in Table 13.  
Non-allergic children included in the study showed no detectable IgE against a broad 
panel of the most common allergens. There were not statistically significant differences 
regarding age and sex between allergic and non-allergic groups.  
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Table 13. Demographics, anamnesis, and response to egg OIT in egg allergic patients. 
Abbreviations: A, anaphylaxis; AA, allergies to aeroallergens; D, digestive; EW, egg white FA, 
other food allergies; NA, not applicable; S, skin; SBFC: single blind food challenge  
 
 
Egg OIT protocol was performed with commercial pasteurized liquid EW (8.3% protein; 
Huevos Guillén, Valencia, Spain). As described in Table 14 the highest tolerated dose 
during the SBFC was used as the starting dose for the OIT protocol. In this protocol, once 
the patients were able to tolerate 2 mL of undiluted EW without symptoms, an open 
challenge with baked goods containing egg was performed. Similarly, after tolerating 4 mL 
of EW, patients were challenged with egg coated foods, with boiled egg after 12 mL, 
French omelette after 20 mL and, finally, with a fried egg after 32 mL. Between hospital 
visits, patients were advised to daily ingest at home the maximum dose achieved during 
their last visit to the unit. Premedication with antihistamines was given to those patients that 
developed adverse reactions during the protocol in order to control the symptoms if 
needed. 
Patient 
Age 
(years) 
Sex AA FA 
SBFC 
Symptom 
SBFC 
dose 
(mL EW) 
Medication 
before OIT 
    OIT 
Symptoms 
OIT 
duration 
(months) 
Tolerance 
after OIT 
(mL EW) 
1 12 F Yes Yes D 4.0 Yes Yes 12 32 
2 5 F No Yes S 0.01 Yes Yes 14 32 
3 6 M No No S 4.0 No No 6.0 32 
4 5 M Yes Yes S 2.0 No Yes 12 32 
5 15 M Yes Yes A 8.0 No No 6.0 32 
6 12 M Yes Yes S 0.1 Yes Yes 18 32 
7 14 M Yes Yes S 0.5 No No 6.0 32 
8 10 M Yes Yes D 0.01 Yes Yes 12 32 
9 14 F Yes Yes S 1.0 Yes Yes 12 32 
10 11 M Yes No S 0.05 No No 8.0 32 
11 11 F Yes No A 0.2 Yes Yes 20 32 
12 13 M No Yes A 0.06 No No 15 32 
13 10 F Yes No A 0.1 Yes Yes 24 2.0-10 
14 9 M Yes Yes D 0.06 Yes Yes 18 2.0-10 
15 9 M Yes Yes A 0.001 Yes Yes 18 2.0-10 
16 14 F Yes Yes S 0.01 Yes Yes 24 2.0-10 
17 15 F Yes Yes S 0.1 No Yes 18 <2 
18 14 M Yes No D 8.0 Yes Yes 9.0 <2 
19 8 F Yes No A 1.0 Yes Yes 7.0 <2 
20 10 F Yes No D 2.0 No NA NA NA 
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In the case of moderate reactions, these were pharmacologically treated and the 
protocol was restarted on the following week at the previously tolerated dose. Hence, the 
length of the protocol underwent stepwise increases depending on the severity of the 
reactions experienced by the patient. In the case of repeated severe reactions 
(anaphylaxis) the desensitization protocol was interrupted. Patients were considered to 
have completed the OIT protocol if they were able to tolerate 32 mL of pasteurized EW 
(equivalent to a full egg white) in less than 24 months. 
Once the patients completed the OIT protocol they maintained during 6 months a daily 
dose of 16 mL of pasteurized EW at home, except for two days per week, when the 
patients were advised to consume a complete egg (omelette, boiled or fried egg). If after 6 
months the clinical tolerance was sustained, the patients were authorized to have a non-
restricted diet with the recommendation to eat eggs 2-3 times per week. 
 
 
 
 
 
 
 
 
 
Table 14. Egg oral desensitization protocol. Once the patients were able to tolerate 2 mL of 
undiluted EW without symptoms, an open challenge with egg-containing bakery was performed. 
Similarly, after tolerating 4 mL of EW, patients were challenged with egg-coated foods, with 
boiled egg after 12 mL, French omelette after 20 mL and, finally, with a fried egg after 32 mL. 
 
 
 
Day EW dilution Dose (mL) Challenge 
1 1/10 0.1 Pasteurized EW 
8  0.5  
15 Undiluted 0.1 Pasterurized EW 
22  0.5  
29  1.0  
36  2.0 Baked goods containing egg 
43  4.0 Egg-coated foods 
50  8.0  
57  12.0 Boiled egg 
64  16.0  
71  20.0 French omelette 
78  24.0  
85  28.0  
92  32.0 Fried egg 
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Efficacy and safety of desensitization 
As described in Table 13, 12 of the 20 patients enrolled in the study (60%) (patients 1 
to 12) completed the protocol being able to tolerate 32 mL of pasteurized EW in a mean 
period of 11.75 months (Mean ± SEM= 11.75 ± 1.34) [interval: 6-20 months]. Although 
according the original schedule, desensitization was planning to be achieved in 3 months, 
dosing regimen was adapted to the patient’s response having to be increased in, 
approximately, 9 months. 50% of this group required premedication with antihistamines, 
and 7 of them developed symptoms during the protocol. The most common symptoms 
were mouth itching and lip edema followed by abdominal pain and/or vomiting. After 24 
months of treatment, four patients (20%) (patients 13 to 16) tolerated between 2.0-10 mL of 
pasteurized EW, being able to consume baked goods containing egg and egg-coated foods 
without having anaphylactic reactions. These patients were considered partially 
desensitized. Obviously, they had the highest number of adverse reactions during the 
protocol. In patients 17 to 19 the protocol was stopped after several attempts, due to 
unacceptable severe adverse effects including, among others, recurrent anaphylactic 
manifestations, uvula edema and severe atopic dermatitis. Finally, only one patient 
(number 20) dropped the study for parental decision.  
To date, no adverse events have been reported by successfully desensitized children 
at 36-48 months after completed OIT protocol. Regarding children who were partially 
desensitized, three of the four forming this group have reached the maximum dose 
programmed through these months, whereas the remaining child continues with partial 
tolerance (9 mL), being able to eat baked good containing egg, egg-coated foods and 
boiled egg without developing negative symptoms. No changes have been reported in 
children who initially failed desensitization. Thus, to date, 75% of patients are on a free egg 
diet. 
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Baseline status of cow´s milk allergic vs. non-allergic children 
Egg-allergic patients displayed significantly higher levels of OVA-, OM- and EW- sIgE 
than not allergic subjects, whose levels were almost zero (P<0.001) (Figure 22A). 
Regarding the allergen-sIgG4 levels, although not statistically significant differences, 
results showed a trend towards higher concentrations of OVA-sIgG4 (P=0.21), OM-sIgG4 
(P=0.38) and EW-sIgG4 (P=0.09) in the non-allergic group when compared with the egg 
allergic group (Figure 19B).  
 
 
 
 
 
 
 
Figure 22. Serum specific (A) IgE and (B) IgG4 to OVA, OM and EW before the beginning of 
OIT in egg allergic children (N=20, green bars) and non-allergic controls (N=15, red bars). Bars 
represent mean ± SEM. Mann-Whitney 2-tailed test and 95% confidence intervals. ***: P< 
0.001; n.s.: non-significant differences. 
 
As presented in Table 15, although non-statistically significant, the mean production of 
Th2 cytokines (IL-5 and IL-13) by OVA-stimulated-PBMCs was higher in the egg allergic 
patients compared with non-allergic children. In contrast, a decreased Th1 cytokine 
concentration (significant for OVA-specific TNF-α) was found in this group of patients. A 
statistically significant higher production was found for OVA-specific IL-10 in non-allergic 
children compared with egg-allergic patients.  
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Table 15. Cytokine production by OVA-stimulated PBMCs from egg allergic children before OIT 
and from non-allergic children. Values are presented as mean ± SEM. P<0.05 by Mann-Whitney 
U-test (2-tailed) was considered significant.  
 
Immunologic outcomes during OIT (Egg OIT outcomes) 
 
Egg OIT outcomes: Specific antibody response 
All the patients that completed the egg OIT protocol (N=12) had a significant decrease 
(>5-fold), in their OVA-, OM- and EW-sIgE levels (Figure 23A) once the protocol was 
finished. Furthermore, a significant increase from baseline was observed in OVA-, OM- and 
EW-sIgG4 after the egg-OIT treatment (Figure 23B). 
 
 
 
 
 
 
 
Figure 23. Serum specific (A) IgE and (B) IgG4 to OVA, OM and EW before (green bars) and 
after (yellow bars) the OIT protocol in patients who tolerated 32 mL of egg white (N=12). Bars 
represent mean ± SEM. Wilcoxon 2-tailed test and 95% confidence intervals. ***: P < 0.001, **: 
P < 0.01, *: P < 0.05 
Cytokine 
Allergic 
(N=20) 
Non-allergic 
(N=9) 
P-value 
IL-5 38.49 ± 22.11 8.95± 4.15 0.26 
IL-13 104.90 ± 35.00 57.27 ± 16.23 0.27 
IFN-γ 22.60 ± 8.49 82.44 ± 34.71 0.11 
TNF-α 96.90 ± 26.94 409.40 ± 161.20 0.042 
IL-10 120.2 ± 19.16 337.60 ± 75.73 0.007 
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Egg OIT outcomes: OVA-specific cytokine production by PBMCs  
When comparing allergen-specific cytokine levels, before and after the egg OIT 
protocol in the group of patients who tolerated 32 mL of EW (N=12), it was found a trend 
towards a reduced IL-5 and IL-13 production by PBMCs after OVA stimulation, together 
with an increase in the concentrations of the Th1 cytokines IFN-γ and TNF-α. Furthermore, 
levels of OVA-specific IL10 were significantly higher when compared with baseline (P< 
0.05) (Table 16). 
 
 
 
 
 
 
 
 
Table 16. Cytokine levels after stimulation for 7 days with OVA of PBMCs from egg allergic 
patients who tolerated 32 mL of egg white before and after completing the egg OIT and baseline 
levels for egg allergic patients who did not successfully completed the protocol. Values are 
presented as mean ± SEM. P<0.05 by Mann-Whitney 2-tailed test was considered significant.  
a 
Before vs. after OIT in patients who completed the protocol 
b 
Before OIT in patients who completed the protocol vs. patients who did not complete the 
protocol 
 
Egg OIT outcomes: Gene expression in OVA-stimulated PBMCs 
Transcription factors FoxP3, Tbet and GATA3 were upregulated in more than 66% of 
the desensitized patients. However, the expression revealed no enough variation to 
consider significant changes as mean RQ values were very close to 1 (Mean ± SEM 
[range] FoxP3 = 1.57 ± 0.22 [0.55-2.83]; T-bet = 1.76 ± 0.28 [0.28-3.93]), GATA3= 1.19 ± 
0.14 [0.29-2.06]) (Figure 24).  
Cytokine  
Egg allergic patients who tolerated 32 mL  
of EW before and after OIT  
(N=12) 
Egg allergic patients who did 
not  successfully complete OIT  
(N=7) 
Before OIT After OIT P-value 
a
 Before OIT P-value 
b
 
IL-5 11.93 ± 9.23 3.83 ± 3.22 0.42 89.51 ± 59.02 0.11 
 
IL-13 79.15 ± 23.93 52.12 ± 21.53 0.41 163.70 ± 90.94 0.28 
 
IFN-γ 24.50 ± 10.45 53.73 ± 19.33 0.20 22.41 ± 17.19 0.91 
 
TNF-α 131.70 ± 39.76 277.10 ± 212.90 0.51 47.25 ± 26.88 0.15 
 
IL-10 97.73 ± 24.03 195.1± 38.75 0.046 141.11 ± 30.39 0.29 
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Figure 24. RQ values of transcription factors in response to intervention in complete number of 
egg allergy patients completed OIT (N=12). Black square represents change from baseline to 
successful OIT. RQ value of 1 means no difference in two times. 
 
 
Baseline immunological status of fully desensitized egg allergic patients vs. partially 
desensitized 
When baseline OVA, OM and EW sIgE levels were compared between the patients 
successfully desensitized to egg (n=12) and those that did not fully complete the protocol 
(N=7), it was found that egg-protein sIgE levels were higher in the latter (Mean ± SEM for  
OVA-sIgE: 14.23 ± 2.51 vs 62.98 ± 29.89 (P=0.047); Mean ± SEM for  OM-sIgE:  22.39 ± 
7.68 vs 82.53 ± 28.33 (P=0.07); Mean ± SEM for EW-sIgE: 23.93 ± 8.30 vs 153.30 ± 99.88 
(P=0.07)). 
Regarding the baseline production of cytokines by OVA-stimulated PBMCs, it was 
observed lower mean values of IL-5 and IL-13, together with higher TNF-α mean level in 
the patients who successfully completed the protocol, although they were non-statistically 
significant changes (Table 16). 
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4.2.3.2. DISCUSSION 
In the current study, the immunological status of the enrolled egg-allergic children was 
initially assessed, and compared with that of a group of non-allergic patients from the same 
age-range. In addition to the presence of egg protein-sIgE antibodies in plasma, 
characteristic of the allergic status (Burks et al., 2012), PBMCs from egg-allergic patients 
showed a diminished OVA-specific TNF-α and IL-10 production, together with a trend 
towards higher IL-5 and IL-13 levels upon OVA stimulation. These findings demonstrating a 
bias towards Th2 type cytokine production in food allergic individuals. We speculate that 
the decreased Th1 and IL-10 responses observed in allergic patients might represent a 
reduction in Th1 and IL-10 regulatory cell populations capable of suppressing Th2 
responses. IL-10 particularly, is known to play an important role in Treg cells function 
(Palomares, 2013). 
The efficiency and safety of the proposed egg OIT protocol were in the range of 
reported in studies by Dello Iacono et al. (2013) and Meglio et al. (2013), in which OIT led 
to the clinical desensitization of 90% and 80% of the children respectively. Due to moderate 
side effects, the actual duration of this desensitization protocol was much longer than 
originally expected, and had to be increased in, approximately, 9 months in relation to the 
original desensitization schedule. Similar results were observed in the course of the CM-
OIT previously reported in this thesis (Section 4.1.1.1.2.). Something similar was reported 
in the study by Staden et al. (2007), where the length of the planned protocol was 
increased from 67 days to 7 months because of adverse reactions. Similarly, Meglio et al. 
(2013) increased their protocol in 150 days owing to intercurrent illnesses. Narisety et al. 
(2009) observed in their milk OIT study that prolonged higher-dose treatment induced new 
immunological changes and enhanced the desensitization effect, suggesting that longer 
treatment courses are more effective and possibly safer. In addition, results in Vickery et al. 
(2010) point out that desensitization periods cannot be planned in advance, making it 
necessary to individualize the dosing according to the patients characteristics. 
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A spontaneous outgrown of egg allergy in the patients included in the study was very 
unlikely due to their high average baseline EW-sIgE levels, exceeding by far the 
established thresholds for clinical reactivity (Sicherer et al., 2014), and their frequent 
adverse responses to the therapy. On the other hand, the current protocol cannot confirm 
whether the patients were tolerant to egg, as the egg intake was not withdrawn after the 
treatment because of ethical reasons. In a previous report by Burks et al. (2012) in which 
egg was avoided for a period of 4 to 6 weeks after a desensitization protocol, more than 
70% of the patients initially desensitized did not pass a subsequent oral food challenge. 
Anyhow, it is worth to mention that all the patients that successfully finished the reported 
egg OIT protocol (12/20) were still able to tolerate a complete egg after passing 36-48 
months of the therapy. Further, 3 out of 4 partially desensitized children have reached the 
maximum dose programmed (32 mL of EW) during this time. Thus, the desensitization rate 
increased to up to 75% patients (15/20). 
The observed changes in antigen sIgG4 production in successful OIT subjects mirror 
those observed in other food OIT protocols where antigen sIgG4 increase at the end of the 
immunotherapy (Blumchen et al., 2010; Itoh et al., 2010, Vickery et al., 2010; Varshney et 
al., 2011; Burks et al., 2012, Meglio et al., 2013). Regarding antigen-sIgE levels, a 
significant reduction, in accordance with other authors (Itoh et al., 2010; Vickerey et al., 
2010; García Rodríguez et al., 2011, Dello Iacono et al., 2013; Meglio et al., 2013; Vila et 
al., 2013), was observed in our study. However, other reports did not find significant 
changes in IgE levels along the OIT protocol (Buchanan et al., 2007; Blumchen et al., 2011; 
Burks et al., 2012; Fuentes-Aparicio et al., 2013). The decrease in the IgE/IgG4 ratio 
observed during the OIT might be a feature of skewing from allergen-specific Th2 to Treg 
cells predominance. This affirmation is supported by the significant increase in IL-10 
production by OVA-stimulated PBMCs as well as the reduction in IL5 and IL13 levels, found 
in the patients able to ingest 32 mL of pasteurized EW without developing symptoms. 
Although in our study we have not measured the populations of egg-specific Treg
 
cells, the 
role of this cell type in tolerance induction after immunotherapy treatments has been 
demonstrated (Varshney et al., 2011; Urra et al., 2012; Fuentes-Aparicio et al., 2014). 
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Tregs, trough IL-10 secretion, are potent suppressors of both total and allergen-sIgE, 
whereas they simultaneously increase IgG4 production. Gene expression outcomes 
showed a lack of treatment-related changes in the expression of Treg (Foxp3), Th1 (Tbet), 
or Th2 (GATA3) transcription factors, despite the existence of measurable variations in 
involved OIT transcripts was already reported by Jones et al. (2009) in their study with 
peanut oral immunotherapy.  
In the present research, lower baseline antigen-sIgE levels appear to be related with a 
successful OIT therapy. A similar observation was made by García-Rodríguez et al. (2011) 
and Vazquez-Ortiz et al. (2014), who found in their studies that elevated baseline levels of 
egg-sIgE were related with a high probability of discontinuation of the protocol. 
Furthermore, although not significant, patients able to tolerate 32 mL of pasteurized EW 
displayed a trend towards lower baseline levels of Th2 cytokines, together with an increase 
in TNF-α secretion after OVA stimulation of PBMCs. In the same line, IL-4 mRNA has been 
proposed as a possible predictive factor of egg allergy resolution by Sicherer et al. (2014).  
Taken altogether, this report presents an efficient and safe egg-OIT protocol characterized 
for the progressive introduction of egg containing foods, which improve substantially the 
patient’s quality of life. Successful OIT was accompanied by a significant increase in egg-
sIgG4 levels and IL-10 production by OVA stimulated PBMCs as well as by a significant 
reduction in egg-sIgE concentration towards a non-allergic phenotype. Results of the study 
highlight the importance of designing individualized protocols taking into account the 
baseline egg-sIgE levels of the patient in order to achieve a successful desensitization.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
5. CONCLUSIONS / CONCLUSIONES 
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CONCLUSIONS 
1. - The establishment of cow's milk protein allergy in infants was related with a deficit in 
the number of circulating Treg, which seems to result in an inadequate control of effector T 
cells, triggering a higher frequency of IL-4 secreting CD4+ T cells. These immune 
alterations would be crucial factors behind the onset of the allergic process and they could 
constitute a therapeutic target for the treatment of this food allergy. 
2. - Treg deficit in cow's milk protein allergic children was not due to a defect in the thymic 
production of Treg, but seems to be related with decreased serum levels of vitamin D. 
Statistical analysis indicates that Treg and vitamin D values could be good predictors to 
discriminate between healthy controls and cow's milk protein allergic children, and also to 
predict the spontaneous achievement of tolerance. 
3. - Egg ROIT approach had a greater rate of success than longer protocol, leading 
children to clinical desensitization to egg proteins in a few days, with most adverse 
reactions being controlled and providing with long-term protection.  
4. - Cow's milk and egg long-course OIT protocols, based on individualized up-dosing and 
characterized by the progressive introduction of different foods containing the implicated 
allergens, were successful to induce desensitization while patient’s quality of life improved 
substantially. The long-term efficacy of these protocols was also demonstrated. 
5. - The cytokine profile after allergen-specific stimulation of PBMCs could be used to 
predict the allergic status of the OIT participants, as allergic children displayed a bias 
toward Th2 type cytokine production and decreased Th1 responses compared with non-
allergic individuals.  
6. - Successful cow's milk and egg OIT were accompanied by significant reductions in 
antigen-specific IgE levels, whereas antigen-specific IgG4 levels were increased. Patients 
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who completed desensitization also showed decreased Th2-cytokine related levels by 
allergen-stimulated PBMCs after treatment. No treatment-related changes were found in 
the gene expression of any studied transcription factors. 
7. - Lower baseline antigen-specific IgE levels were suggested as predictors to accurately 
define the efficacy and the risk of adverse reactions during egg OIT. High baseline CN-
sIgG4 levels seemed to have important biological significance in cow's milk OIT and could 
be proposed as predictors of negative clinical response to therapy. A decrease in OVA-
specific IL-13 at short time of immunotherapy could be a useful biomarker of positive 
response to egg in rush protocols of egg OIT.  
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CONCLUSIONES 
1.- El establecimiento de la alergia a proteínas de la leche de vaca en lactantes se 
relacionó con un déficit en el número de Treg circulantes, lo que parece conducir a un 
control inadecuado de las células T efectoras y aumentando la frecuencia de células T 
CD4+ secretoras de IL-4. Estas alteraciones inmunitarias serían factores cruciales en el 
inicio del proceso alérgico y podrían constituir una posible diana terapéutica para el 
tratamiento de esta alergia alimentaria. 
2.- El déficit de Treg en los niños alérgicos a proteínas de leche de vaca no se debió a un 
defecto en la producción tímica de Treg, sino que estuvo relacionado con una disminución 
de los niveles séricos de vitamina D. El análisis estadístico indica que los valores de Treg y 
vitamina D podrían ser buenos predictores para discriminar entre individuos sanos y los 
niños alérgicos a proteínas de la leche de vaca, y también serían de utilidad para predecir 
el desarrollo espontáneo de tolerancia. 
3.- La ITO rápida al huevo tuvo una mayor tasa de éxito que el protocolo de larga duración, 
llevando a la desensibilización a las proteínas del huevo en pocos días. En estos 
pacientes, la mayor parte de las reacciones adversas fueron controladas y se proporcionó 
a los niños una protección a largo plazo. 
4.- Los protocolos de ITO de larga duración a la leche de vaca y al huevo, basados en el 
aumento individualizado de la dosis y caracterizados por la introducción progresiva de 
diferentes alimentos conteniendo los alérgenos implicados, se mostraron exitosos en la 
inducción de desensibilización, conduciendo a mejoras sustanciales en la calidad de vida 
del paciente. La eficacia a largo plazo de estos protocolos ha sido también demostrada. 
5.- El perfil de citoquinas secretadas tras la estimulación alérgeno-específica de PBMCs 
podría ser utilizado para predecir el estado alérgico de los participantes en la ITO, al 
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mostrar los niños alérgicos un sesgo hacia la producción de citoquinas de tipo Th2 con 
disminución de las respuestas Th1 en comparación con los individuos no alérgicos. 
6.- La ITO exitosa a la leche de vaca y al huevo se acompañó de reducciones significativas 
en los niveles de IgE específica a alérgenos, mientras que los niveles de IgG4 alérgeno-
específicos aumentaron. Los pacientes que alcanzaron la desensibilización también 
mostraron una disminución en los niveles de citoquinas Th2 secretadas por PBMCs 
estimuladas con alérgenos, una vez finalizado el tratamiento. No se encontraron cambios 
significativos en la expresión génica en ninguno de los factores de transcripción 
estudiados. 
7.- Niveles basales más bajos de IgE específica a alérgenos podrían servir como 
predictores a la hora de definir con mayor precisión la eficacia potencial y el riesgo de 
reacciones adversas durante los protocolos de ITO al huevo. Los niveles basales más 
elevados de IgG4 específica a caseína parecen tener un significado biológico importante 
en la ITO a la leche de vaca, por lo que podrían ser propuestos como posibles predictores 
de una respuesta clínica al tratamiento negativa. La disminución de IL-13 específica a OVA 
al poco tiempo de tratamiento podría ser un biomarcador útil de respuesta positiva en los 
protocolos de ITO rápida al huevo.  
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